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1. INTRODUCTION 
1.1 Antimicrobial peptides and innate immunity 
Antimicrobial peptides (AMPs) are important components of the non-
specific innate immunity and form a first line of defense against infection by 
pathogenic microorganisms. They are widespread in nature, being produced 
at all levels of the evolutionary scale: in bacteria and fungi, as well as in 
higher eukaryotes as reported below [Brown and Hancock, 2006]. 
 
Schematic representation of some living organisms producing AMPs 
In animals, AMPs are located at those anatomical sites that easily come 
into contact with microorganisms, such as the skin and the mucosal or 
epithelial surfaces of the respiratory, genitourinary and gastrointestinal tracts 
[Bals, 2000]. They are also mostly found in circulating granulocytic 
leukocytes. 
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AMPs are promptly synthesized at low metabolic cost, stored in large 
amounts into granules for extracellular secretion. Peptide antibiotics differ 
from the classical antibiotics, which are synthesized by microorganisms and 
made stepwise, with different enzymes at each step [Boman, 1995]. Indeed, 
AMPs are encoded by genes and ribosomally synthesized as pre-propeptides. 
The synthesis of AMPs can be constitutive or inducible by microbial 
components. However, it depends on the cell type and differentiation state. 
In animals, including humans, normal flora of bacteria exists on the 
skin, in the mouth, in the intestine, in the reproductive organs and in the air 
ways. It is likely that the control of the natural flora is due to a continuous 
production of peptide antibiotics. 
The main advantage of AMPs as factors of the innate immunity is that 
they can function without high specificity and memory. The innate immune 
system can respond in a matter of hours before the adaptive immunity is 
activated. The time needed to synthesize and process a pre-propeptide with 
100-150 residues is certainly shorter than the time required to produce two 
heavy and two light immunoglobulin chains, the production of which also 
requires the differentiation of a memory cell to a plasma cell. This is a very 
important aspect considering the difference in the growth rate between a 
bacterium (generation time 20-30 min) and a lymphocyte (24-48 hours of 
doubling time). Thus, a primary bacterial infection can never be eliminated 
by a clonally-based mechanism, because this response is not fast enough. 
Even in a secondary microbial infection (when memory cells are present), it 
would likely take too long time to mobilize antibodies and/or specific effector 
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cells to curb a bacterial infection without the help of innate immune 
components [Boman, 1995]. 
Overstimulation of innate immunity, however, leads to a syndrome 
termed sepsis. Innate immunity is triggered when bacterial molecules (for 
example lipopolysaccharide, LPS) interact with host pattern recognition 
receptors including Toll-like receptors (TLRs). After TLRs binding, effector 
mechanisms that assist the prevention or resolution of infections are 
stimulated. Stimulation of innate immunity by natural mechanisms, for 
example using TLR agonists, creates the risk of inducing or exacerbating 
potentially harmful pro-inflammatory responses [Hancock and Sahl, 2006]. 
AMPs are known to play an important role in both innate and adaptive 
immunity [Zasloff, 2002]. AMPs from higher eukaryotes also act as 
intracellular signaling molecules and coordinate the innate and adaptive host 
defense responses, influencing processes like cytokine release, cell 
proliferation, angiogenesis, wound healing, chemotaxis, control and 
resolution of the inflammatory response (Fig. 1.1). Some of these properties 
would be considered pro-inflammatory, but AMPs actually suppress TLR 
signaling responses, by blocking the LPS-stimulated production of cytokines, 
like tumor necrosis factor-alpha (TNF-α), and therefore, the emergence of 
septic shock syndrome in animal models [Hancock and Sahl, 2006]. Note that 
the LPS-binding properties of many AMPs are believed to play an important 
role in detoxifying LPS during infection (Rosenfeld et al, 2006b). In addition, 
some AMPs, like human defensins and LL-37, are chemoattractive peptides 
for leukocytes. Specifically, they can have a dual role: (i) killing 
microorganisms, at high concentrations, and (ii) attracting leukocytes to the 
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site of infection, at low concentrations [Dürr and Peschel, 2002], thus 
providing a link between the innate and adaptive immunity. 
 
1.2 AMPs: structural features and mechanism of action 
AMPs vary significantly in their sequences, suggesting that a specific 
sequence is not crucial for their biological activity. Despite substantial 
variations in chain length (8-50 amino acids), sequence and conformation, 
most AMPs share some important features: i) a net positive charge at neutral 
pH, due to the presence of basic amino acids; ii) a composition of 
approximately 30% of hydrophobic residues in their primary structure; iii) a 
random coil conformation in water solution; iv) the possibility to adopt in a 
hydrophobic environment an amphipathic structure with a hydrophobic side 
facing a hydrophilic one. The cationic character of AMPs, which can be 
reinforced by a C-terminal amidation, as well as the tendency to adopt an 
Figure 1.1 Biological roles of host defense peptides. Both 
direct antimicrobial killing and innate immune modulation 
occur for the majority. Although certain peptides have one 
or the other activity, preferentially. 
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amphipathic conformation are crucial factors for their antimicrobial activity. 
AMPs have a preferential selectivity for prokaryotic and transformed 
eukaryotic cell membranes (such as virally infected and tumor cells) that 
depends on the different lipid composition of bacterial and transformed cell 
membranes with respect to normal eukaryotic membranes [Nikaido and 
Vaara, 1985; Utsugi et al, 1991]. In particular, before reaching the target 
cytoplasmic membrane, which has a high transmembrane potential (-140 
mV), peptides must traverse, by electrostatic interactions, the surface of the 
outer bacterial membranes that are negatively charged because they are 
composed of LPS, in Gram-negative bacteria [Nikaido and Nakae, 1979] or 
of teichoic acids-rich peptidoglycan layer, in Gram-positive ones. 
After this self-promote uptake in the periplasmic space, a common step 
for the killing mechanism of cationic AMPs is their electrostatic interaction 
with the negatively-charged microbial inner membrane that is composed 
predominantly of phosphatidylethanolamine (PE), phosphatidylglycerol (PG) 
and cardiolipin (CL). The membrane can be a means for the peptide to reach 
internal targets or can be lysed (Fig. 1.1), depending on the target, the 
biophysical peptide’s properties and its concentration [Brogden, 2005]. 
In the first case, AMPs exert their activity selectively against bacteria 
through an apparently non-membranolytic mode of action. An interaction 
with the plasma membrane or with a hypothetical transporter/receptor protein 
allows their translocation into the cytosol. Once inside the cell, the AMP 
binds to one or more macromolecular target(s) and alters its/their activity 
affecting various vital cells processes: for example, the arrest of DNA 
synthesis, the breakage of single-strand DNA, the inhibition of chaperone-
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assisted protein folding, the production of hydrogen peroxide, the activation 
of apoptosis in eukaryotic cells or autolysis in bacterial targets. 
In the second case, the electrostatic binding is followed by membrane 
destabilization (i.e. transmembrane channels formation) [Lehrer et al, 1993; 
Boman, 1995] with release of metabolites. Some general mechanisms have 
been proposed to describe the molecular events taking place during the 
membrane-permeation process. 
In the barrel-stave model [Ehrenstein and Lecar, 1977], after the 
initial electrostatic binding to the outer leaflet of the membrane, the peptide 
adopts an amphipathic alpha-helical structure, self associates on the surface 
of the membrane and then inserts into the phospholipid bilayer to form 
transmembrane bundles/channels (Fig. 1.2). In this structure, the hydrophobic 
peptide region aligns with the lipid core region of the bilayer, while the 
hydrophilic surface points inward, producing an aqueous pore. A minimum 
number of peptide molecules (at least 6) is thought to be necessary for the 
formation of a channel. Because peptides insert into the hydrophobic core of 
the membrane, their interaction with the target membrane is driven 
predominantly by hydrophobic interactions. 
 
Figure 1.2 Scheme of the barrel-stave model. Hydrophilic regions of the peptide are shown coloured 
red, hydrophobic regions of the peptide are shown coloured blu [Brogden, 2005]. 
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The toroidal-pore model [Ludtke et al, 1996; Matsuzaki et al, 1996] 
differs from the barrel-stave model in that the peptides are always associated 
with the phospholipid head-groups, even when they are perpendicularly 
inserted into the lipid bilayer. This model predicts no peptide aggregation. 
The polar faces of the peptides associate with the polar head groups of the 
lipids. The lipids in these openings then tilt from the normal position and 
connect the two leaflets of the membrane, forming a continuous bend from 
the top to the bottom in the fashion of a toroidal hole. The pore is lined by 
both the peptides and the lipid head groups, which are likely to screen and 
mask cationic peptide charges (Fig. 1.3). In contrast with the barrel-stave 
model, toroidal pores are short-lived and reversible structures which can leak 
water-soluble substances. 
 
Figure 1.3 Scheme of the toroidal-pore model. Hydrophilic regions of the peptide are shown 
coloured red, hydrophobic regions of the peptide are shown coloured blu [Brogden, 2005]. 
 
The carpet model [Shai, 2002] proposes that peptides adsorb to the 
membrane surface interacting with the anionic phospholipid head groups and 
cover the membrane in a carpet-like manner (Fig. 1.4). Subsequently, 
peptides orient their hydrophobic surface towards the membrane and the 
hydrophilic one towards the solvent. When a threshold concentration of 
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peptide monomers is reached, they cause membrane permeation and transient 
pores can be formed. Holes like these may allow the passage of low 
molecular weight molecules. Higher peptide concentrations can lead to the 
membrane disintegration in a detergent-like manner eventually leading to the 
formation of micelles (Fig. 1.4). Contrary to the barrel-stave model, in the 
carpet-like model, peptide interaction with the target membrane is 
electrostatically driven and peptide molecules are not inserted into the 
hydrophobic core of the membrane, neither they do assembly with their 
hydrophilic surfaces facing each other. 
 
Figure 1.4 Scheme of the carpet-like model. Hydrophilic regions of the peptide are shown coloured 
red, hydrophobic regions of the peptide are shown coloured blu [Brogden, 2005]. 
 
The sinking raft model [Pokorny et al, 2002] proposes a side-by-side 
aggregation of peptides on the membrane, with the peptide helices parallel to 
the surface, creating a mass imbalance across the lipid bilayer with a 
consequent increase in local curvature. The peptide aggregate behaves as a 
“raft” that sinks deeper into the outer leaflet of the membrane (sinking raft) 
inducing the formation of a transient pore and peptide translocation across the 
lipid bilayer (Fig. 1.5). 
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Figure 1.5 Sinking raft model for peptide-induced 
transient pore formation and peptide translocation across 
the bilayer. The alpha-helices are shown as cross 
section, the darker half circles representing the 
hydrophobic faces and the lighter half circles the polar 
faces. 
 
The Shai-Matsuzaki-Huang (SMH) model proposes a common 
mechanism which agrees with the various models. In the SMH model, 
peptides interact first with the outer leaflet of the membrane in a carpet-like 
fashion (Fig. 1.6 A). Subsequently, they insert into the membrane and thin its 
outer leaflet generating a displacement of lipids, because of an expansion of 
the surface area relative to the inner leaflet (Fig. 1.6 B). This leads to an 
alteration of the membrane structure with “wormhole” formation, as in the 
toroidal-pore model (Fig. 1.6 C). Transport of lipids and peptides into the 
inner leaflet (Fig. 1.6 D) and diffusion of peptides inside the cells (Fig. 1.6 E) 
or a collapse of the membrane (Fig. 1.6 F) can then occur. 
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The selectivity of many cationic AMPs toward bacteria is generally 
attributed to their membranes composition that is organized in such a way 
that the outermost leaflet of the bilayer is heavily populated by lipids with 
negatively charged phospholipid headgroups. In contrast, the outer leaflet of 
the membranes of plants and animals is composed principally of lipids with 
no net charge (such as phosphatidylcholine and sphingomyelin); most of the 
lipids with negatively charged headgroups are segregated into the inner 
 
 
Figure 1.6 The Shai-Matsuzaki-Huang model. 
Transport of lipids and 
peptides into the inner 
leaflet
A
B
C
D
E
F
Collapse of the membrane
into  fragments
Toroidal pore 
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leaflet, facing the cytoplasm. The presence of cholesterol in the target 
membrane in general reduces the activity of the AMP, due either to 
stabilization of the lipid bilayer or to interactions between cholesterol and the 
peptide [Sood and Kinnunen, 2008; Torrent et al, 2011]. Generally, studies 
on the interaction of AMPs with model phospholipid membranes have 
revealed a lower affinity to zwitterionic phospholipids compared to acidic 
phospholipids [Williams et al, 1990; Pouny et al, 1992; Gazit et al, 1994; 
Strahilevitz et al, 1994; Gazit and Shai, 1995; Oren and Shai, 1996; Latal et 
al, 1997; Matsuzaki et al, 1999; Oren et al, 1999a; Oren et al, 1999b; Hetru et 
al, 2000]. 
1.3 AMPs and resistance 
AMPs kill rapidly a broad spectrum of microorganisms, inducing a 
damage hard to fix rather than acting via a receptor-mediated mechanism. 
This makes it difficult for the bacteria to develop resistance, which would 
require a change in membrane composition, a very expensive solution for the 
majority of microbes [Zasloff, 2002]. Commonly used drugs operate on 
specific intracellular targets and do not modify the bacterial morphology, 
making it easy for the microorganisms to become resistant to those drugs 
[Yeaman and Yount, 2003]. The rate of acquisition of resistance to AMPs by 
a sensitive microbial strain is several orders of magnitude lower than that 
needed to conventional antibiotics [Kraus and Peschel, 2006]. However, it 
has been shown that in vivo exposure of bacteria to slowly increasing AMP 
concentrations, over several hundred generations, can result in reversible 
physiological adaptation and/or spontaneous, inheritable resistance to the 
peptide used [Rosenfeld et al, 2006a]. For example, it was recently observed 
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the existence of variants of Enterococcus faecalis that are resistant to 
different doses of the fungal AMP alamethicin [Mehla and Sood, 2011]. 
However, it remains unclear how fast such adaptation can occur in vivo - 
where the presence of a cocktail of defense agents will create a selection 
pressure that differs greatly from that present in an in vitro experiment, using 
just one AMP -, how specific these adaptations might be and what the fitness 
costs are. 
An AMP-resistance strategy used by microorganisms is based on 
reducing the net anionic charge of the bacterial cell envelope. This decrease 
reduces the affinity of AMPs for the bacterial membrane, and contributes to 
bacteria resistance to various cationic antimicrobial molecules [Ernst et al, 
2001; Peschel, 2002]. Bacterial cell-envelope contains anionic molecules 
such as peptidoglycan, teichoic acids, lipid A (the conserved highly 
hydrophobic and toxic region of LPS) or phospholipids. They are formed by 
complex biosynthesis processes, and it is unlikely that microorganisms can 
replace these essential macromolecules with novel structures that would be 
less favorable for AMP interactions. However, many bacteria can acquire 
protection against AMPs by reducing the net negative charge of their surface. 
The teichoic acid polymers found in the cell walls of Gram-positive bacteria 
have a strong anionic character, due to the phosphate groups in their 
glycerophosphate repeating units [Neuhaus and Baddiley, 2003]. Many 
bacteria can partially neutralize this negative charge by modifying teichoic 
acid with D-alanine residues that bear positively charged amino groups. 
Staphylococcus aureus uses a similar concept to change the net negative 
charge of the major membrane lipid phosphatidylglycerol into a net positive 
charge by inserting L-lysine residues [Peschel et al, 2001]. Several Gram-
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negative bacteria incorporate positively charged aminoarabinose into lipid A, 
which contains anionic phosphate groups, thereby reducing its affinity to 
AMPs [Ernst et al, 2001; Miller et al, 2005]. However, even bacteria which 
are capable of these modifications can be inactivated by many AMPs at high 
concentrations, as the neutralization of the cell envelope remains incomplete. 
The bacterial capacity to reduce the anionic net charge of their surface seems 
to have certain limits and some AMPs preserve activity against this type of 
strains [Midorikawa et al, 2003; Weidenmaier et al, 2004]. Several bacterial 
pathogens have evolved mechanisms to interfere with some specific activity 
of certain AMPs. This is because they rely on the recognition and 
extracellular extrusion of AMPs from the bacterial membrane. S. aureus 
produces the exoprotein staphylokinase which, in addition to its fibrinolytic 
activity, can bind and inactivate alpha-defensins from human neutrophils [Jin 
et al, 2004]. Streptococcus pyogens produces two inhibitors of complement, 
SIC [Frick et al, 2003], and the cell-wall-anchored M1 proteine [Nizet, 2005] 
that bind AMPs with high affinity, preventing them from accessing to the 
bacterial cytoplasmic membrane. In addition, AMPs are substrate for the 
mtrCDE multiple drug resistance exporter of Neisseria gonorrhoeae [Shafer 
et al, 1998] and Neisseria meningitides [Tzeng, 2005]. AMP-capturing and 
AMP-extruding molecules depend on the direct recognition of certain AMP 
sequences or structural motifs. Accordingly, the SIC proteins of S. pyogens 
mediate resistance to the human beta-defensins 2 and 3 (hBD2 and hBD3), 
but not to human beta-defensin 1 (hBD1). Another strategy used by bacteria 
to inactivate AMPs is to produce peptidases and proteases that degrade these 
peptides. Therefore, making peptide structures more rigid, for example 
through the introduction of disulphide bridges, renders AMPs considerably 
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more resistant to proteolysis. In addition to disulphide bridges, the 
introduction of proline residues and the C-terminal amidation might render 
AMPs more resistant to proteases. However, despite the virtues of disulphide 
bridges and structural stabilization they afford, linear AMPs have not 
disappeared during the course of evolution. Notably, only a small number of 
amino acid positions in most AMP sequences are essential for antimicrobial 
activity, while many other residues can be exchanged without loss of 
function. In conclusion, it can be assumed that most AMP-resistant 
mechanisms do not provide complete protection and do result in a reduced 
susceptibility to AMPs. The simultaneous presence of many variants of 
AMPs makes it considerably more difficult for microorganisms to develop 
AMP resistance. Indeed, AMPs have been effective for billions of years 
[Hancock and Sahl, 2006]. 
1.4 Amphibian AMPs 
Amphibians are a kind of animals forced to survive in various habitat 
full of pathogenic microbes. Therefore, they are endowed with an excellent 
chemical defense system composed of peptides with pharmacological and 
antimicrobial activities. Among the several sources of natural peptide 
antibiotics, amphibian skin is the richest [Simmaco et al, 1998; Rinaldi, 
2002], especially that of frogs of the genus Rana, which has a worldwide 
distribution with approximately 250 different species [Conlon et al, 2004]. 
Frog skin AMPs are produced by dermal serous glands, which are mainly 
located in the dorsal region of the animal and are controlled by sympathetic 
axons. The cytoplasm of the cells is rich in granules, where AMPs are stored, 
and the lumen is reduced to a small empty cavity. Contraction of myocytes 
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surrounding the glands, as a reaction to stress or injury, causes a synchronous 
discharge of their content, in a holocrine mechanism. 
1.5 The esculentin family 
Each species of ranid frog produces its own specific set of peptides 
[Conlon et al, 2004]. From skin secretions of Pelophylax lessonae/ridibundus 
(previously classified as Rana esculenta [Conlon, 2008]), a large variety of 
AMPs have been isolated [Simmaco et al, 1993; Simmaco et al, 1994; Ali et 
al, 2003]. Among them, the esculentin-1 family represents the most potent 
one, being active against Gram-positive and Gram-negative bacteria as well 
as fungi (lethal concentration values ranging from 0.1 to 1.5 μM), with 
negligible effects on eukaryotic cells. All members of this family are 46-
amino acid residues long and contain a C-terminal hepta-membered ring 
stabilized by a disulfide bridge. They have a net charge of +5 at neutral pH 
and adopt an amphipathic alpha-helical structure in membrane mimetic 
environments (i.e. 30% trifluoroethanol, TFE). Their sequences are reported 
below (basic residues in red, acid residues in blue; identical residues marked 
with an asterisk). 
        ******  **  ********* ********** ********** ****** 
Esc-1  GIFSKLGRKK IKNLLISGLK NVGKEVGMDV VRTGIDIAGC KIKGEC 
Esc-1a GIFSKLAGKK IKNLLISGLK NVGKEVGMDV VRTGIDIAGC KIKGEC 
Esc-1b GIFSKLAGKK LKNLLISGLK NVGKEVGMDV VRTGIDIAGC KIKGEC 
 
Since a little amount of esculentin-1 can be recovered from frog skin 
secretions, analogues of this peptide were produced by recombinant 
expression in E. coli of a fusion protein which is sequestered in inclusion 
1. INTRODUCTION 
18 
 
bodies [Ponti et al, 1999]. The peptide was inserted at the N-terminus of the 
protein GABA transaminase, from which it could be released by cyanogen 
bromide (CNBr) cleavage. Two esculentin analogues of 47-amino acid 
residues were produced: the esculentin-C, a cyclic analogue carrying the 
substitution Met28Leu and an additional Met at position 47, for CNBr 
cleavage of the recombinant fusion protein; the esculentin-L, a linear 
esculentin analogue, which had the same structure of esculentin-C but carried 
also the substitutions Cys40Ser and Cys46Ser. It was demonstrated that the 
antimicrobial activity of these analogues, tested in vitro against a number of 
bacterial strains, was very similar to that of the natural peptide. This indicates 
that the presence of a disulfide bridge at the C-terminal region is not essential 
for antimicrobial and cytolytic properties of the peptide. 
Esculentin-1 and its analogues displayed a strong activity in vitro 
against plant pathogens [Ponti et al, 1999]. They shared the N-terminal 
sequence Gly-Ile-Phe-Ser with a defensin subfamily from spinach [Segura et 
al, 1998]. These findings reinforced the possibility that esculentin can be 
properly processed in plants, thus conferring an enhancement of the 
physiological response to infections. Ponti et al, [2003] reported the 
transgenic expression of esculentin-C in Nicotiana tabacum. The peptide was 
detected in the intercellular fluid, as secretion product, and then tested against 
phytopathogens. The results of this study showed the absence of peptide 
toxicity to the plants and a resistance enhancement of transformed plants 
toward bacteria (Pseudomonas syringae pv tobaci and Pseudomonas 
aeruginosa ATCC 15692) and yeast (Phytophthora nicotianae) infections 
[Ponti et al, 2003]. From the HPLC purification of esculentin in the 
intercellular fluid, a degradation of the C-terminal region was found to occur 
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and all the shorter peptides (1-35, 1-34, 1-23, 1-22) were found to retain the 
antimicrobial activity. 
Note that the 19-46 fragment, common to all esculentin-1 family 
molecules, was also isolated from skin secretions: it was devoid of 
antimicrobial activity, possibly due to its low net positive charge (+1 versus 
+5 of the whole molecule) at neutral pH [Simmaco et al, 1994]. These data 
suggested that the antimicrobial properties of esculentin-1 are mainly exerted 
by its N-terminal region. 
1.6 The 1-18 fragment of esculentin-1b, Esc(1-18) 
Since no antimicrobial activity was detected for the 19-46 fragment of 
esculentin-1, it was investigated whether this activity was retained in the N-
terminal portion of the molecule. The 1-18 fragment was not found in the 
HPLC fractionation of the secretion, possibly because of its proteolytic 
degradation. Therefore, its antimicrobial activity was analyzed in detail on a 
synthetic peptide (Esc1-18), amidated at the C-terminus to maintain a net 
charge of +5 at neutral pH and to increase its stability [Mangoni et al, 2003]. 
Note that the amidation at the carboxyl-end is a very common post-
translational modification in linear AMPs from frog skin [Mangoni et al, 
2000; Mangoni, 2006; Nicolas and El Amri, 2009]. 
The biological activity on bacteria (either Gram-positive or Gram-
negative strains), yeasts and human erythrocytes of this peptide was 
compared to that of the full-length recombinant peptide, esculentin-C 
[Mangoni et al, 2003]. This study showed that the antimicrobial activity of 
Esc(1-18) was quite similar to that of the esculentin-C (with lethal 
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concentration values ranging from 0.1 to 1.5 μM) and that the activity of the 
18-mer was greater than that of the full-length peptide against the filamentous 
fungus P. nicotianae. Moreover, Esc(1-18) showed a lower hemolytic 
capacity compared to esculentin-C. Since no activity was found for the 1-15 
N-terminal segment of esculentin-1 [Roice et al, 2001], which contains the 
same number of positive charges as Esc(1-18), we can assume that the three 
C-terminal amino acids of Esc(1-18) (Ile-Ser-Gly) contribute to either 
stability of the amphipathic structure and/or hydrophobicity of the molecule. 
These data indicated that the antibiotic activity of esculentin-C was located in 
its N-terminal portion, and that the first 18 residues are required to display 
antimicrobial properties. 
1.7 The 1-21 fragment of esculentin-1a, Esc(1-21) 
To better investigate the antibacterial activity of the esculentin family, 
an analogue containing 21 amino acids was synthesized and tested against 
different P. aeruginosa ATCC strains and clinical isolates. This peptide was 
named esculentin-1a (1-21), Esc(1-21), since it shares the first 20 residues 
with the natural esculentin-1a. Differently from Esc(1-18), Esc(1-21) carries 
the substitution Leu-11-Ile and three additional C-terminal residues (Leu-
Lys-Gly) which give it a higher net positive charge at neutral pH (+6), a 
feature that is important for the electrostatic interaction with the negatively-
charged membranes of Gram-negative bacteria. 
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1.8 Candida albicans pathogen 
Candida albicans is a widespread opportunistic fungal pathogen 
capable of growing as unicellular budding yeast or as filamentous hyphae, a 
trait termed fungal dimorphism. 
Candida species are normally harmless commensal of the gastro-
intestinal and urinary tracts of human beings. However, under some 
circumstances, e.g., when the immune system is weakened or competing 
bacterial flora is eliminated following a broad-spectrum antibiotic treatment, 
Candida cells can switch from yeast, more suited for dissemination in the 
bloodstream [Gow et al, 2002; Saville et al, 2003; Huang et al, 2012], to 
hyphae responsible for promoting tissue penetration [Kumamoto and Vinces, 
2005; Berman, 2006; Sudbery, 2011], during superficial (e.g., oral and 
vaginitis) and systemic invasive candidoses (Fig. 1.7) [Mayer et al, 2013]. 
The capability to produce hyphae confer a greater resistance to 
phagocytosis compared with yeast and the ability to invade epithelial layers. 
In particular, the hyphal state is essential for adhesion to mucosal surfaces 
and initiation of clinical infectious diseases [Odds, 1987; Berman and 
Sudbery, 2002]. Candida cells defective in the formation of hyphae (e.g. 
mutations that block the transition to both forms [Kohler and Fink, 1996; 
Sharkey et al, 1999]) are both avirulent in animal models [Lo et al, 1997] and 
more sensitive to macrophage engulfment and growth inhibition [Marcil et al, 
2002]. 
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Figure 1.7 Steps in invasion by Candida albicans of an 
epithelial cell surface [Gow et al, 2011]. 
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1.9 Pseudomonas aeruginosa pathogen 
Pseudomonas aeruginosa is an opportunistic bacterial pathogen 
capable of causing life-threatening infections, including ocular keratitis, burn 
wound infections, and lung infections in cystic fibrosis (CF) patients [Hassett 
et al, 2002; Bjarnsholt et al, 2009; Brugha and Davies, 2011; Bjarnsholt, 
2013]. A major reason for its prominence as a pathogen is its high intrinsic 
resistance to antibiotics due in part to many elaborate virulence factors and 
the formation of biofilm matrices. Biofilms are sessile communities of 
bacteria [Costerton et al, 1999; Fux et al, 2005; Hoiby et al, 2011] that are 
very difficult to eradicate (Fig. 1.8). 
 
Figure 1.8 Pseudomonas aeruginosa bacterium. (A) Planktonic form. (B) Biofilm form. 
 
The formation of Pseudomonas biofilms is very common in the lungs 
of cystic fibrosis patients with chronic infections. The colonization of the 
respiratory tract by this pathogen usually starts with the tissue adhesion of 
non-mucoid and motile strains. Subsequently, motility is repressed and 
bacteria frequently evolve a mucoid phenotype forming thicker biofilms. 
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Bacterial biofilms are a structured consortium of embedded cells into a self-
promoted polymeric matrix consisting of anionic polysaccharides (mainly 
alginate), proteins, and extracellular DNA [Moreau-Marquis et al, 2008; 
Flemming and Wingender, 2010]. These confer bacterial population 
protection from antibiotics, chemicals, as well as opsonization and 
phagocytosis by host immune cells [Kuchma and O’Toole, 2000; Stephens, 
2002; Mah et al, 2003]. 
1.10 Caenorhabditis elegans: a simple infection model 
C. elegans is a convenient infection model for its simple, transparent 
body, invariant cell lineage, small size (1 mm in length), and rapid generation 
cycle [Brenner, 1974]. The two sexes of C. elegans are males (XO) and self-
fertilizing hermaphrodites (XX) producing both sperm and eggs. 
The C. elegans tissues that are in regular contact with microbes are the 
hypodermis and the intestine. The hypodermis is a single layer epithelium 
that surrounds the animal and is a multinucleate syncytium that secretes 
collagen to form a tough outer cuticle [Chisholm and Hardin, 2005]. C. 
elegans feeds on microbes that are ingested by the pharynx, which helps 
degrade food sources before they reach the intestine. The intestine is 
comprised of 20 epithelial cells that are mostly in pairs of cells that form a 
tube that runs the length of the animal [McGhee, 2007]. The intestinal cells 
share many morphological similarities with human intestinal epithelial cells, 
including actin-rich microvilli on the apical side of cells that absorb nutrients 
from the lumen (Fig. 1.9). 
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Figure 1.9 Features of the C. elegans intestine. (A) Simplified 
body plan of C. elegans. (B-C) Close-up of the intestinal cells 
[Balla and Troemel, 2013]. 
 
Feeding-based infections of C. elegans are relatively straight forward to 
perform, which aids studies of intestinal infections in this host. The primary 
food source in a laboratory setting is the E. coli strain OP50, but other 
bacteria and fungi also support growth and reproduction [Brenner, 1974; 
Mylonakis et al, 2002]. In our experiments, a feeding-based infection model 
has been developed, which involves simply substituting a microbial pathogen 
in place of the normal food source of E. coli. Interestingly, many virulence 
factors used by yeasts and bacteria to kill C. elegans play important roles in 
inducing pathogenesis in mammals, as well [Sifri et al, 2003; Mylonakis and 
Aballay, 2005; Sifri et al, 2005]. The lifespan of C. elegans on E. coli is only 
about 2 weeks, which makes it easy to assess whether pathogens cause a 
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shortening of lifespan. Because C. elegans nematodes are transparent, these 
infections provide the opportunity to visualize both intestinal and microbial 
cells in vivo during the course of infection. 
C. elegans does not appear to have adaptive immune system, such as 
phagocytes [Irazoqui et al, 2010]. It responds to bacterial and fungal 
pathogens by a vast repertoire of genes that could provide defense. Indeed, 
about 17% of the genes in the C. elegans genome are predicted to encode 
secreted proteins, and a third of those are upregulated by exposure to 
pathogens [Suh and Hutter, 2012]. These factors are part of expanded gene 
families and include some proteins conserved with mammals, e.g. the 
secreted C-type lectins endowed with antimicrobial activity. Furthermore, C. 
elegans produces its own AMPs, such as nlps or neuropeptide-like proteins 
and caenacins. 
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2. AIM OF THE STUDY 
The aim of this work was to evaluate the antimicrobial activity and the 
mechanism of action of two N-terminal derivatives of esculentin-1 peptide: 
Esc(1-18) and Esc(1-21) with the purpose to develop them as new anti-
infective agents. The first one was assayed against the yeast and hyphal forms 
of the human pathogen C. albicans under both in vitro and in vivo conditions 
using a C. elegans infection model. The second one was utilized against the 
planktonic and biofilm forms of another relevant human pathogen, such as P. 
aeruginosa. 
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3. MATERIALS AND METHODS 
3.1 Materials 
Synthetic all-L and all-D Esc(1-18), the rhodamine-labelled form of the 
all-L peptide [rho-Esc(1-18)] and Esc(1-21) were purchased from Selleck 
Chemicals (Houston, TX, USA). The purity of the peptides, their sequences 
and concentrations were determined as described in [Mangoni et al, 2003]. 
Sytox Green was from molecular probes (Invitrogen, Carlsbad, CA, U.S.A.); 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), poly-
L-lysine (150,000-300,000 mol wt), 2’,7’-dichlorofluorescein diacetate 
(DCFHDA), crystal violet (CV) and 2-nitrophenyl β-D-galactoside (ONPG) 
were all purchased from Sigma (St. Louis, MO, U.S.A.). All other chemicals 
were reagent-grade. 
3.2 Microorganisms and nematode strains 
The following C. albicans strains were used: the reference ATCC 
10231, ATCC 90028 and the clinical isolates C. albicans n. 1s and C. 
albicans n. 1r. The wild-type C. elegans strain N2 was used in all 
experiments and propagate on nematode grow medium (NGM) plates 
containing E. coli OP50 as a food fource [Stiernagel, 2006]. C. albicans 
ATCC 10231 was used for all the experiments with C. elegans. 
The strains of P. aeruginosa used for the antimicrobial assays were: the 
standard non-mucoid ATCC 27853 [Li J. Turnidge et al, 2001] and PAO1, 
the clinical multidrug resistant (MDR) isolates MDR1, MDR2, and MDR3 
and the following strains from Cystic Fibrosis (CF) patients: the mucoid 
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AA11 and non-mucoid TR1 isolated at the onset of chronic lung 
colonization; both mucoid AA43 and TR67 isolated after years of chronic 
colonization, according to what was reported in [Bragonzi et al, 2005; 
Bragonzi et al, 2009]. These CF strains were chosen from the strains 
collection of the CF clinic Medizinische Hochschule of Hannover, Germany 
[Bragonzi et al, 2009]. Mode of action studies and β-galactosidase activity 
measurements were carried out with P. aeruginosa PAO1 carrying plasmid 
pPrsal190 [Rampioni et al, 2007], kindly provided by Prof. Livia Leoni 
(Roma Tre University, Rome, Italy). 
3.3 Circular dichroism (CD) analysis 
CD experiments were performed using a JASCO J-600 
spectropolarimeter with a 1 mm path length cell. The CD spectra of the 
peptides were recorded at 25°C at 0.2 nm wavelength intervals in the 195- 
250 nm range. CD spectra were collected for Esc(1-18) at a concentration of 
100 μM in water and in different mixtures with increasing the TFE/water 
volume ratio. Esc(1-21) was used at a concentration of 5 μM in 10 mM 
sodium phosphate buffer pH 7.4 (NaPB) or in a suspension of lipid vesicles 
composed of phosphatidylethanolamine (PE)/phosphatidylglycerol (PG) (7:3, 
w:w) to mimic the Gram-negative cell membranes. CD data from eight scans 
were averaged. 
3.4 Hemolytic activity 
The hemolytic peptide activity was determined using fresh human 
erythrocytes. The blood was centrifuged and the erythrocytes were washed 
three times with 0.9% NaCl. Peptide solutions were incubated with the 
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erythrocyte suspension (1x10
7
 cells/ml) at 37°C for 2 h. Then, the extent of 
hemolysis was measured on the supernatant, from the optical density at 540 
nm. Hypotonically lysed erythrocytes were used as a standard for 100% 
hemolysis. 
3.5 Determination of the minimal peptide concentration inhibiting 
the growth of free-living microorganisms  
(i) Yeasts: susceptibility testing was performed by the microbroth dilution 
method according to the procedures outlined by the National committee 
for Clinical Laboratory Standards (2001) using sterile 96-well plates. 
Serial 2-fold dilutions of Esc(1-18) in 50 μl of Wing broth (WB) were 
prepared through the wells of a microtiter plate. Afterwards, aliquots 
(50μl) of yeast cells grown to the mid-log phase at 28°C, at a 
concentration of 7x10
4
 colony forming units (CFU)/ml in WB, were added 
to each well. The range of peptide concentration used was 0.5-32 μM. 
Minimal inhibitory concentration (MIC) was determined as the lowest 
peptide concentration at which 100% inhibition of growth was observed 
after 16-18 h at 37°C. 
(ii) Bacteria: Aliquots (50 μl) of bacteria at a concentration of 2x106 
(CFU)/ml in Mueller Hinton broth (MH) were added to 50 μl of MH 
containing the peptide in serial two-fold dilutions. The MIC was 
determined as above-mentioned. 
(iii) To evaluate the potential peptide-induced resistance, multiple exposures 
of the bacterial suspension to serial two-fold dilutions of the peptide or a 
conventional antibiotic (ciprofloxacin) were performed using a diluted 
inoculum (1:10.000), from the bacterial culture grown at ½ MIC. After 15 
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MIC cycles (total duration 30 days), the drug/peptide was removed and 
bacteria were grown for two passages in antibiotic-free medium (20 h 
each). Afterwards, the MIC assay was carried out as described above. 
3.6 Anti-biofilm activity 
Biofilm formation was performed by adapting the procedure described 
in [Ceri et al, 2001; Falciani et al, 2012] using the Calgary Biofilm Device 
(Innovotech, Innovotech Inc. Edmonton, Canada). Briefly, 96-well plates, 
each well containing 150 μl of the bacterial inoculum (1x107 cells/ml) in 
Luria-Bertani (LB) medium, were sealed with 96 pegs-lids on which biofilm 
cells can build up. Afterwards, the plates were placed in a humidified orbital 
incubator at 35°C for 20 h under agitation at 125 rpm. Once the biofilms 
were allowed to form, the pegs were rinsed twice with phosphate buffered 
saline (PBS) to remove planktonic cells. Each peg-lid was then transferred to 
a “challenge 96-well microtiter plate”, each well containing 200 μl of a 
twofold serial dilution of Esc(1-21) in PBS. The “challenge plate” was 
incubated at 37°C for 2 h. Peptide activity on preformed biofilm was 
evaluated by three independent methods: 
(i) Visual observation of bacterial growth. The peg-lid was removed from the 
“challenge plate”, rinsed with PBS, and used to cover a 96-well “recovery 
microtiter plate”, each well containing 200 μl LB. The “recovery plate” 
was sealed, incubated at 37°C for 4 h, and then observed for detection of 
any visible growth of bacteria detached from the peptide-treated biofilm. 
Growth of bacteria in a particular well indicates re-growth of planktonic 
cells from surviving biofilm. Minimum biofilm eradication concentration 
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(MBEC) was defined as the minimum peptide concentration preventing 
re-growth of bacteria from the treated biofilm, within 4 h. 
(ii) Numbering of living bacterial cells after peptide treatment. To determine 
viable cell counts after peptide treatment, pegs were broken from the lid 
and each peg was transferred into an Eppendorf tube containing 500 μl of 
PBS. After sonication to remove bacterial cells from the peg, aliquots of 
bacterial suspension were plated on LB-agar plates for counting. CFU 
were expressed as a percentage with respect to the control (peptide-
untreated biofilms). The minimum bactericidal concentration (MBCb) was 
definied as the lowest peptide concentration required to reduce the number 
of viable biofilm cells of ≥ 3 log10 (99.9 % killing) after 2 h [Harrison et 
al, 2010]. Viable biofilm cells were also determined by the reduction of 
MTT to its insoluble formazan (Fig. 3.1) MTT is a tetrazolium salt which 
is reduced to an insoluble formazan product, by mitochondrial reductases, 
giving a purple color. The intensity of the color is directly proportional to 
the number of viable cells. 
 
Figure 3.1 Reduction of the yellow tetrazole to purple insoluble 
formazan, by metabolically active cells. 
Briefly, after peptide treatment, the peg lid was washed with PBS and used to 
close another 96-well microtiter plate, each well containing 200 μl of 0.5 
mg/ml MTT in PBS. The plate was incubated at 37°C for 4 h. Afterwards, 
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50 μl of 25% sodium dodecyl sulphate (SDS) were added to each well to 
dissolve formazan crystals. Bacterial viability was determined by 
absorbance measurements at 595 nm [Mangoni et al, 2005] and calculated 
with respect to control cells (bacteria not treated with the peptide). 
(iii) Evaluation of biomass. To determine the biofilm biomass, peptide-
treated pegs were washed in PBS, fixed in 99% methanol for 15 min at 
room temperature, and air-dried. Then, by using a 96-well microtiter plate, 
pegs were stained with 200 μl of a CV solution (0.05 % in water). After 20 
min, the excess CV was removed by washing the pegs with water. Finally, 
bound CV was released from pegs by adding 200 μl of 33 % acetic acid. 
The absorbance was measured at 600 nm.  
3.7 Time-killing of free-living microorganisms (yeasts and bacteria) 
(i)Yeasts: The peptide’s effect on the viability of yeast cells was determined 
by the MTT colorimetric method. Briefly, about 1x10
6
 CFU of C. albicans 
ATCC 10231 in 100 μl of 10 mM sodium phosphate buffer (NaPB), pH 
7.4, were incubated at 37°C with Esc(1-18) at different concentrations. At 
different time intervals, samples were centrifuged for 5 min (1,4 x g) and 
resuspended in 100 μl RPMI 1640 medium (Sigma) supplemented with 
0.5 mg/ml MTT. After 2 h incubation at 37°C, formazan crystals were 
solubilized by adding 100 μl of 10 % SDS. The absorbance at 590 nm of 
triplicate samples was measured spectrophotometrically with a microplate 
reader (Infinite M200; Tecan, Salzburg, Austria). Cell viability was 
expressed as percentage of survival with respect to the control (yeast cells 
not treated with the peptide). 
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(ii) Bacteria: about 1x10
5
 or 1x10
6
 CFU in 100 μl PBS (as indicated in the 
Results section) were incubated at 37°C with Esc(1-21) at 0.5 or 1 μM. 
Aliquots of 10 μl were withdrawn at different intervals, diluted in MH, 
and spread onto LB-agar plates. After overnight incubation at 37°C, the 
number of CFU was counted. Controls were run without peptide and in the 
presence of peptide solvent (water). Bactericidal activity was defined as 
the peptide concentration necessary to cause a reduction in the number of 
viable bacteria of ≥ log10 CFU/ml. 
3.8 Peptide’s effect on the viability of hyphae 
RPMI supplemented with 2 mM L-glutamine and 0.165 M 
morpholinepropanesulfonic acid (pH 7.0) was used as the hyphal growth-
promoting (HP) medium for C. albicans [Hawser et al, 1996; Cleary et al, 
2011]. Yeast-form cells of C. albicans ATCC 10231 were collected from 
fresh cultures on Sabouraud agar plates and suspended in HP medium at 
3x10
5
 or 1x10
5
 cells/ml. Each well of a 96-well flat-bottom poly-L-lysine-
coated microplate received 100 μl of Candida suspension. The plate was 
incubated at 37°C for 3 h (Fig. 3.2) or a longer time (12 h and 18 h), 
respectively. 
Figure 3.2 Phase-contrast image of C. albicans ATCC 
10231 hyphae. Hyphae were obtained after 3 h growth 
of 3x104 yeast cells in 100 μl HP medium at 37°C. 
Scale bar is 10 μm long. 
 
The medium in the wells was then discarded and the adhesive Candida 
hyphae were treated with different concentrations of Esc(1-18) (100 μl in 
NaPB) at different time intervals at 37°C. The peptide’s effect on hyphae 
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viability was determined by the MTT method [Islas-Rodriguez et al, 2009]. 
Briefly, peptide-containing NaPB was removed; 100 μl of MTT solution (0.5 
mg/ml in HP medium) were added and the plate was incubated at 37°C for 4 
h. Afterwards, formazan crystals were solubilized by adding 100 μl of 10% 
SDS. The absorbance at 590 nm of triplicate samples was measured. The 
minimal fungicidal concentrations (MFC50 and MFC90) were defined as the 
minimal peptide concentrations causing a reduction in hyphae viability by 
50% and 90%, respectively, within 60 min, compared with the control (cells 
not treated with the peptide). 
3.9 Inhibition of hyphal development 
The peptide’s ability to inhibit hyphal development from yeast budding 
cells was evaluated on C. albicans ATCC 10231. Briefly, 1x10
5
 yeast cells in 
WB were transferred into poly-L-lysine-coated wells of a 96-well plate and 
incubated at 37°C for 3 h in the presence of different concentrations of Esc(1-
18). The inhibition of hyphal development was visualized microscopically 
under an inverted microscope (Olympus CKX41) at x 40 magnification and 
photographed with a Color View II digital camera. 
3.10 Membrane permeabilization of C. albicans and P. aeruginosa 
(i) Sytox Green assay 
a. To asses the ability of Esc(1-18) to alter the membrane permeability of 
yeast cells of C. albicans ATCC 10231, 1x10
6
 CFU in 95 ul of NaPB 
supplemented with 1 μM Sytox Green were loaded into the wells of a 96-
microtiter plate. After 20 min in the dark, 5 ul of peptide were added 
[Marcellini et al, 2009]. The increase in fluorescence, owing to the binding 
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of the dye to intracellular DNA, was measured every 10 min at 37°C in the 
microplate reader (excitation and wavelengths were 485 and 535 nm, 
respectively). Controls were cells without peptide. 
b. In the case of 3 h-grown hyphae, HP medium was removed from each well 
and replaced by 95 μl of NaPB supplemented with 1 μM Sytox Green, as 
above. Also in this case, controls were given by hyphae without peptide. 
c. To assess the ability of Esc(1-21) to alter the bacterial membrane 
permeability of planktonic cells of Pseudomonas, 1x10
6
 cells in 100 μl of 
PBS were mixed with 1 μM Sytox Green for 5 min in the dark. After 
adding the peptide, the increase in fluorescence was measured every 5 min 
as described above. Controls were cells without peptide, whereas the 
maximal membrane perturbation was obtained after treating bacteria with 
the highest peptide concentration used (32 μM) followed by the addition 
of 1 mM ethylenediaminetetraacetic acid (EDTA) + 0,5% Triton X-100 
(final concentration) to completely destabilize the lipopolysaccharide-
outer membrane and solubilize the phospholipid bilayer of the cytoplasmic 
membrane [Uccelletti et al, 2010]. Note that the addition of EDTA + 
Triton X-100 to the bacteria with the highest peptide concentration did not 
induce any change in the fluorescence intensity, thus excluding any 
possible interference between the peptide and the detergent used. 
d. In the case of 20-h preformed biofilm, after 2-h peptide treatment in the 
“challenge microtiter plate” (each well containing 200 μl of a twofold 
serial dilution of Esc(1-21) in PBS supplemented with 1 μM Sytox Green), 
pegs were broken from the lid and each peg was transferred into an 
Eppendorf tube together with the corresponding 200 μl from the 
“challenge well”. After sonication to detach bacterial cells from the peg, 
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the cell suspension of each sample (200 μl volume) was transferred into 
wells of another microtiter plate for fluorescence measurement as 
described above. Also in this case, controls were given by cells without 
peptide, whereas the maximal membrane perturbation was obtained after 
treating biofilm cells with the highest peptide concentration (48 μM), 
followed by the addition of 1 mM EDTA + 0.5% Triton X-100 to dissolve 
the extracellular matrix [Baillie and Douglas, 2000] and make the bacterial 
membranes fully permeable [Uccelletti et al, 2010]. 
(ii) -galactosidase assay. 
The ability of Esc(1-21) to cause more pronounced damage to the 
cytoplasmic membrane of Pseudomonas was determined by measuring the 
extracellular release of β-galactosidase, using ONPG as a substrate 
[Marcellini et al, 2009]. For the planktonic form, P. aeruginosa PAO1 that 
constitutively expresses the β-galactosidase (see 3.2 section) was grown at 
37°C in LB to an OD590 nm of approximately 0.8, washed twice, centrifuged 
for 10 min (1,4 x g) and resuspended in PBS at the same OD. About 1x10
6
 
cells (in 100 μl PBS) were incubated with different concentrations of Esc(1-
21) for 30 min at 37°C. Controls were bacteria without peptide, whereas the 
maximal membrane perturbation was obtained as described for the Sytox 
Green assay on planktonic cells (see 3.10 (i)c section). At the end of the 
incubation time, 2-μl aliquots were withdrawn, diluted 1:100 in LB, and 
spread on LB plates for counting. Afterwards, 450 μl of PBS was added to 
the remaining bacterial suspension, which was passed through a 0.2-μm filter. 
The hydrolysis of 2 mM ONPG, added to the culture filtrate, was recorded at 
420 nm (Fig. 3.3) using a spectrophotometer (UV-1700 Pharma Spec 
Shimadzu). 
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Figure 3.3 β-galactosidase hydrolysis of the colourless ONPG to produce 
galactose and the yellow o-nitrophenol, which absorbs light at 420 nm. 
In the case of preformed biofilm, pegs were broken from the lid of the 
“challenge plate”, transferred into Eppendorf tubes together with the 
corresponding 200 μl from the wells of the “challenge plate”, and then 
sonicated. Then, 2-μl aliquots of the cell suspension were withdrawn and 
diluted as described above, for counting. One ml of PBS was added to the 
sonicated cell suspension, which was filtered; hydrolysis of 2 mM ONPG 
was followed as described above. Controls and maximal membrane 
perturbation were obtained as for the Sytox Green assay on biofilm cells (see 
3.10 (i)d section). 
3.11 Scanning electron microscopy (SEM) on planktonic and biofilm 
cells 
Approximately 1x10
6
 bacterial cells in PBS were treated with the 
peptide at different concentrations for 30 min at 37°C and then fixed with 
2.5% glutaraldehyde in 0.2 M cacodylate buffer (pH 7.2). The samples were 
deposited on glass coverslips of 12-mm diameter. Afterwards, they were 
washed three times in cacodylate buffer, post-fixed with 1% (w/v) osmium 
tetroxide for 1 h, and dehydrated using a graded ethanol series (70; 85; 95%). 
After the passage in 100% ethanol, the samples were air-dried (overnight) 
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and gold coated by sputtering (SCD 040 Balzers device, Bal-Tec). The 
samples were examined with a scanning electron microscope (SEM) (FEI 
Quanta Inspect FEG, USA). 
To visualize biofilm-colonized pegs, after 20 h of biofilm formation by 
P. aeruginosa on Calgary microtiter plates, pegs were broken from the lid, 
washed with PBS and fixed with 2.5% glutaraldehyde in 0.2 M cacodylate 
buffer. Pegs were placed in this solution at 4°C for 16 h. Following this 
fixing step, the pegs were washed in 0.2 M cacodylate buffer for 
approximately 10 min. Then, they were post-fixed, dehydrated, and gold 
coated as described above. The pegs were examined under the same scanning 
electron microscope and those portions containing bacterial cells were 
photographed. 
3.12 Measurement of reactive oxygen species (ROS) in C. albicans 
The formation of endogenous ROS in C. albicans yeast and hyphal 
forms was measured by a fluorometric assay with DCFH-DA according to 
[Bland et al, 2001; François et al, 2006]. 
After diffusion into the cell, DCFH-DA is deacetylated by cellular 
esterases to a non-fluorescent compound, 2’, 7’-dichlorodihydrofluorescein 
(DCFH) which is rapidly oxidized by ROS to the highly fluorescent 2’, 7’-
dichlorofluorescein (DCF) (Fig. 3.4). The fluorescence intensity is 
proportional to the ROS levels within the cell cytosol. 
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Figure 3.4 Detection of ROS production using 
DCFH-DA. DCFH-DA enters the cells and is 
cleaved by intracellular esterases to DCFH and 
oxidized by ROS to the highly fluorescent 
molecule DCF. 
Briefly, yeast culture in Sabouraud was centrifuged and resuspended in 
NaPB containing 20 μM DCFH-DA. After 30 min incubation at 37°C in the 
darkness, the cell culture was centrifuged, washed once with NaPB to remove 
DCFH-DA and then resuspended in NaPB. About 1x10
6
 cells in 95 μl were 
transferred into wells of a microtiter plate and mixed with 5 μl of peptide at 
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different concentrations or water (in control samples) and incubated at 37°C. 
In the case of hyphal cells, after their formation on poly-L-lysine-coated 
wells (as described above), 20 μM DCFH-DA in NaPB was added (100 μl 
volume). After 30 min incubation at 37°C, the probe was removed and the 
cells were washed with NaPB. Then, 100 μl of peptide solution in NaPB at 
different concentrations or NaPB without peptide (in control samples) were 
added to each well. Fluorescence emitted by the cells was measured with the 
microplate reader (excitation and emission wavelengths were 485 and 535 
nm, respectively) after 10, 20, 30, 60, 120 and 180 min of incubation. As a 
positive control for ROS production, both yeast and hyphal cells were treated 
with 2 mM H2O2 [Phillips et al, 2003] and the results were read after 30, 60, 
120 and 180 min incubation time. 
3.13 Apoptosis assay on C. albicans 
Apoptosis in Candida cells was assessed by using the HT TiterTACS 
kit (Trevigen, Gaithersburg, MD) which allows quantitative colorimetric 
analysis in both adherent and suspension cell cultures. This assay is based on 
the incorporation of biotinylated nucleotides by the terminal 
deoxynucleotidyl transferase at the 3’ OH end of the DNA fragments that are 
formed during apoptosis. The biotinylated nucleotides were detected by using 
a streptavidin-horseradish peroxidase with a specific colorimetric substrate. 
TACS-Nuclease was used to generate DNA breaks in every cell, providing an 
appropriate positive control. Briefly, both yeast and hyphal cells were treated 
or not with 16 μM of Esc(1-18) in NaPB for 20 and 60 min. Afterwards, cells 
were washed twice in PBS and fixed in 3.7% formaldehyde, post-fixed in 
methanol and stored at +4°C until required. Cell permeabilization and 
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TUNEL (terminal dUTP Nicked End Labelling) reaction were carried out 
according to the kit’s manufactures. 
3.14 Staining protocols: fluorescent probes for microscopic assessment 
of peptide’s distribution and fungal membrane integrity 
To visualize, in a single preparation, the distribution of Esc(1-18) and 
to detect, at the same time, the membrane permeabilization induced by the 
peptide on both yeast and hyphal forms of Candida, we used rho-Esc(1-18) 
and the two following fluorochromes: (i) the double-stranded DNA-binding 
dye DAPI, to stain the nuclei of all cells and (ii) the green fluorescent probe 
Sytox Green, which is unable to traverse the cytoplasmic membrane of intact 
cells. After exposure of yeast cells (1x10
6
 CFU in NaPB) to 16 μM rho-
Esc(1-18) (100 μl as a final volume in a 1.5 ml eppendorf tube) for 30 min at 
37°C, the microbial culture was centrifuged, washed three times with NaPB 
and incubated with 100 μl of 1 μM Sytox Green (in NaPB) for 15 min at 
room temperature. The sample was centrifuged as described above and 
washed three times with NaPB. Afterwards, 100 μl of DAPI solution (10 
μg/ml in NaPB) were added [Mangoni et al, 2004]. After 15 min at room 
temperature, the sample was centrifuged to remove DAPI solution, and 
washed three times. The pellet was resuspended in a drop of NaPB and 
poured onto a glass slide which was further covered with a round cover glass. 
The slide was then examined by phase-contrast and fluorescence microscopy. 
Both phase-contrast and fluorescence images were recorded using the 
Olympus optical microscope equipped with an oil-immersion objective 
(x100). 
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In the case of hyphae, 96-well glass bottom microplates (MGB096-1-2-
LG-L, Matrical Bioscience Spokane WA, USA) were used and coated with 
poly-L-lysine. More precisely, 3x10
4
 yeast cells in HP medium were added to 
each single well and the plate was incubated at 37°C for 3 h to permit hyphal 
development. Incubation with 16 μM of rho-Esc(1-18) (100 μl final volume 
in NaPB) was carried out for 30 min at 37°C. The peptide solution was then 
removed and the wells were washed three times with NaPB. Afterwards, 
Sytox Green solution in NaPB was added to single wells (100 μl final 
volume). After 15 min at room temperature, Sytox Green was removed, and 
each well was washed three times before adding 100 μl of DAPI solution. 
After 15 min at room temperature and appropriate washings, 50 μl of NaPB 
were added to each well before observation under the inverted microscope at 
x 100 magnification. In all cases, controls were run in the absence of peptide. 
3.15 C. elegans infection 
Freshly grown Candida cells were picked from a single colony and 
inoculated into 2 ml of yeast extract-peptone-dextrose (YPD) broth. Cells 
were grown overnight with agitation at 28°C. Fungal lawns used for C. 
elegans infection assays were prepared by spreading 100 μl of the overnight 
culture of C. albicans (diluted 1:100 in distilled water) on brain heart 
infusion (BHI) agar plates. The plates were then incubated for approximately 
20 h at 28°C before being seeded with adult hermaphrodite nematodes from a 
synchronized culture grown at 16°C [Stiernagel, 2006]. About 100-200 
worms were washed with M9 buffer [Stiernagel, 2006] and placed in the 
middle of C. albicans lawns. The infection was performed at 25°C for 20 
minutes. 
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3.16 Worm survival assay 
The infected worms were washed several times with M9 buffer to 
remove C. albicans cells from their surface. Twenty worms were then 
transferred into plates (3-cm diameter) containing 2 ml of liquid medium 
(79% M9, 20% BHI, 10 μg/ml cholesterol and 90 μg/ml kanamycin) 
according to [Breger et al, 2007]. The peptide was either added to the plates, 
or omitted as indicated. The plates were incubated at 25°C and examined for 
worm survival after 24 h. Plates were hand shaken and worms were 
considered to be dead if they did not respond to being touched by a platinum 
wire pick. Living nematodes maintain a sinusoidal shape, whereas dead 
nematodes appear as straight, rigid rods as the corpses become filled with 
fungal cells [Moy et al, 2006]. The experiments were done in triplicate. 
3.17 Peptide’s effect on the number of yeast cells and their switch to 
the hyphal form, within the nematode intestine 
Twenty infected nematodes in triplicate were treated (or not in case of 
controls) with the peptide at 25°C for 24 h. afterwards, for each replicate, 
worms were broken with 50 μl of M9 buffer-1% Triton X-100. Appropriate 
dilutions of whole-worm lysates were plated on YPD agar plates for colony 
counts after two days of incubation at 30°C. The experiments were performed 
a minimum of three times. In parallel, to evaluate the effect of Esc(1-18) on 
the morphology of fungal cells, peptide-treated and untreated infected worms 
were mounted onto pads of 3% agarose in M9 buffer supplemented with 20 
mM sodium azide to paralyze them. Animals were then observed under a 
Zeiss AXIOVERT25 microscope and photographed with a Zeiss AxioCam 
camera using Axiovision 4.6 (Zeiss) software. 
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In another set of experiments, infected nematodes were treated with 25 
μM rho-Esc(1-18) for 3 h and then observed by fluorescence microscopy as 
reported above. 
3.18 Statistical analysis 
Data are presented as mean ± SD, and the Student’s test (GraphPad 
Prism 4.0 software) was used to determine the statistical significance between 
experimental groups. The difference was considered significant if the p-value 
was less than 0.05. 
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4. RESULTS 
4.1 Structural properties of the Esc(1-18) and Esc(1-21) fragments 
Table 1 Primary structure of the fragments. 
Peptide Sequence 
Esc(1-18) GIFSKLAGKKLKNLLISG-NH2 
Esc(1-21) GIFSKLAGKKIKNLLISGLKG-NH2 
 
CD spectra of Esc(1-18) (whose amino acidic sequence is indicated in 
Table 1) dissolved in water and in different water/TFE solutions are shown in 
Fig. 4.1. The helicity degree increased with increasing the TFE content. The 
maximum helicity was achieved in the 40% v/v TFE/water solution [Manzo 
et al, 2012]. 
 
Figure 4.1 Circular dichroism spectra of Esc(1-18) in water and in different 
TFE/water (v/v) mixtures. 
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NMR analysis showed that in 50% TFE solution, the N-terminal part of 
the peptide, encompassing the first 11 residues, displayed a right-handed 
helical conformation, whereas the C-terminal portion was basically unfolded 
[Manzo et al, 2012]. This peptide conformation is clearly amphipathic, with 
the hydrophobic and hydrophilic residues neatly arranged on the opposite 
sides. The only interruption of this global amphipathicity occurs right at the 
end of the helical region, where the residues K10 and L11 appears to be 
dislocated (Fig. 4.2). 
 
 
 
 
 
 
Figure 4.2 3D NMR structure of the first 11 amino 
acids of the N-terminal Esc(1-18) peptide in a 50% 
v/v TFE/water solution. Hydrophilic and 
hydrophobic residues are represented in blue and 
yellow, respectively [Manzo et al, 2012]. 
 
Preliminary data about the structural properties of Esc(1-21) (whose 
amino acid sequence is showed in Table 1) were also obtained by means of 
CD analysis. While the peptide was disordered in solution (NaPB), it adopted 
an α-helical structure when associated with PE/PG vesicles mimicking the 
4. RESULTS 
48 
 
Gram-negative cell membrane (data not shown). Similarly to the Esc(1-18) 
peptide, the side chains are oriented in an amphiphilic arrangement, with all 
charged residues segregated to one face of the helix (data not shown). 
4.2 Anti-Candida activity of Esc(1-18) 
4.2.1 In vitro activity 
4.2.1.1 Anti-Candida activity of all-L/all-D Esc(1-18) enantiomers 
The activity of Esc(1-18) against C. albicans yeast cells was evaluated 
by the microdilution broth assay using a standard inoculum of 3.5 x 10
4
 
CFU/ml. Against all the strains tested, the MIC value was 4 μM with the 
exception of C. albicans n.1r strain. Note that the same MIC value was 
obtained when samples were incubated at 28°C instead of 37°C (data not 
shown). In our experiments the reference strain ATCC 10231 was selected as 
a representative strain to perform further additional studies, since it is a well-
characterized standard strain with the ability to grow under both yeast and 
hyphal forms under the experimental conditions. As most of the experiments 
described below required a higher number of yeast cells, an inoculum of 
1x10
6
 and 1x10
7
 CFU/ml was also used to determine the MIC which was 
found to be directly related to cell number: 16 and 64 μM, respectively. 
In order to confirm a fungicidal activity of Esc(1-18), a killing kinetics 
study was carried out on the 3 h-grown hyphae after peptide treatment at 
different concentrations, by the MTT colorimetric assay. A dose-dependent 
candidacidal activity was observed, with approximately 80% reduction in cell 
survival within the first 20 min at 16 μM (Fig. 4.3A), whereas approximately 
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90% killing of hyphal population was recorded after a longer incubation time 
(60 min) at the same concentration of 16 μM (MFC90). 
Furthermore, to find out whether the killing activity was a 
stereospecific mechanism mediated by recognition of chiral targes, we also 
used the all-D enantiomer of Esc(1-18). Interestingly, it was found to display 
the same MIC (4 μM) of the all-L isoform, as well as a similar fungicidal 
activity (Fig. 4.3B). 
 
Figure 4.3 killing kinetics of all-L Esc(1-18) (panel A) and all-D Esc(1-18) (panel B) on C. albicans 
ATCC 10231 hyphal cells in NaPB. Hyphae, obtained after 3 h growth of 3x104 yeast cells, were 
incubated with different peptide concentrations at 37°C. Data points represent the mean of triplicate 
samples ± SD from a single experiment, representative of three independent experiments. The killing 
activity was determined by the colorimetric MTT assay and is expressed as percentage with respect to 
the control sample (cells not treated with the peptide) at the corresponding time intervals. Peptide 
concentrations used are the following: 0.25 μM (◊); 0.5 μM (○); 1 μM (●); 2μM (□); 4 μM (∆); 8 μM 
(▲); 16 μM (■); 32 μM (♦). 
Note also that both all-L and all-D Esc(1-18) showed similar killing 
kinetics also against the yeast cells of this pathogen (see Luca et al, 2013a. 
Fig. 1a). Interestingly, when the peptide was tested on the fungal biofilm 
obtained after 12 h or 18 h growth of hyphae (Fig. 4.4 upper panels), its 
efficacy to cause 50% and 90% fungal killing was found to be only 4-fold or 
8-fold lower than that recorded against 3h-grown hyphae (see Luca et al, 
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2013a. Table 2). Phase-contrast images of Candida biofilm treated or not 
treated with the peptide at its MFC90 (64 μM), after MTT colorimetric assay, 
are reported in Fig. 4.4 (lower panels). 
 
Figure 4.4 Phase-contrast 
images of Candida biofilm 
obtained after 12 h and 18 h 
growth of yeast cells at 37°C 
(upper panels). The peptide’s 
effect on the viability of 12 h-
grown biofilm is shown after 
the MTT colorimetric assay 
(lower panels). The black 
color in the peptide-untreated 
(control) sample indicates 
viable cells, whereas the 
transparency in the peptide-
treated sample, indicates the 
presence of dead yeast and 
hyphal cells. Scale bar is 20 
μm long. 
 
 
 
4.2.1.2 Membrane perturbation of both yeast and hyphal forms 
We have analyzed whether Esc(1-18) was able to alter the membrane 
permeability of Candida hyphae by monitoring the intracellular influx of 
Sytox Green upon peptide’s addition. Sytox Green (MW 900 Da) is a cationic 
dye which is not able to enter intact cells, but only those having membrane 
breakages whose size is enough to allow its entrance. 
12 h growth 18 h growth
treated
12 h growth
control
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Figure 4.5 Membrane permeabilization of C. albicans ATCC 10231 hyphae obtained after 3 h growth 
of yeast cells (3x104 cells per well). Samples were incubated with 1 μM Sytox Green in NaPB. Once 
basal fluorescence reached a constant value, the all-L Esc(1-18) (panel A) or all-D Esc(1-18) (panel B) 
was added (arrow, t = 0) and changes in fluorescence (λexc = 485 nm, λems = 535 nm) were monitored 
for 60 min at different intervals. Peptide concentrations used are the following: 0.25 μM (◊); 0.5 μM 
(○); 1 μM (●); 2μM (□); 4 μM (∆); 8 μM (▲); 16 μM (■); 32 μM (♦). Control (*) is given by cells 
without peptide. Data points represent the mean of triplicate samples from a single experiment, 
representative of three independent experiments. 
The all-L Esc(1-18) peptide disturbed the structural organization of the 
membrane of the filamentous form of Candida in a concentration-dependent 
manner (Fig. 4.5A) which directly correlates with its killing activity. 
Likewise to the results found for the all-L peptide, a dose-dependent 
membrane perturbation was detected for the all-D enantiomer, with a kinetic 
overlapping that of the all-L peptide (Fig. 4.5B), thus excluding the 
involvement of specific/chiral components of the lipid membrane in the 
peptide-induced membrane perturbation process. 
A very similar outcome for both Esc(1-18) enantiomers was also 
obtained on the yeast cells (data not shown). 
In our experiments, the polyene antifungal drug amphotericin B was 
also used for comparison. This drug has the ability to interact with membrane 
constituents and to induce pore formation [Hong et al, 1999; Younsi et al, 
2000] causing a fungicidal activity in 2-3 h, depending on the strain [Canton 
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et al, 2004]. We have obtained only a modest increase in fluorescence 
intensity within the first 20 min after the addition of amphotericin B, even 
when used at a concentration 64-fold higher the MIC. However, it gradually 
increased with time reaching its maximum value, which was found to be 
identical to that obtained with 16 μM Esc(1-18), within 3 h (data not shown). 
ROS determination – We evaluated whether the membrane 
perturbation was the final result of more complex intracellular signaling 
events, such as the production of reactive oxigen species (ROS) whose 
accumulation would rapidly lead to oxidation of phospholipids and other 
macromolecules leading to membrane damage. For that purpose, we analyzed 
the peptide’s ability to induce ROS formation by using the cell permeant 
fluorigenic dye DCFH-DA (see 3.12 section). 
As illustrated in Fig. 4.6, a very low level of fluorescence intensity was 
recorded in yeast (Fig. 4.6A) and hyphal cells (Fig. 4.6B) only after a long 
incubation time with the peptide (120 and 180 min) compared to the results 
found when these cells were exposed to the ROS-inducer H2O2, whose 
fungicidal effect was previously found to occur after ~3 h incubation [Phillips 
et al, 2003]. Overall, our results indicate a lacking production of ROS by 
Esc(1-18)-treated Candida, at the killing time (10-20 min) and only a rather 
weak production of ROS when yeast cells are treated with the peptide for a 
much longer time (3h). 
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Figure 4.6 Effect of Esc(1-18) on the 
production of ROS by yeasts (panel A) 
and hyphal cells (panel B). 
(A) Logarithmically growing C. albicans 
cells (1x106) were suspended in NaPB, 
preincubated with 20 μM DCFHDA at 
37°C and then treated with the peptide at 
different concentrations: 16 μM (red 
rhomb); 8 μM (black square) and 4 μM 
(green triangle) for 3 h. Fluorescence 
emitted by the cells was recorded as 
reported in 3.12 section. As a positive 
control for ROS production, cells were 
treated with 2 mM H2O2 (black circle) 
and the results were read after 30, 60, 
120 and 180 min incubation time. 
Fluorescence of control samples (cells 
pre-incubated with the probe, but 
without any treatment) at any time was 
subtracted from all values. 
(B) Hyphal cells were incubated with 
DCFHDA in NaPB for 30 min. 
Afterwards, the probe was removed and 
cells were treated with the peptide or 
H2O2, as above. The results are the mean 
of triplicate samples from a single 
experiment representative of three 
independent experiments. 
 
Cell apoptosis – To know if Esc(1-18) treatment of Candida cells 
induced a programmed cell-death, both yeast and hyphal cells were assessed 
for apoptotic markers i.e. DNA fragmentation, detected by TUNEL assay 
(see 3.13 section). As shown in Fig. 4.7 (panels A and B), no significant 
differences were found between peptide-treated and untreated cells. We 
chose 16 μM Esc(1-18), because this concentration was found to cause 
approximately 80% killing of both yeast and hyphal cells within 20 min. 
Note that similar results were obtained after a longer incubation time with the 
peptide (60 min, data not shown), hence excluding apoptosis as a possible 
cell death mechanism caused by Esc(1-18). 
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Figure 4.7 Quantitation of 
apoptosis in yeast (panel A) and 
hyphal (panel B) cells after 
treatment with 16 μM Esc(1-18) 
at 37°C for 20 min using the 
HT-TiterTACS kit. Cells were 
fixed and labeled according to 
the protocol prior to colorimetric 
analysis. Afterwards, they were 
incubated with TACS-
SapphireTM substrate and the 
colorimetric reaction was 
stopped with 0.2N HCl after 30 
min and measured at 450 nm. 
Untreated cells were those not 
treated with the peptide; positive 
control was given by nuclease 
treated cells. The results are the 
mean of triplicates ± SD from a 
single experiment, representative 
of three independent 
experiments. (*) indicates p < 
0.01 versus untreated cells. Note 
that no statistical significance 
was found between peptide-
treated and untreated samples. 
 
 
Importantly, these results are in line with the lacking production of 
ROS, whose accumulation is one of the phenotypical markers of yeast cells 
undergoing apoptosis [Madeo et al, 1999]. 
4.2.1.3 Fluorescence studies 
To visualize both the peptide’s distribution and alteration of the cell 
membrane integrity, either yeast or hyphal forms were treated with 16 μM of 
rho-Esc(1-18), followed by DAPI (for nuclei detection) and Sytox Green 
staining. We noted that rhodamine did not affect the anti-Candida activity of 
Esc(1-18) since the MIC value of rho-Esc(1-18) was equal to that of the 
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unlabelled peptide. As shown in Fig. 4.8, rho-Esc(1-18) appeared to be 
distributed evenly over the yeast cells and hyphae, and the membrane 
perturbation (as detected by the green fluorescence of Sytox Green) occurred 
in a similar manner along the entire cell structure. 
 
Figure 4.8 Detection of peptide distribution and membrane perturbation of both C. 
albicans ATCC 10231 yeast cells and hyphae. Cells were treated with 16 μM of 
rho-Esc(1-18) for 30 min and then stained with DAPI and Sytox Green as described 
in 3.14 section. In all cases, controls were run in the absence of peptide. Samples 
were then examined by light (a) and fluorescence microscopy (b, c, d) at x 100 
magnification. Blu (b), red (c) and green (d) fluorescence indicate the distribution of 
DAPI, the labeled-Esc(1-18) and Sytox-Green, respectively. Scale bars are 5 μm 
long and apply to all images. 
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4.2.1.4 Inhibition of hyphal development 
It is largely known that C. albicans hyphae represent the most virulent 
phenotype of this pathogen and that the ability of a drug to prevent the 
morphological change of fungal cells from their budding shape into the 
filamentous form would be extremely advantageous. We therefore studied the 
capability of Esc(1-18) to block hyphal formation and found out that this 
effect was more pronounced when 1x10
6
 CFU/ml were used. Indeed, a clear 
inhibition of germ tubes was detected after a 3 h treatment of yeast cells with 
sub-inhibitory concentrations of Esc(1-18) (Fig. 4.9). More precisely, the 
minimal peptide concentration causing such inhibition was found to be 4 μM, 
corresponding to ¼ the MIC (16 μM with 1x106 CFU/ml). Importantly, this 
effect was maintained up to 24 h, despite the achieved high cell density, due 
to cell proliferation (data not shown). 
Figure 4.9 Effect of Esc(1-
18) on the development of 
C. albicans hyphae. Freshly 
grown yeast cells (1x105 in 
100 l WB) were put into 
the wells of a 96-well 
microtiter plate and 
incubated with different 
concentrations of peptide at 
37°C. After 3 h, samples 
were observed under an 
inverted microscope at 40 x 
magnification and 
photographed. Scale bar is 
20 μm long and applies to 
all images. 
 
Interestingly, when the all-D enantiomer of Esc(1-18) was used, no 
inhibition of hyphae formation was detected at concentrations below its MIC 
0.5 M 1 M
2 M 4 M 8 M
control
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(Fig. 4.10) which was equal to that of the all-L peptide, 4 μM. This suggests 
that a specific mechanism (i.e. inhibition of a unique pathway) is presumably 
subtending such event, rather than being the result of a global insult to the 
cells. 
 
Figure 4.10 Effect of all-D Esc(1-18) on the development of hyphal form of C. albicans ATCC 10231. 
Freshly grown yeast cells (1x105 in 100 μl WB) were put into the wells of a 96-well microtiter plate 
and incubated with different concentrations of the peptide at 37° C. After 24 h, samples were observed 
under an inverted microscope at 40 x magnification and photographed. Scale bar is 20 μm long and 
applies to all images. 
 
4.2.2 In vivo activity 
4.2.2.1 Peptide effect on C. elegans survival 
When infected wild-type nematodes were transferred to liquid medium 
(see 3.16 section), yeast cells underwent hyphal development, presumably 
induced by environmental factors of the animal’s intestine. This usually 
results in a very aggressive infection leading to worm lethality in about 40 h. 
Indeed, hyphae penetrate and destroy the cuticle to finally pierce through the 
body (Fig. 4.11). In our case, Esc(1-18) was added to the worms, at 50 μM, 
after 20 min of their exposure to Candida. Interestingly, the peptide increased 
C. elegans survival by more than 50% within 24 h (Fig. 4.12A), causing 
control 1/8 MIC 1/4 MIC 1/2 MIC MIC
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approximately 40% reduction in the number of CFU within the nematode’s 
intestine (Fig. 4.12B). 
 
Figure 4.11 A representative nematode, 40 h after infection with C. albicans ATCC 10231. The sample 
was stained for 5 min with 5 mM Calcofluor White which is a specific cell-wall probe. Hyphae 
protruding from the cuticle are clearly visible in the zoom. 
 
Figure 4.12 Effect of Esc(1-18) on the 
survival of nematodes (panel A) and 
the number of live Candida cells 
within the worm’s gut (panel B). 
(A) Survival of infected C. elegans 
upon peptide treatment at 50 μM 
[INF+Esc(1-18)] was analyzed after 24 
h in comparison with untreated 
infected nematodes (INF). Control 
uninfected worms treated with the 
peptide [UI+Esc(1-18)] exhibited 
100% viability. (*) indicates p < 0.05 
compared to values from INF. (B) 
CFU were determined in the gut of 20 
live worms after 24 h of peptide 
treatment. Infected nematodes not 
treated with the peptide (INF) were 
included for comparison. The reported 
values represent the means of at least 
three independent experiments; the 
error bars indicate SD. 
 
*
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4.2.2.2 In vivo inhibition of hyphal development and peptide 
localization 
In line with our in vitro results, Esc(1-18) dramatically hampered 
hyphae formation within the worm’s gut, in 3 h (Fig. 4.13A). In order to 
accurately assess the in vivo distribution of the peptide, the rho-Esc(1-18) 
analog was used. As illustrate in Fig. 4.13B, the peptide was homogeneously 
confined to the worm’s intestinal lumen and uniformly associated with the 
cell perimeter of Candida cells. 
Figure 4.13 Panel A: morphology of Candida cells within the gut of a representative infected animal, 
after 3 h treatment with 50 μM Esc(1-18) (T). A representative infected nematode not treated with the 
peptide (UT) is included for comparison. Arrows indicate germ tube formation or yeast budding cells in 
the untreated or peptide-treated sample, respectively. Scale bar is 8 μm long. Panel B: in vivo 
distribution of rho-Esc(1-18). Nematodes were infected with C. albicans ATCC 10231 yeast cells for 
20 min and then treated with 25 μM of the labeled peptide. Fluorescence photomicrograph of a 
representative worm, 3 h after the addition of the peptide at 25°C. The red fluorescence indicates the 
peptide distribution within the worm’s intestinal lumen around the fungal cells.  
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4.3 Anti-pseudomonas activity of Esc(1-21) 
4.3.1 Antimicrobial activity on planktonic cells 
First of all, we evaluated the possible tendency of Esc(1-21) to induce 
resistance against P. aeruginosa (see 3.5 (iii) section), a bacterial species that 
frequently develops resistance against different conventional antibiotics. To 
this end, we performed multiple exposures of the bacterial suspension to 
serial two-fold dilutions of the peptide or a conventional antibiotic, i.e. 
ciprofloxacin, that is normally used against P. aeruginosa human infections 
and that is known to induce resistance. 
 
 
Figure 4.14 P. aeruginosa PAO1 resistance induced by Esc(1-21) (●) 
and ciprofloxacin (■). The double arrow indicates drug removal. (●) 
and (■) indicate MIC values after drug removal. 
Interestingly, after 11 cycles of exposure to ciprofloxacin, the MIC of 
this antibiotic was found to be 32-fold higher than the initial value, whereas 
the MIC of Esc(1-21) increased by only 4-fold (Fig. 4.14). Moreover, if, after 
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15 cycles, drugs were removed, bacteria were grown in the absence of them 
and subsequently re-exposed to ciprofloxacin or Esc(1-21), the MIC 
remained 32-fold higher or went back to the initial value, respectively, 
indicating that Esc(1-21) does not induce resistance. 
The activity of Esc(1-21) in inhibiting bacterial growth in liquid 
medium was tested on reference P. aeruginosa strains (ATCC 27853 and 
PAO1), MDR-clinical isolates, and strains from CF patients. The peptide had 
the same activity against all the microorganisms tested, with a MIC value of 
4 μM except for MDR2 (8 μM). 
We then performed killing kinetics experiments in PBS. The peptide 
caused approximately 99.9% killing of the reference PAO1 strain (Fig. 4.15) 
within 15 min, at a concentration of 1 μM. Similar results were obtained with 
all the other strains under study (data not shown) thus excluding the 
inhibition of intracellular processes (e.g. DNA, protein or cell wall synthesis) 
as the major mechanisms underlying the bactericidal activity of Esc(1-21). 
Figure 4.15 Time-kill curves of 
Esc(1-21) on P. aeruginosa 
PAO1 strain. Bacteria (1x106 
CFU/ml) were incubated with 
0.5 μM (▲) or 1 μM (■) of 
peptide in PBS at 37°C. The 
control (●) is given by bacteria 
without peptide. Data points 
represent the mean of triplicate 
samples ± SD from a single 
experiment, representative of 
three independent experiments. 
The dotted line indicates 99.9% 
bacterial killing. 
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4.3.2 Anti-Biofilm activity 
The activity of Esc(1-21) on 20-h pre-formed biofilm of P. aeruginosa 
ATCC 27853 was tested by using three different methods (see 3.6 section): 
(i) visual observation of bacterial growth; (ii) evaluation of living bacterial 
cells after peptide treatment, and (iii) estimation of the peptide’s effect on the 
bacterial biomass. 
The minimum peptide concentration able to inhibit re-growth of 
bacteria from peptide-treated biofilm (MBEC) was found to be 6 μM. 
Moreover, as indicated by the results of colony counts of biofilm cells or the 
MTT reduction assay (see 3.6 (ii) section) the peptide was found to cause a 3-
log10 reduction in the number of viable biofilm cells at 12 μM, a 
concentration 2-fold higher the MBEC. However, when CV staining was 
performed, we obtained from 15 to 32% biofilm biomass at those peptide 
concentrations giving rise to almost total microbial death (from 48 to 12 μM, 
respectively), suggesting that such a percentage was only related to the 
presence of lifeless biological material (see Luca et al, 2013b. Table 3 and 
Table 4). 
4.3.3 Mode of action 
4.3.3.1 Membrane perturbation assays and SEM 
The capability of Esc(1-21) to perturb the cytoplasmic membrane of 
planktonic cells of P. aeruginosa PAO1 was monitored by the Sytox Green 
assay. The data revealed that the membrane perturbation occurs in a dose-
dependent manner and within the first 15 min from peptide addition, with a 
kinetic overlapping that of the microbial killing (Fig. 4.16). 
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Figure 4.16 Effect of Esc(1-21) on the membrane-perturbation of the planktonic form 
of P. aeruginosa PAO1. Cells (1x107 CFU/ml) were prepared as described before (see 
3.10 (i)c section). After peptide addition (arrow, t = 0) changes in fluorescence were 
monitored and plotted as the percentage of the maximal membrane perturbation. Data 
points represent the average values of three independent experiments, with SD not 
exceeding 2.5%. Peptide concentrations used were the following: 0.125 μM (hyphen); 
0.25 μM (diamond); 0.5 μM (square); 1 μM (filled circle); 2 μM (triangle); 4 μM 
(cross); 8 μM (filled triangle); 16 μM (filled square); 32 μM (filled diamond). Control 
(circle) is given by bacteria without peptide. 
 
Note that in order to get an optimal detection of membrane-perturbation 
by the Sytox Green assay a higher number of bacterial cells (1x10
7
 CFU/ml) 
was needed compared to the regular amount (1x10
6
 CFU/ml) used for MIC 
and killing kinetic assays. 
However, to directly compare the killing and the membrane-
perturbation activities of Esc(1-21), we performed both assays using the same 
number of cells (1x10
7
 CFU/ml) and incubation time (Fig. 4.17A). 
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As reported in Fig. 4.17A, the percentage of cell viability gradually 
decreased at increasing peptide concentrations, in parallel with an increasing 
membrane perturbation. Moreover, to expand our knowledge on the extent of 
membrane lesions induced by the peptide, we assessed the release of large 
intracellular compounds, such as the cytoplasmic β-galactosidase, from 
peptide-treated cells. To this end, a recombinant Pseudomonas strain 
constitutively expressing this enzyme, was used (see 3.10 (ii) section). Esc(1-
21) provoked ~50-60% enzyme leakage at those concentrations (from 8 to 32 
μM) causing the complete microbial death (Fig. 4.17A). Hereafter, to directly 
observe the peptide’s effect on the morphology of bacterial cells, we used 
scanning electron microscopy. Untreated bacteria appeared smooth, whereas 
cells treated with Esc(1-21) elicited a remarkable modification of the cell 
shape with the formation of blebs (pustules) and cell debris arising from them 
(Fig. 4.17B). 
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Figure 4.17 Effect of Esc(1-21) on the viability, membrane perturbation and morphology of the 
planktonic form of P. aeruginosa PAO1. Planktonic cells (1x107 CFU/ml in PBS) were incubated with 
the peptide at different concentrations for 30 min at 37°C. (A) The percentage of surviving CFU (black 
bars) is given with respect to the control (bacteria not treated with the peptide). Membrane perturbation 
was evaluated by the Sytox Green (white bars) and β-galactosidase (gray bars) assay. The Sytox Green 
fluorescent signal and the β-galactosidase enzymatic activity were expressed as percentage with respect 
to the maximal membrane perturbation obtained after cell lysis (see 3.10 (i)c section). All data points 
represent the means of three independent measurements ± SD. (B) Scanning electron microscopy of 
cells treated at 8 μM (causing ~100% killing, as shown in A). Controls are cells not treated with the 
peptide. 
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The ability of Esc(1-21) to cause damages on 20-h biofilm cells was 
also studied by both the Sytox Green and β-galactosidase assays, after 2 h 
peptide treatment (Fig. 4.18A). Interestingly, we obtained similar results to 
those found for the free living form, although a weaker damage to the cell 
membrane was recorded, as demonstrated by the minor leakage of β-
galactosidase at those peptide concentrations causing ~100% microbial 
killing. Moreover, as evinced from electron microscopy analysis (Fig. 4.18B) 
protrusions from the cells surface were observed, with an evident 
disintegration of the extracellular matrix, becoming less packed and thinner, 
confirming the results obtained by the CV staining (see 4.3.2 section). 
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Figure 4.18 Effect of Esc(1-21) on the viability, membrane perturbation and morphology of the 20-h 
biofilm growth of P. aeruginosa PAO1. Bacterial biofilms grown on pegs were treated with the peptide 
at different concentrations for 2 h at 37°C. (A) The percentage of surviving biofilm cells (black bars) 
and membrane perturbation measured by using Sytox Green (white bars) and β-galactosidase (gray 
bars) assays were expressed as described for the planktonic cells. All data points represent the means of 
three independent measurements ± SD. (B) Scanning electron microscopy of biofilm cells treated at 24 
μM (causing ~95% killing, as shown in A). Controls are cells not treated with the peptide. 
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4.4 Hemolytic activity 
The ratio between antimicrobial and hemolytic activity is defined as the 
therapeutic index. It is necessary for AMPs to have a high therapeutic index, 
which indicates a high antimicrobial potency but low citotoxicity. 
Both Esc(1-18) and Esc(1-21) peptides showed a very weak activity 
against human erythrocytes, causing approximately 10% hemolysis at a 
concentration 16-fold higher the MIC (64 μM) and were practically not 
hemolytic at lower concentrations. 
As mentioned above, the selectivity of AMPs towards microbial cells 
with respect to mammalian ones mainly depends of the different lipid 
composition between their membranes. Specifically, microbial membranes 
are much richer in anionic phospholipids which favor electrostatic interaction 
with the cationic AMPs. 
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5. DISCUSSION 
C. albicans and P. aeruginosa are two human commensal 
microorganisms. In certain circumstances they can give rise to opportunistic 
infections at different human anatomical regions such as oral, systemic 
infections and vaginitis (in the case of C. albicans) or otitis, keratitis 
infections associated with burns, wounds, pulmonary epithelium (especially 
in patients with cystic fibrosis) or with colonization of medical devices e.g. 
catheters and implants (in the case of P. aeruginosa). 
Both of these microorganisms can hardly be eradicated when, under 
certain conditions, they become pathogenic. C. albicans is capable of 
reaching the bloodstream, colonizing different tissues, penetrating them and 
switching from the yeast to the hyphal form. P. aeruginosa strains can 
colonize lungs, repress motility and adhere to the lung-tissue evolving a 
mucoid phenotype able to secrete anionic polysaccharides and to produce 
sessile communities, with a protective layer around the cells that confers 
more resistance to antibiotic therapy. 
Conventional antibiotics/antimycotics are frequently ineffective mainly 
because of their undesiderable side effects, emergence of resistant strains or 
because their lacking activity against pathogenic forms (i.e. hyphae, 
biofilms). Due to these reasons, novel anti-infective agents are of great 
interest to the medical community. In this context, we have studied two 
derivatives of a frog skin AMP: Esc(1-18) and Esc(1-21) and focused our 
attention mainly on their antimicrobial efficacy and mechanism of action. 
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Both of them are cationic and have an N-terminal amphipathic α-helical 
structure, as confirmed by CD spectra and/or by NMR analysis. More 
specifically, the C-terminal part of Esc(1-18) appears to be unfolded and the 
hydrophobic cluster of residues (L14-L15-I16), which is located in the 
middle of this region, may act as an anchoring tail favoring the peptide’s 
incorporation into the phospholipid bilayer. 
Our natural microbial flora consists of nearly 2 kg microbes (mainly 
bacteria) in the digestive tract and about 200 g microbes on the outer 
surfaces. Importantly, when the host’s immune system is compromised, these 
bacteria (most of which double in number every 20 min) can take over. 
Therefore, for a surviving host, an effective defense system must be faster 
than the growth rate of an invading microorganism. 
Here, we have shown that both peptides display a MIC around 4 μM 
against reference strains and clinical isolates of both C. albicans and P. 
aeruginosa pathogens and have a good therapeutic index, being slightly 
hemolytic at a concentration 16-fold greater the MIC. They have a fast 
microbicidal activity causing approximately 85-99% fungal/bacterial killing 
at 1-16 μM within 15-20 min (Figs. 4.3 and 4.15), with a concomitant 
membrane perturbation process. 
The membrane perturbation process caused by Esc(1-18) on yeast and 
hyphal cells of Candida is not a consequence of intracellular signaling 
events, such as apoptosis (Fig. 4.7) and/or production of ROS (Fig. 4.6), but 
is presumably the result of a direct interaction of the peptide with the 
membrane. Moreover, we can also exclude that the membrane perturbation is 
the consequence of a binding-site mediated insertion of Esc(1-18) into the 
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fungal membrane, as supported by the same results of the all-L and all-D 
enantiomers of Esc(1-18) in terms of membrane perturbation (Fig. 4.5) and 
MIC. 
Esc(1-21) is able to perturb the membrane of planktonic and sessile 
Pseudomonas cells where the degree of injury enhances in parallel with the 
peptide dosage, presumably enlarging the size of membrane breakages that 
lead to an increasing loss of bulky intracellular compounds, such as the β-
galactosidase (Figs. 4.17A and 4.18A). Note that such membrane damage is 
also supported by SEM images of the peptide-treated cells. 
As mentioned above, in Cystic Fibrosis patients, the two major 
problems during chronic lung infections are the development of antibiotic-
resistant strains and the formation of bacterial biofilm, both difficult to 
eradicate. Esc(1-21) does not induce resistant strains in vitro (Fig. 4.14) even 
after multiple exposure to the peptide. This peptide is also able to inhibit re-
growth of cells from Pseudomonas-treated biofilm and to eliminate biofilm 
cells within 2 h at a concentration 3-fold higher the MIC. 
In vivo experiments, conducted on Candida-infected C. elegans, 
demonstrate that Esc(1-18) is able to prolong worm survival by 2-fold within 
24 h and to hinder hyphal development from the yeast form. Presumably, 
these findings are due to a direct effect of Esc(1-18) on Candida cells, 
reducing their number (Fig. 4.12) and avoiding their shift to the more virulent 
and toxic phenotype (Fig. 4.13A). Even if this mini-host model cannot 
substitute for mammalian models, it offers a number of advantages over 
vertebrates, including the possibility to infect the C. elegans gastrointestinal 
tract upon cells ingestion by the nematode, which is an accurate 
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representation of what physiologically takes place in susceptible human 
hosts, where fungal cells in the intestinal mucosa can disseminate to other 
organs. 
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Abstract Bombinins H are mildly cationic antimicrobial
peptides isolated from the skin of the anuran genus Bombina,
the fire-bellied toad. Some members of this peptide family
coexist in skin secretions as diastereomers in which a single
D-amino acid (alloisoleucine or leucine) is incorporated as a
result of the post-translational modification of the respective
gene-encoded L-amino acid. Here we report on the antimi-
crobial properties and membrane interactions of bombinins
H2 and H4. The latter differs from H2 by the presence of a
D-alloisoleucine at the second N-terminal position. Specifi-
cally, we have evaluated the antimicrobial activity of H2 and
H4 against a large panel of reference and clinical isolates
of Gram-negative and Gram-positive bacteria; performed
membrane permeation assays on both intact cells and model
membranes (lipid monolayers and liposomes) mimicking
the composition of the plasma membrane of Gram-negative/
positive bacteria; used biochemical tools, such as trypsin-
encapsulated liposomes and capillary electrophoresis, to
monitor the peptides’ ability to translocate through the
membrane of liposomes mimicking Escherichia coli inner
membrane. The results revealed interesting relationships
between the presence of a single D-amino acid in the
sequence of an antimicrobial peptide and its target microbial
cell selectivity/membrane-perturbing activity.
Keywords Bombinins H  Antimicrobial peptides 
Peptide-membrane interaction  Liposomes 
Capillary electrophoresis  Frog skin
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Introduction
Naturally occurring gene-encoded antimicrobial peptides
(AMPs) are an extremely diverse group of anti-infective
molecules whose function is crucial for the host immune
response (Boman 2003; Ganz 2003; Giuliani and Rinaldi
2010; Selsted and Ouellette 2005). Besides being key
components of the innate immune system of all living
organisms, rapidly killing a broad spectrum of microbes,
they interact with the host itself, triggering events (e.g.,
anti-endotoxin activity, chemotactic activity) that comple-
ment their role as antibiotics (Beisswenger and Bals 2005;
Hancock and Diamond 2000).
Furthermore, the mechanism of action of the majority of
AMPs is based on the permeation of the microbial cell
membrane, causing damage that is hard to fix (Mangoni
et al. 2007). This limits the induction of microbial resis-
tance to AMPs and makes them attractive molecules for the
development of alternative anti-infective agents (Easton
et al. 2009). The search for new therapeutics is strongly
required because of the growing emergence of resistant
pathogens to the commercially available antibiotics/
antimycotics, most of which interfere with intracellular
processes (Yeaman and Yount 2003). Although AMPs do
possess a wide variety of structural and conformational
features, many of them share selected properties such as
being usually cationic at neutral pH, and displaying the
tendency to form amphipathic structures upon interacting
with the membrane of the pathogen (Dempsey et al. 2010;
Shai 1999).
Among the natural sources for peptide antibiotics, the
granular glands of amphibian skin constitute one of the
richest storehouses (Rinaldi 2002; Simmaco et al. 1998).
An interesting and unique family of AMPs is the short and
mildly cationic bombinins H, from the skin secretion of
Bombina genus, the fire-bellied toad (Simmaco et al. 2009).
Their existence was predicted from the sequence of the
bombinin precursors, obtained via cDNA cloning (Gibson
et al. 1991; Simmaco et al. 1991). Bombinins H are 17–20
residue AMPs with an amidated C-terminus (Mangoni
et al. 2000). However, their most surprising feature is the
presence of a D-amino acid (alloisoleucine or leucine) at
the second N-terminal position in some of them, as a
consequence of post-translational modification (there is no
codon for a D-amino acid) of the respective gene-encoded
L-isoleucine or L-leucine (Kreil 1994; Mor et al. 1992).
During this reaction, the chirality of the a-carbon is
changed and the enzyme responsible for this L- to
D-isomerization has been purified and characterized from
the skin secretions of B. variegata (Jilek et al. 2005).
The discovery of a D-amino acid in ribosomally syn-
thesized peptides of animal origin first occurred in the
opioid skin peptides dermorphins and delthorphins from
the South American frogs Phyllomedusa sauvagei and
P. bicolour (Erspamer et al. 1989; Montecucchi et al. 1981),
and later in other neuropeptides and toxins from inverte-
brates (Buczek et al. 2005; Kamatani et al. 1989; Kreil
1997; Kuwada et al. 1994; Torres et al. 2002). However,
bombinins H are the first example of natural AMPs with a
single D-amino acid in their sequence. Furthermore, in
contrast with opioid peptides, the D-amino acid–containing
AMPs coexist with their all-L counterparts.
In this paper, we focussed our attention on a pair of
bombinins H: the all L-peptide H2 (IIGPVLGLVGS
ALGGLLKKI-NH2) and its diastereomer H4, which differs
from H2 by the presence of a D-alloisoleucine in position 2.
Both peptides have a ?3 net charge at pH 7. Previous
studies on their antimicrobial properties in agar medium
revealed a stronger activity for the D-amino acid–contain-
ing bombinin H4. In addition, mode of action studies
pointed out that both peptides are capable of permeating
the membrane of Gram-negative bacteria, causing the
release of large cytosolic components, such as the
b-galactosidase, with H4 having a faster killing kinetic
(Mangoni et al. 2000). In order to enlarge our knowledge
on the anti-infective properties of these two compounds
and to explore whether the mechanism underlying their
different antimicrobial activity is related to a different
ability to permeate the microbial cell membrane, the fol-
lowing experiments were performed: (1) antimicrobial
assays to determine the minimum inhibitory concentration
(MIC) value on a large panel of reference and clinical
isolates of Gram-negative and Gram-positive bacteria; (2)
membrane permeation assays on both intact cells and
model membranes (lipid monolayers and liposomes)
mimicking the composition of the plasma membrane of
Gram-negative/positive bacteria; (3) biochemical assays,
using trypsin-encapsulated liposomes and capillary elec-
trophoresis, to monitor the peptides’ ability to translocate
through the membrane of liposomes mimicking the Esch-
erichia coli inner membrane.
Although more quantitative information should be
obtained in the future, considering simulation of peptide
dynamics in lipid membranes as well, an interesting rela-
tionship between the target cell selectivity/membrane-
perturbing activity and the presence of a single D-amino
acid in the sequence of an AMP has emerged from
these investigations.
Materials and methods
Materials
Synthetic bombinins H2 and H4 were purchased from
GENEPEP (Prades-le-Lez, France). The purity of the
578 Eur Biophys J (2011) 40:577–588
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peptides, their sequence and concentrations were deter-
mined as previously described (Mangoni et al. 2000).
L-a-phosphatidylethanolamine (PE), L-a-phosphatidyl-DL-
glycerol (PG), cardiolipin (CL), fluorescein isothiocyanate
dextrans of 4, 20, and 70 kDa average molecular mass
(FITC-D4/D20/D70), calcein, ammonium thiocyanate, and
iron (III) chloride hexahydrate were obtained from Sigma.
Trypsin (EC 3.4.21.4, sequencing grade) was purchased
from Roche Diagnostics, Mannheim, Germany. Soybean
trypsin inhibitor (SBTI) was obtained from ICN Biomed-
icals (Irvine, CA, USA). Imidazole was purchased from
Merck (Whitehouse Station, NJ, USA). SYTOXTM Green
was from Molecular Probes (Invitrogen, Carlsbad, CA,
USA). All other chemicals used were of reagent grade.
Microorganisms
The following bacteria were used for the microbiological
assays. Gram-negatives: Acinetobacter baumannii ATCC
19606, A. baumannii 1 (clinical isolate), Escherichia coli
D21, E. coli O111:B4, E. coli ATCC 25922, Pseudomonas
aeruginosa 3 (clinical isolate), P. aeruginosa ATCC 27853,
and Yersinia pseudotuberculosis YPIII. Gram-positives:
Staphylococcus aureus ATCC 29213, S. aureus Cowan I,
S. epidermidis ATCC 12228 and the clinical isolates
S. aureus 8, S. aureus 43300, S. aureus 11270, S. capitis n.1,
S. epidermidis 18, and Enterococcus faecalis 9546.
Antibacterial activity of the peptides
Susceptibility testing of peptides was performed by
adapting the microbroth dilution method outlined by the
Clinical and Laboratory Standards Institute (CLSI 2006),
using sterile 96-well plates (Falcon, Franklin Lakes, NJ,
USA). Stock solutions of peptides were prepared in serial
twofold dilutions in 20% ethanol; 5 ll was then added to
45 ll of Mueller-Hinton broth (MHB; Oxoid, Cambridge,
UK), previously put into the wells of the microtiter plate.
Afterwards, aliquots (50 ll) of bacteria in mid-log phase,
at a concentration of 2 9 106 colony-forming units (CFU)/
ml, were added to each well. The range of peptide dilutions
used was 1.56–50 lM. Inhibition of growth was deter-
mined by measuring the absorbance at 595 nm with a
microplate reader (Infinite M200, Tecan, Salzburg, Aus-
tria) after 18–20 h incubation at 37C. Antibacterial
activities were expressed as MIC, the minimum concen-
tration of peptide causing 100% inhibition of bacterial
growth.
Bactericidal activity
The bactericidal activity of H2 and H4 against the Gram-
positive S. aureus ATCC 29213 and S. aureus Cowan I was
evaluated as previously described (Mangoni et al. 2008).
Briefly, exponentially growing bacteria in MHB were
harvested by centrifugation and then resuspended in fresh
MHB or phosphate-buffered saline (PBS) to obtain a
density of 1 9 107 CFU/ml. Ten ll of the bacterial sus-
pension was incubated at 37C for 90 min in the presence
of different concentrations of peptide (serial twofold dilu-
tions ranging from 6.25 to 50 lM) dissolved in MHB or
PBS, to a final volume of 100 ll.
Following incubation, appropriate aliquots were plated
onto Luria-Bertani agar plates to accurately determine the
99.9% killing. The number of surviving bacteria was
counted after overnight incubation at 37C. Bactericidal
activity was expressed as the peptide concentration nec-
essary to induce a reduction in the number of viable bac-
teria of C3 log10 CFU/ml (Maisetta et al. 2006). Controls
were run without peptide and in the presence of peptide
solvent (20% ethanol) at a final concentration of 1%.
Bacterial membrane permeabilization
To assess the ability of bombinins H to alter the bacterial
membrane permeability, 1 9 106 cells in 100 ll of PBS
were mixed with 1 lM SYTOXTM Green for 5 min in the
dark. After adding peptide, the increase in fluorescence,
due to the binding of the dye to intracellular DNA, was
measured at 37C in the microplate reader (excitation and
emission wavelengths were 485 and 535 nm, respectively).
The peptide concentrations ranged from 3.125 to 50 lM.
Controls were given by cells without peptide, whereas the
maximum membrane perturbation was obtained after lys-
ing bacteria in 1% (v/v) Triton X-100.
Measurement of penetration of bombinins H2 and H4
in lipid monolayers
Insertion of H2 and H4 into monolayers formed of either
PE/PG (7:3, w/w) and PG/CL (6:4, w/w) was evaluated as
an indication of the peptides’ ability to bind and penetrate
microbial targets’ plasma membranes. To this end, lipid
mixtures in chloroform were spread at an air/buffer
(50 mM potassium phosphate, pH 7, with 0.1 mM EDTA)
interface, and penetration was monitored by measuring
surface pressure (p) with a Wilhelmy wire attached to a
microbalance (DeltaPi, Kibron, Helsinki) connected to a
PC and using circular glass wells (subphase volume
0.5 ml). After evaporation of lipid solvent and stabilization
of monolayers at different initial surface pressures (p0), the
peptide (1 lM, final concentration) was injected into the
subphase, and the increment in surface pressure of the lipid
film upon intercalation of the peptide dissolved in the
subphase was followed for the next 35 min. The difference
between the initial surface pressure and the value observed
Eur Biophys J (2011) 40:577–588 579
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after the penetration of bombinins H into the film was taken
as Dp. Surface activity of H2 and H4 at the air/buffer
interface was also evaluated in the absence of lipids, by
injecting increasing amounts of the peptide into the sub-
phase and measuring the variation of p0 with time. All
measurements were performed at room temperature.
Preparation of calcein/dextran-loaded liposomes
and leakage measurement
Calcein-loaded liposomes of different compositions (PE/
PG, 7:3 w/w and PG/CL, 6:4 w/w) were prepared as pre-
viously described (Rinaldi et al. 2002). Briefly, phospho-
lipids were dissolved in chloroform and mixed with a
calcein solution (60 mM in phosphate buffer, pH 7.0). The
mixture was then sonicated until becoming homogeneous.
Liposomes were prepared by reverse phase evaporation
(Szoka and Papahadjopoulos 1978). Free calcein was
removed through gel filtration (Sephadex G-50), with a
1.5 9 15 cm column, equilibrated and eluted with 50 mM
potassium phosphate buffer, pH 7.4 containing 0.1 mM
EDTA. The lipid concentration was determined by the
Stewart method (Stewart 1980). Calcein loaded in lipo-
somes is self-quenched (Allen 1981) and its leakage was
monitored as a relief of quenching (excitation and emission
wavelengths were 490 and 517 nm, respectively) with a
Perkin-Elmer LS 55B spectrofluorimeter. The maximum
fluorescence intensity corresponding to 100% calcein
release was determined by addition of Triton X-100 (0.2%,
v/v, final concentration), which produced the total
destruction of the vesicles. The leakage value was calcu-
lated according to the equation:
Leakage ð%Þ ¼ 100  ðF  F0Þ=ðFt  F0Þ
where F and Ft denote the fluorescence intensity before and
after the addition of the detergent, respectively, and F0
represents the fluorescence of intact vesicles.
Liposomes loaded with FITC-D4/D20/D70 were pre-
pared as reported elsewhere (Rinaldi et al. 2001). The
release of dextran from loaded vesicles upon interaction
with bombinin H2 and H4 was examined fluorimetrically;
excitation and emission wavelengths were 494 and
520 nm, respectively. In a typical experiment, an aliquot of
the peptide solution in 20% (v/v) ethanol was incubated
with a suspension of dextran-loaded vesicles in 50 mM
buffer (sodium phosphate, pH 7.4 with 0.1 mM EDTA,
SPB), at a final lipid concentration of 50 lM. The mixture
(2 ml, final volume) was stirred gently for 10 min in the
dark and centrifuged at 27,000g for 30 min. The superna-
tant was recovered, and its fluorescence intensity was
measured. The total dextran release was determined by the
addition of 20 ll of 10% (v/v) Triton X-100 to the vesicle
suspension. The leakage value was calculated as described
above for calcein. All experiments were carried out at room
temperature.
Preparation and degradation of peptides
by trypsin-loaded liposomes
Trypsin-loaded liposomes were prepared from a 7:3 (w/w)
mixture of PE and PG. The lipid mixture in chloroform was
vacuum-dried and hydrated with 5 mM SPB containing
100 lg/ml trypsin, to a final lipid concentration of 2.5 mg/
ml. After five cycles of freeze-thawing, liposomes were
extruded 21 times through two stacked 400 nm filters, as
described previously (MacDonald et al. 1991). Free trypsin
was removed by gel filtration on a Sephadex G-50,
1.5 9 15 cm column, equilibrated and eluted with 5 mM
SPB. Liposomes were stored at 4C and used within 48 h.
Trypsin-loaded liposomes were suspended in 5 mM SPB
supplemented with 10 lg/ml of imidazole, an internal
standard for capillary zone electrophoresis (CZE), and with
or without 20 lg/ml of SBTI, at a lipid concentration of
250 lg/ml. The concentration of SBTI was sufficient to
effectively inhibit all trypsin activity after liposomes
were lysed by adding an aliquot of Triton X-100 (0.1% v/v,
final concentration), as reported in Den Hertog et al.
(2004). The suspension of lipid vesicles was subsequently
incubated with 60 lM of each bombinin H or 40 lM of the
control membrane-inactive peptide cystatin cysS1–15
(SSSKEENRIIPGGIY), corresponding to the first 15 N-
terminal amino acids of cystatin S (Den Hertog et al. 2004).
At different time intervals, 50 ll aliquots were withdrawn,
boiled for 5 min to inhibit all trypsin activity, lysed in 0.1%
Triton X-100, and analyzed by CZE. Degradation of pep-
tides implied digestion, by trypsin, of the peptide inter-
nalized within the liposome.
Capillary zone electrophoresis
Purity and degradation of peptides was analyzed by CZE
on a BioFocus 2000 Capillary Electrophoresis System
(Bio-Rad, Hercules, CA, USA) equipped with an uncoated
fused silica capillary of 50 lm internal diameter and a
length of 24 cm. Samples were loaded by pressure injec-
tion at 20 lbf in-2 s-1 (where 1 lbf in-2 = 6.9 kPa), and
peptide separation was performed according to the manu-
facturer’s instructions at 10 kV (anode at the detector side)
and 20C, using 0.1 M phosphate buffer, pH 2.5, as the
electrolyte. Online UV detection was performed at 200 nm.
The running time of the analysis was 20 min, and data
were analyzed using BioFocus Integrator software. The
level of peptide degradation was quantified in the electro-
pherogram by comparing the relevant peak heights of the
sample with that of the internal standard imidazol.
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Results
Antimicrobial activity
In our previous studies, the antimicrobial activity of H2
and H4 was tested on standard Gram-negative and Gram-
positive bacterial strains using the inhibition zone assay in
agar medium (Mangoni et al. 2000). Here, to deepen our
understanding of the antibacterial activity of these two
peptides, we analyzed their ability to inhibit the microbial
growth in liquid medium, employing the commonly used
serial twofold dilution method. This allowed us to deter-
mine the MIC values, as defined in the ‘‘Materials and
methods’’ section. A large panel of standard and clinical
isolates of Gram-negative and Gram-positive bacterial
strains, most of which have not been studied previously,
was investigated. The results are reported in Table 1. They
indicated that bombinin H4 had the same or a higher
activity than that of H2 against Gram-negative bacteria. In
contrast, the opposite behavior was detected toward Gram-
positive species, with bombinin H2 having a two- to
fourfold lower MIC—and thus a stronger activity—than
H4 against almost all of the tested microorganisms. Note
that our previous data using the inhibition zone assay had
shown a slightly higher activity of H4 than H2 against the
Gram-positive S. aureus Cowan I (Mangoni et al. 2000).
This could be due to a different solubility and diffusion of
the peptides through a solid medium.
We next examined the bactericidal activity of the two
diastereomers against some representative Gram-positive
bacterial strains (i.e., S. aureus ATCC 29213 and S. aureus
Cowan I), by counting the number of viable cells after
90 min of incubation with the peptide, in both MHB and
PBS. Specifically, PBS was used to assay the bactericidal
activity of bombinins H in a medium whose ionic strength
(150 mM sodium salt compared to 100 mM of MHB) was
closer to that of biological fluids (Li et al. 2003). Surpris-
ingly, both peptides caused 99.9% killing of the microbial
population at the same concentration (Table 2). When
tested in MHB, the two diastereomers displayed a bacte-
ricidal activity at 50 lM (Table 2), a peptide concentration
fourfold higher than the corresponding MICs of H2, and
equal or twofold higher the MIC, in the case of H4
(Table 1). When tested in PBS, both peptides were found
to be more active, with a bactericidal activity at 12.5 and
25 lM, against S. aureus ATCC 29213 and S. aureus
Cowan I, respectively. Interestingly, these two peptide
concentrations were equal or twofold higher than the cor-
responding MICs of H2 on these two strains, but they were
twofold lower than the MICs of H4 (Table 1).
Mode of action studies on intact cells
As mentioned above, previous reports had emphasized the
ability of these two bombinins H to permeate the mem-
brane of Gram-negative bacteria with a stronger effect for
the D-amino acid–containing peptide H4 (Mangoni et al.
2000).
Here, the activity of the two diastereomers on the
membrane permeability of Gram-positive bacteria, such as
S. aureus ATCC 29213, was studied by measuring the
intracellular influx of SYTOXTM Green (Fig. 1). This
cationic dye (mw & 600), which is excluded by intact
membranes but not by those having lesions of a size large
enough to allow its entrance (Marcellini et al. 2009), dra-
matically increases its fluorescence when bound to
Table 1 Antibacterial activity of bombinins H2 and H4 on selected
bacterial strains
Bacterial strain MIC (lM)
H2 H4
Gram-negative
A. baumannii ATCC 19606 12.5 12.5
A. baumannii 1 50 12.5
E. coli D21 [50 [50
E. coli O111:B4 [50 50
E. coli ATCC 25922 [50 50
P. aeruginosa 3 [50 [50
P. aeruginosa ATCC 27853 [50 [50
Y. pseudotuberculosis YPIII 12.5 12.5
Gram-positive
E. faecalis 9546 [50 [50
S. aureus ATCC 29213 12.5 25
S. aureus Cowan I 12.5 50
S. aureus n.8 [50 [50
S. aureus 11270 12.5 50
S. aureus 43300 12.5 50
S. capitis n. 1 12.5 25
S. epidermidis ATCC 12228 12.5 12.5
S. epidermidis n.18 [50 [50
Table 2 Bactericidal activity of bombinins H2 and H4 on two
S. aureus strains in MHB and PBS
Bacterial strain Peptide Bactericidal activitya
MHB PBS
S. aureus ATCC 29213 H2 50 12.5
H4 50 12.5
S. aureus Cowan I H2 50 25
H4 50 25
a The bactericidal activity is expressed as the concentration of pep-
tide (lM) that is sufficient to reduce the number of viable bacteria
of C3 log10 CFU/ml after 90 min of incubation
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intracellular nucleic acids. As indicated in Fig. 1b, bomb-
inin H4 augmented the membrane’s permeability to
SYTOXTM Green to a larger extent with respect to H2
(Fig. 1a). In addition, H4 caused the complete alteration of
the plasma membrane’s structure, at 2 9 MIC (Fig. 1b).
Conversely, in the case of bombinin H2 (Fig. 1a), a peptide
concentration fourfold higher than the MIC was not enough
to completely disintegrate the membrane.
Mode of action studies on model membranes
Peptide insertion into PE/PG and PG/CL monolayers
Monomolecular lipids have been increasingly used as suit-
able model systems to analyze the interaction of peptides
(and proteins) with biological membranes (Brockman 1999;
Maget-Dana 1999; Zhao and Kinnunen 2002). We therefore
used PE/PG (7:3, w/w) and PG/CL (6:4, w/w) monolayers to
mimic the lipid composition of the bacterial plasma mem-
brane of the Gram-negative E. coli and the Gram-positive
S. aureus, respectively (Epand and Epand 2009).
The surface activity of H2 and H4, recorded in the
absence of lipids, is shown in Fig. 2. Both peptides were
found to be highly surface active, with surface pressure
rising rapidly with increasing peptide concentration.
Maximum surface pressure reached 30.4 and 33.9 mN/m
for H2 and H4, respectively, at a peptide concentration of
2 lM. Of note, H4 was always found to be more surface
active than H2, especially at lower peptide concentrations.
Bombinins H2 and H4 efficiently and readily penetrated
into PG/CL and PE/PG monolayers, as demonstrated by the
increase in film surface pressure (Fig. 3a, b).
Through analysis of measurements in terms of Dp ver-
sus p0, the critical surface pressure corresponding to the
lipid lateral packing density preventing the intercalation of
H2 and H4 into the PG/CL film could be derived by
extrapolating the Dp - p0 slope to Dp = 0, giving a
value &43 mN/m for both peptides (Fig. 3a). In the case
of the PE/PG monolayer, this value increased to 44 and 47
mN/m for H2 and H4, respectively (Fig. 3b). It is well
appreciable that in the case of both PE/PG and PG/CL
films, H4 displayed a constantly stronger intercalation
activity with respect to H2, although this difference was
not dramatic. Such differences were not found when the
intercalation of H2 and H4 was tested in neutral dipalmi-
toylphosphatidylcholine (DPPC) monolayers (data not
shown), showing that the lipid composition of the model
Fig. 1a, b Effect of bombinins H2 and H4 on the membrane
permeation of S. aureus ATCC 29213. Cells (1 9 107 CFU/ml) were
incubated with 1 lM SYTOXTM Green in PBS. Once basal fluores-
cence reached a constant value, the peptide was added (arrow, t = 0)
and changes in fluorescence were monitored (kexc = 485 nm,
kems = 535 nm) and plotted as the percentage of fluorescence relative
to that of bacteria fully permeated by the addition of Triton X-100
(1%, v/v, final concentration). All readings were normalized by
subtracting fluorescence values of control (bacteria without peptide).
Data points represent the average values of three independent
experiments, with SD not exceeding 5%. Peptide concentrations used
for bombinin H2 (a) and H4 (b) were as follows: 3.125 lM (open
triangle), 6.25 lM (filled square), 12.5 lM (open circle), 25 lM
(filled circle), and 50 lM (filled triangle)
Fig. 2 The surface activity of bombinins H2 and H4. The adsorption
of peptides at the air/buffer (potassium phosphate 50 mM, pH 7, with
0.1 mM EDTA) interface was monitored as increasing surface
pressure (p0) over time. The maximum values of these surface
pressures were plotted against peptide’s final subphase concentration.
Values are means ± SD of three independent measurements
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membrane drove the different behavior of H2 and H4, and
that the stronger film intercalation activity detected for H4
was not (only) due to its inherently greater surface activity.
The kinetics of the insertion of the peptides into lipid
monolayers was also analyzed and found to be comparable
for both H2 and H4 and both monolayer compositions
(Fig. 3c, d). In general, the kinetics were characterized by a
very fast initial peptide intercalation subsequent to the
peptide’s injection into the subphase, followed by a rather
stable value of p, with a few signs of relaxation or pep-
tide’s reorganization. This general kinetics pattern was
apparently independent from the specific peptide tested and
from initial surface pressure (Fig. 3c, d).
The very rapid kinetics of intercalation recorded resem-
bles that found previously for the frog skin-derived AMP
temporins (Zhao and Kinnunen 2002) and fits well with the
strong surface activity of bombinins H, as discussed above.
Peptide-induced liposome permeabilization
The ability of H2 and H4 to destabilize bacterial mem-
branes by a nonstereospecific process was confirmed by
employing calcein-loaded PE/PG and PG/CL liposomes.
Different concentrations of each peptide were added to a
suspension of lipid vesicles (50 lM final lipid concentra-
tion), and membrane permeabilization was monitored by
following fluorescence recovery due to calcein leakage from
the liposomes. Figure 4 (panels a and c) shows the kinetics
and the dose-response of peptide-induced calcein release
from PE/PG liposomes. The data highlighted a comparable
membrane-perturbing activity for both bombinins H with a
slightly stronger effect for the isoform H4, at a peptide
concentration range of 1–2.5 lM. For both peptides, the
vesicle-permeabilization activity increased in a concentra-
tion-dependent manner and reached the maximum effect at a
peptide concentration of 2.5 lM. Similarly to what was seen
with calcein-loaded vesicles, when the peptides were ana-
lyzed for their ability to cause the release of fluorescently
labeled dextrans of different size (4/20/70 kDa) from PE/PG
liposomes, both H2 and H4 displayed basically the same
activity, with the probe being released in a manner that
depended significantly on the size of the solute (Table 3).
The results obtained with PG/CL liposomes are reported
in Fig. 4 (panels b and d). Both bombinins H displayed a
generally lower activity on this membrane composition
than that recorded for PE/PG liposomes. Interestingly, in
this case, bombinin H4 appeared to be remarkably more
potent than the all-L H2, giving rise to a total membrane
permeation at a peptide concentration (3.5 lM) that was
approximately fourfold lower than that needed for H2.
These observations are in line with the results of the
membrane-permeability assay described above, using
intact cells (Fig. 1) and are consistent with the suggestion
that the two isomers bind and perturb the membrane of
Gram-positive bacteria with a different effectiveness.
Peptide translocation through a PE/PG membrane
To get insight into the ability of these two frog skin pep-
tides to translocate through a model of E. coli inner
Fig. 3a–d Insertion of H2 and
H4 into lipid monolayers.
Increments of surface pressure
of PG/CL (a) and PE/PG
(b) monolayers due to the
addition of 1.0 lM H2 and H4
into the subphase are illustrated
as a function of initial surface
pressure. Typical kinetics of
surface pressure increase related
to H2 penetration into a PG/CL
film (c; p0 = 11.8, with 1.0 lM
peptide) and of H4 into a PE/PG
monolayer (d; p0 = 14.2, with
1.0 lM peptide) are shown as
representative of general trends.
X-axis shows elapsed time (s).
Peptide injection into the
subphase took place at &200 s
(arrow)
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membrane, an enzyme digestion assay was developed. As
described in ‘‘Materials and methods,’’ to this end, trypsin-
loaded PE/PG liposomes were incubated with peptides. In
the absence of liposomes, both bombinins H were sus-
ceptible to trypsin action (two trypsin cleavage sites are
present at the C-terminal region of each peptide), as proved
by the appearance of novel peaks in the electropherograms
of the peptide samples upon enzyme treatment (data not
shown).
When trypsin-loaded liposomes were used, in the case of
bombinin H2, only two very small peaks, at a migration
time in capillary electrophoresis (tm) of approximately 9
and 11 min, could be detected within 2 h of incubation
with the peptide (Fig. 5a, gray and white bars, respec-
tively), whereas in the presence of SBTI, no peptide deg-
radation was discerned at all (Fig. 5b). On the other hand,
with bombinin H4, a partial degradation of the peptide was
detected within the first 60 min of incubation with the
liposomes, as indicated by the presence of three peaks at 4,
9, and 11 min tm (Fig. 5c, light gray, gray and white bars,
respectively). Note that the peak at 4 min tm was not
present in the electropherograms of H2. In addition, the
amount of one specific degradation product (peak at 9 min
tm) increased with the incubation time, making up to 30%
of total digestion products after 2 h (Fig. 5c). In the pres-
ence of SBTI, H4 degradation was strongly reduced
(Fig. 5d), probably due to the influx of SBTI through the
peptide-induced membrane cracks and, therefore, to the
inhibition of trypsin activity inside the liposome.
Discussion
The secretory glands of amphibian skin produce a multi-
tude of bioactive peptides, many with antimicrobial activ-
ities, thus representing important constituents of the innate
immune system of these animals (Boman 2000; Zasloff
2002). In particular, from the Bombina genus, several
bombinin peptides have been discovered, as well as the
structurally unrelated bombinins H, whose peculiar char-
acteristic is the presence of a D-amino acid in the sequence
of some of them. Most AMPs are unfolded in solution and
acquire their active conformation only upon binding to
their target membrane (Bechinger and Lohner 2006).
Bombinins H2 and H4 are not an exception to this rule.
Fig. 4 Calcein leakage from
PE/PG (7:3, w/w; panels a and c)
or PG/CL (6:4, w/w; panels b and
d) vesicles, after bombinin H2
(left panels) and H4 (right
panels) treatment. Calcein
release from liposomes (50 lM
final lipid concentration) was
detected fluorimetrically
(kexc = 490 nm,
kems = 517 nm). The
percentage of leakage was
calculated as described in
‘‘Materials and methods’’. Data
points represent the average
values of three independent
measurements, with SD not
exceeding 3%. Peptide
concentrations used were as
follows: 0.25 lM (open circle),
0.5 lM (asterisk), 0.75 lM
(filled circle), 1 lM (open
square), 1.5 lM (filled square),
2.5 lM (open triangle), 3 lM
(filled diamond), 3.5 lM (open
diamond), 7.5 lM (cross
symbol), 10 lM (filled triangle),
15 lM (filled inverted triangle)
Table 3 Effect of bombinins H2 and H4 (5 lM) on the release of
FITC-labeled dextrans from PE/PG liposomes
FITC-dextrans Dextran release (%)
H2 H4
FITC-D4 84.1 ± 2.8 85.2 ± 3.1
FITC-D20 57.8 ± 2.6 59.0 ± 3.0
FITC-D70 27.0 ± 1.5 30.0 ± 2.2
Probe release relative to that of controls, where the total liposome
disruption was obtained by adding Triton X-100. Values are
means ± SD from three independent experiments. The lipid con-
centration was 50 lM in 50 mM SPB
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Molecular dynamic simulations have shown that both
peptides have an intrinsic propensity to fold when still in
water, with H4 being less constrained and more flexible
due to the inability of its D-alloisoleucine in position 2 to
establish intramolecular contacts (Bozzi et al. 2008).
Environmental conditions, as well as the composition
and the physical state of the phospholipid bilayer may be
crucial for the ultimate peptide structure and mechanism of
action. Circular dichroism (CD) spectra have shown that in
a membrane-mimicking environment, such as trifluoro-
ethanol, both H2 and H4 adopt predominantly an amphi-
phatic a-helical structure (Bozzi et al. 2008; Mangoni et al.
2000). More detailed CD and FTIR analyses of H2 and H4
structural features in lipid bilayers of different composition
have confirmed that both peptides adopt mainly an
a-helical structure—with H2 being slightly more helical
than H4 in all membranes—and display a b-sheet compo-
nent ranging from 14 to 33% (Mangoni et al. 2006). The
same study also revealed that H2, but not H4, has the
tendency to aggregate in membranes, in the form of
aggregated strands (Mangoni et al. 2006).
In the present work, we have found that the two diaste-
reomers H2 and H4 do possess different antimicrobial
activity, with H4 being generally more active on Gram-
negative bacteria (either standard or clinical strains), but less
active on the majority of Gram-positive bacteria with respect
to H2, when the microbroth dilution method is used to
determine the MIC. Presumably, when the peptides are used
in a bacterial growth medium at low concentrations, H2 is
more potent than H4 in blocking those cellular functions that
are involved in the control of the microbial growth, in Gram-
positive bacteria, without significantly affecting the integrity
of the plasma membrane and hence the bacterial viability.
Nevertheless, a different outcome is found when the two
peptides are tested for their bactericidal activity against a
representative Gram-positive bacterial species, i.e., S. aur-
eus. Indeed, when bacteria are incubated in MHB (the same
growth medium used for MIC assays), 99.9% killing of the
microbial population is caused by H4 at a concentration
equal or twofold higher than its MIC (Table 2), while in the
case of H2, a peptide concentration fourfold higher the
corresponding MIC is necessary to get the same bactericidal
effect. This could be due to the formation of larger mem-
brane ruptures by H4, compared to H2, which is in agree-
ment with the higher affinity of H4 towards PG/CL
phospholipid monolayers (Fig. 3) and to its higher mem-
brane-perturbing activity for this lipid composition. These
latter effects are highlighted by the results of the
Fig. 5a–d Detection of bombinin H2 (left panels) and H4 (right
panels) translocation into PE/PG (7:3, w/w) liposomes, using the
trypsin digestion assay. Trypsin-loaded liposomes (250 lg/ml) were
incubated with 60 lM peptides either in the absence (panels a and
c) or in the presence (panels b and d) of SBTI. At different time
points (0, 60, and 120 min), aliquots were taken, boiled for 5 min, and
lysed in 0.1% Triton X-100. Samples were analyzed by CZE using
imidazole as internal standard. Peptide degradation is indicated by the
appearance of peptide fragments with different tm. Black bars indicate
the peaks area at 7 min tm, corresponding to the intact peptides. Light
gray, gray, and white bars indicate peaks at 4, 9, and 11 min tm,
respectively. All values are the averages of three different experi-
ments with SD not exceeding 2.5% and are expressed as percentages
with respect to the internal standard
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permeabilization of PG/CL liposomes when monitoring the
calcein release (Fig. 4), and by the results of the permeabi-
lization of S. aureus cell membrane when monitoring the
intracellular influx of SYTOX Green (Fig. 1).
In the case of Gram-negative bacteria, a higher antimi-
crobial and membrane-perturbing activity was formerly
demonstrated for the D-isoform H4 (Mangoni et al. 2000).
However, working with PE/PG liposomes to mimic the lipid
composition of E. coli inner membrane, we have observed
that both bombinins H are similarly capable of injuring this
type of membrane (Fig. 4 and Table 3), although a slightly
stronger membrane-perturbing activity of H4 with respect to
H2 is discernable, and this is also true in the case of the
peptides’ intercalation into a PE/PG monolayer (Fig. 3).
Therefore, the discrepancies found between these two dia-
stereomers when intact bacteria are used might be attributed
to differences in their diffusion process through the Gram-
negative cell wall before reaching the target cytoplasmic
membrane. Note that the outer membrane component of the
cell wall of Gram-negative bacteria, the first barrier AMPs
are faced with before reaching the plasma membrane, is
made by a complex mixture of lipopolysaccharides (LPS),
phospholipids, lipoproteins, and proteins.
In addition, our membrane translocation experiments,
employing PE/PG trypsin-loaded liposomes, have indi-
cated only a tiny degradation of the all-L H2 in the absence
of the trypsin inhibitor SBTI. A possible explanation for
this finding is that H2 molecules present in the sample bind
the model membrane resembling that of Gram-negative
bacteria in a highly aggregated peptide-lipid molecular
complex not available for trypsin cleavage, but efficient
enough to perturb the membrane causing the leakage of
either the low-molecular-weight calcein and of liposome-
preincapsulated dextrans of increasing size (Table 3). The
aggregation tendency of H2 has been reported before
(Mangoni et al. 2006) and discussed above, and both H2
and H4 were shown previously to cause the release of
b-galactosidase from E. coli cells in a dose-dependent
manner (Mangoni et al. 2000).
Thus, as found for other frog-skin AMPs such as tem-
porins (Rinaldi et al. 2001), it is very likely that bombinins
H cause marker leakage from lipid vesicles (and possibly
from microbial target cells)—not thanks to a total mem-
brane disruption (detergent-like effect), but rather by per-
turbing the bilayer organization on a local scale.
Concerning H4, a partial peptide degradation by trypsin
entrapped into PE/PG liposomes was detected. This might
be related to a more flexible conformation of H4, compared
to the more structured and aggregated H2 (Bozzi et al.
2008; Mangoni et al. 2006), which would make it easier for
H4 to traverse the phospholipids bilayer.
Overall, we can conclude that bombinins H2 and H4 are
membrane-active peptides whose different bactericidal
activity on Gram-negative and Gram-positive bacteria can
be assigned to a different behavior in their binding affinity
and permeation of the target cytoplasmic membrane, and/
or in their translocation through the cell wall/plasma
membrane of the target cell. In general, we can state that
the D-amino acid–containing bombinin H4 is more efficient
than bombinin H2 at disturbing bacterial membranes.
Bombinin H4 was also earlier indicated to be more
active against the protozoan pathogen Leishmania, binding
a model of its membrane with a fivefold greater affinity
than bombinin H2 (Mangoni et al. 2006).
In the case of Gram-positive bacteria, such as S. aureus,
the data reported in this work show a higher ability of
bombinin H4 to wreck the structure of phospholipid
bilayers of these microorganisms, as supported by the
results obtained working with intact cells and model
membranes (Figs. 1, 3, and 4).
On the other side, in the case of Gram-negative strains,
the higher membrane-perturbing activity of H4 (Mangoni
et al. 2000) would reflect its easier partition into the inner
cytoplasmic membrane. Furthermore, a partial membrane
crossing activity could occur for H4, but not for H2, also in
living bacteria. Once having crossed the membrane, H4
might influence the activity of intracellular functions, thus
reinforcing the membrane perturbation effect and contrib-
uting to killing the microbial cell.
However, we cannot rule out, at this stage, the possi-
bility that additional factors (e.g., interaction with pepti-
doglycan, LPS layer, and other cell surface components)
could induce mechanical stress affecting the cell wall/
membrane structure and thus the antimicrobial activity of
the two bombinin diastereomers in a different way.
Finally, both bombinins H were also found to preserve
their antimicrobial properties in high-ionic strength media
resembling physiological environments, which is an
important feature for molecules to be used as templates for
the development of new drugs.
Importantly, besides getting insight into the molecular
mechanism of a pair of natural peptide diastereomers at the
level of Gram-positive and Gram-negative bacterial
membranes, these studies have expanded our knowledge of
the effect of a single L-to-D epimerization on the target cell
selectivity of an AMP and its mode of action.
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Alanine scanning analysis
and structure–function relationships
of the frog-skin antimicrobial peptide
temporin-1Ta‡
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The increasing resistance of bacteria and fungi to the available antibiotic/antimycotic drugs urges for a search for new anti-
infective compounds with new modes of action. In line of this, natural CAMPs represent promising and attractive candidates.
Special attention has been devoted to frog-skin temporins, because of their short size (10–14 residues long) and their unique
features. In particular, temporin-1Ta has the following properties: (i) it is mainly active on Gram-positive bacteria; (ii) it can
synergize, when combined with temporin-1Tl, in inhibiting both gram-negative bacterial growth and the toxic effect of LPS;
(iii) it preserves biological activity in the presence of serum; and (iv) it is practically not hemolytic. Rational design of CAMPs
represents a straightforward approach to obtain a peptide with a better therapeutic index. Here, we used alanine scanning
analogs to elucidate the contribution of the side chains of each amino acid residue to the peptide’s antimicrobial and hemolytic
activity. Beside providing insight into the biophysical attributes and the critical positions within the peptide sequence, which
govern the antimicrobial/hemolytic activity of this temporin isoform, our studies assist in optimizing the design of temporin-
based lead structures for the production of new anti-infective agents. Copyright c© 2011 European Peptide Society and John
Wiley & Sons, Ltd.
Keywords: temporin; alanine scanning; antimicrobial peptides; frog skin
Introduction
Because of the increasing frequency of bacterial and fungal
strains resistant to existing drugs, the identification of alternative
antibiotics with a new mode of action to slow down the alarming
trend of resistance is vital. Primitive innate defence mechanisms
in the form of gene-encoded CAMPs [1–3], originally discovered
in insects [4,5], are now considered well-suitable candidates for
the design and development of new therapeutics [6–9]. These
relatively low-molecular weight peptides were later found to be
present in all living organisms, sometimes in large quantities
freely circulating or sequestered in compartments throughout
the organism [10,11]. However, beside being crucial components
of the host innate immunity, CAMPs also mediate the adaptive
immuneresponse,bycausingmast-celldegranulation,byactingas
chemo-attractants [1,12] or by blocking the LPS-induced cytokine
production and subsequent septic shock syndrome [13–15]. In
contrast to conventional antibiotics, most of which work by
interfering with a specific biochemical reaction within the cell,
numerousCAMPsarebelieved toperturb themicrobialmembrane
in a non-receptor-mediated fashion. Despite substantial variation
in their chain length and structural conformation, most CAMPs
do possess: (i) a size ranging from 11 to 50 amino acids; (ii) a net
positive charge at neutral pH; and (iii) an amphiphatic structure
upon contact with the membrane of the target cell [16–18].
The search for novel CAMPs as lead structures of natural origin
has led to the discovery of interesting peptides from the skin
glands of amphibian anura. Among them, a marked attention has
been devoted to the short and mildly cationic temporins. Initially
isolated from the skin of the European red frog Rana temporaria
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[19], new members were then identified in skin secretions of
other ranid frogs of both American and Eurasian origin, enlarging
the temporin family to more than 100 different isoforms [20].
Temporins are among the smallest CAMPs (10–14 residues long,
except for temporin-SHf and temporin-LTabearing8and17amino
acids, respectively [21,22]), and with a net charge ranging from
+2 to +3. Indeed, with the exclusion of temporin-1Ja, carrying an
aspartic acid (net charge 0), and a few isoforms devoid of basic
or acidic amino acids (net charge +1, due to the free N-terminal
amino group), all the remaining members have only a single or
a double positively charged residue in their sequence [20]. This
low cationic character is unique and is an exception compared
to known CAMPs from other sources [23,24]. In addition, unlike
the majority of Ranidae CAMPs, such as brevinins, ranalexins,
ranatuerins, and esculentins [25,26], temporins lack the C-terminal
heptapeptide ringstabilizedbyadisulfidebridgeandareamidated
at their carboxyl end as a result of a post-translational enzymatic
reaction [27]. Generally, temporins are active particularly against
Gram-positive bacteria, Candida species, and fungi, including
antibiotic-resistant strains [28,29]. A large number of studies
has revealed that their bacterial killing process is rapid and
concomitant with the perturbation of the microbial membrane
[20,30]. Furthermore, recent papers have shown the existence
of a synergistic effect in two pairs of temporins (temporin-1Ta
+ temporin-1Tl and temporin-1Tb + temporin-1Tl) in inhibiting
both theGram-negativebacterialgrowthandthe toxiceffectof the
outer membrane component LPS [31,32]. Interestingly, LPS was
foundtobethekeymoleculeunderlyingthemolecularmechanism
of both types of synergism [33], and this finding represents the
first case reported so far in the literature. While temporin-1Tl is
highly active on a wide range of microorganisms, but with a
lytic effect on red blood cells, temporin-1Ta is mainly active on
Gram-positive bacteria and is not hemolytic. This might be linked
to the lower α-helical content of temporin-1Ta than Tl, and, as
a result, to its inability to deeply insert into the hydrophobic
core of zwitterionic membranes, such as those of eukaryotic
cells [34]. Importantly, rational design of CAMPs represents an
attractive approach to the improvement of their antimicrobial
properties.
Here, to address the influence of each amino acid residue of
temporin-1Ta on the selective activity of this peptide, an Ala-
scanning analysis was carried out. Besides getting insight into
the structure–function relationships of this temporin isoform,
the results of our studies provide important information for the
optimization of temporin-based anti-infective agents and the
design of temporin analogs to be employed in biophysical studies
for a better understanding of their membrane-active properties.
Materials andMethods
Peptide Synthesis
Nα-Fmoc-protected amino acids, HBTU, HOBt, and Rink amide
resin were purchased from GL Biochem Ltd (Shanghai, China).
Peptide synthesis solvents, reagents, as well as CH3CN for HPLC
were reagent grade and were acquired from commercial sources
and used without further purification unless otherwise noted. The
syntheses of temporin-1Ta analogs were performed in a stepwise
manner via the solid-phase method [35]. For example, for the
synthesis of Ta, Nα-Fmoc-Leu-OHwas coupled to Rink amide resin
(0.5 g, 0.7 mmol NH2/g). The following protected amino acids
were then added stepwise: Nα-Fmoc-Ile-OH, Nα-Fmoc-Gly-OH,
Table 1. Analytical data for temporin-1Ta and its analogs
HPLCa MS (M+H)
Peptide k′ Foundb Calculated
1Ta 6.86 1397.13 1396.79
Ta A1 7.87 1321.90 1320.69
Ta A2 8.40 1355.70 1354.71
Ta A3 8.09 1370.51 1370.75
Ta A4 7.98 1355.54 1354.71
Ta A5 8.00 1355.81 1354.71
Ta A6 7.55 1411.10 1410.82
Ta A7 10.37 1312.62 1311.68
Ta A8 9.23 1368.69 1368.74
Ta A9 8.13 1355.18 1354.71
Ta A10 8.85 1381.80 1380.79
Ta A11 7.41 1411.30 1410.82
Ta A12 8.21 1354.62 1354.71
Ta A13 7.66 1354.36 1354.71
a k′ [(peptide retention time – solvent retention time)/solvent retention
time].
b Molecular masses were determined by LC-MS.
Nα-Fmoc-Ser-OH, Nα-Fmoc-Leu-OH, Nα-Fmoc-Val-OH, Nα-Fmoc-
Arg(Pbf)-OH, Nα-Fmoc-Gly-OH, Nα-Fmoc-Ile-OH, Nα-Fmoc-Leu-
OH, Nα-Fmoc-Pro-OH, Nα-Fmoc-Leu-OH, and Nα-Fmoc-Phe-OH.
Each coupling reactionwas accomplished using a threefold excess
of aminoacidwithHBTUandHOBt in thepresenceofDIEA. TheNα-
Fmoc protecting groups were removed by treating the protected
peptide resin with a 25% solution of piperidine in DMF (1 × 5 min
and 1 × 20 min). The peptide resin was washed three times with
DMFandthenextcouplingstepwas initiated inastepwisemanner.
All reactionswereperformedunderanAratmosphere. Thepeptide
resin was washed with DCM (3×), DMF (3×) and DCM (4×), and
the deprotection protocol was repeated after each coupling step.
The N-terminal Fmoc group was removed as described above
and the peptide was released from the resin with TFA/Et3SiH/H2O
(90 : 5:5) for 3 h. The resin was removed by filtration and the crude
peptide was recovered by precipitation with cold anhydrous ethyl
ether to give a white powder which was purified by RP-HPLC on
a semi-preparative C18-bonded silica column (Vydac 218TP1010,
1.0×25 cm) using a gradient of CH3CN in 0.1% aqueous TFA (from
10 to 90% in 30 min) at a flow rate of 1.0 ml/min. The product
was obtained by lyophilization of the appropriate fractions after
removal of the CH3CN by rotary evaporation. Analytical RP-HPLC
indicated a purity >98% and molecular weights were confirmed
by LC-MS (6110 Quadrupole, Agilent Technologies) (Table 1).
Microorganisms
The strains used for the antimicrobial assays were the following:
the Gram-negative bacteria Escherichia coli ATCC 25922, Yersinia
pseudotuberculosis YPIII; the Gram-positive bacteria Bacillus mega-
teriumBm11,StaphylococcusaureusCowan I,Staphylococcuscapitis
1, and the yeast Candida albicans ATCC 10231.
Antimicrobial Assay
Susceptibility testing was performed by adapting the microbroth
dilutionmethodoutlinedby the Clinical and Laboratory Standards
Institute using sterile 96-well plates (Falcon, NJ, USA). Aliquots
J. Pept. Sci. 2011; 17: 358–365 Copyright c© 2011 European Peptide Society and John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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(50 µl) of bacteria in mid-log phase at a concentration of 2 × 106
CFU/ml inculturemedium(MHB)wereaddedto50 µl ofMHBbroth
containing the peptide in serial twofold dilutions in 20% ethanol.
The ranges of peptide dilutions used were 1.25–40 µM. The same
procedure was followed with yeast strains, but using Winge
medium [36]. Inhibition of microbial growth was determined
by measuring the absorbance at 600 nm, after an incubation of
18–20 h at 37 ◦C (30 ◦C for yeasts), with a 450-Bio-Rad Microplate
Reader. Antimicrobial activities were expressed as the MIC, the
concentration of peptide at which 100% inhibition of microbial
growth is observed after 18–20 h of incubation.
Hemolytic Assay
The hemolytic activity of the peptides was determined using fresh
human erythrocytes from healthy donors. Blood was centrifuged
and the erythrocytes were washed three times with 0.9% NaCl.
Peptides dissolved in 20% ethanol were added to the erythrocyte
suspension (5%, v : v), at a final concentration ranging from 1.25
to 40 µM in a final volume of 100 µl. Samples were incubated
with agitation at 37 ◦C for 40 min. The release of hemoglobin was
monitored bymeasuring the absorbance (Abs) of the supernatant
at 540 nm. Control for zero hemolysis (blank) consisted of
erythrocytes suspended in the presence of peptide solvent (20%
ethanol at a final concentration of 0.6%). Hypotonically lysed
erythrocytes were used as a standard for 100% hemolysis. The
percentage of hemolysis was calculated using the following
equation: % hemolysis = [(Abssample − Absblank)/(Abstotal lysis −
Absblank)] × 100.
Circolar Dicroism
All CD spectra were recorded using a JASCO J710 spectropo-
larimeter at 25 ◦C with a cell of 1 mm path length. The CD spectra
were acquired by the range from 260 nm to 190 nm 1 nm band-
width, four accumulations, and 100 nm/min scanning speed. The
CD spectra of the peptides at a concentration of 100 µM were
performed inwater (pH= 7.4), in SDS (20 mM) and inDPC (20 mM)
micellar solutions.
Results
Antibacterial Activity
In order to assess the role of each individual amino acid
in the antimicrobial activity of temporin-1Ta, we performed
an Ala scan study by systematically replacing single residues
with the neutral amino acid Ala. The antimicrobial activity of
these analogs was analyzed by the microbroth dilution method
against two Gram-negative bacteria (E. coli ATCC 25922 and
Y. pseudotuberculosis YPIII), three Gram-positive bacteria (S. aureus
Cowan I, B. megaterium Bm11 and S. capitis 1), and the yeast
C. albicans ATCC 10231. The results are shown in Table 2. The data
pointed out that the following substitutions had marked impact
on the antimicrobial activity of the natural peptide, exhibiting
multiple MIC values (2-4-8-fold higher) than those of temporin-
1Ta, against allmicroorganisms. Thesewere: (i) the replacement of
the N-terminal Phe (Ta A1); (ii) the substitution of the hydrophobic
Leu in positions 2, 4, 9, and 13 (Ta A2, Ta A4, Ta A9, and Ta A13);
(iii) the change of Ile in positions 5 and 12 (Ta A5 and Ta A12);
(iv) the change of the positively charged Arg7 (Ta A7), as well as
(v) the replacement of the hydrophobic Val8 (Ta A8). In contrast,
substitution of Pro3, Gly6, Ser10 or Gly11 with Ala (Ta A3, Ta A6,
Ta A10, Ta A11) preserved the antibacterial activity of the parent
peptide on Y. pseudotuberculosis, B. megaterium, and S. capitis, and
increased its activity against both the Gram-positive bacterium S.
aureus and the yeast C. albicans, giving two to fourfold lower MICs
(Table 2).
Hemolysis
Hemolytic activity was determined against human erythrocytes,
as described in the Experimental section. The data highlighted a
correlation between the antibacterial and the hemolytic activities.
Indeed, the most active antimicrobial analogs (Ta A3, Ta A6, Ta
A10, and Ta A11) also displayed the highest hemolytic activity at a
peptide concentration range from20 to40 µM,while a comparable
hemolysis caused by the parent peptide 1Ta was observed at the
lower concentrations (Table 3). An exception was given by Ta A3
and Ta A11, whose lytic effect was found to be two to threefold
more potent than that of 1Ta, also at 10 µM. Interestingly, a
considerable enhancement of hemolytic activity was induced by
the presence of Ala at the N-terminus of the natural temporin
(Ta A1), as well as by the replacement of the single basic residue
Arg7 (Ta A7) (Table 3). Conversely, all the other analogs with Ala
substitution in positions 2, 4, 5, 8, 9, 12, and 13 appeared to be
almost devoid of toxic effect on human erythrocytes (Table 3).
Conformational Studies
The secondary structureof theanalogsTaA1-A13was investigated
using CD spectroscopy in water, SDS/water, and DPC/water
solutions. CD spectra in water (pH 7.4) demonstrated the
presence of disordered conformers for all compounds, with a
minimum close to 198 nm (data not shown). In contrast, in
SDS and DPC micelles solution, which were used to mimic the
negatively charged (microbial) and the zwitterionic (eukaryotic)
cellmembranes, respectively, theshapeof theCDspectra indicated
that peptides adopted a defined secondary structure. In particular,
the CD spectra displayed two minima around 209 and 222 nm,
characteristic ofα-helix structures (Figure 1). Helical contentswere
predicted from the CD spectra using the SOMCD method [38]
(Table 2). Generally, helical contents observed in SDS and DPC
micelle solutions were similar, with a certain reduction in SDS
(about 5–10%) compared to DPC. The highest helical content was
noted in Ta A3, Ta A6, and in Ta A11 (about 70% and 60% in
DPC and SDS, respectively). In these peptides, the replacement
of a proline (Ta A3) or a glycine residue (Ta A6 and Ta A11)
clearly increased the helical content compared to that of the
native peptide 1Ta (55% and 50% in DPC and SDS, respectively).
An increase of the α-helical content with respect to 1Ta was
also observed in Ta A7. In contrast, replacement of the aliphatic
residues Leu2,4,9, Ile5, and Val8 reduced the helical percentage.
In particular, Ta A5 and Ta A9 showed the lowest helicity (about
50% and 46% in DPC and SDS, respectively) probably due to the
central position of the replaced amino acids along the peptide
sequence. Note that earlier studies had evidenced that in both
SDS and DPC micelles, temporin-1Ta adopted an amphiphatic
α-helix when considering the central residues 6–9 [34]. Finally,
no variation in the α-helical content was detected when Ile12 and
the C-terminal Leu13 were replaced, whereas substitution of Phe1
or Ser10 (Ta A1 or Ta A10) increased the helical content of the
native peptide in DPC (60 or 56%, respectively), but not in SDS
solution.
wileyonlinelibrary.com/journal/jpepsci Copyright c© 2011 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2011; 17: 358–365
3
6
1
ALANINE SCANNING OF TEMPORIN-1TA
Ta
b
le
2
.
Te
m
p
o
ri
n
-1
Ta
A
la
-s
ca
n
co
m
p
ar
is
o
n
w
it
h
re
sp
ec
tt
o
ch
ar
g
e,
H
,µ
H
,%
h
el
ic
it
y,
an
d
M
IC
o
n
d
iff
er
en
tm
ic
ro
b
ia
ls
tr
ai
n
s
%
H
el
ix
M
IC
(µ
M
)
G
ra
m
-n
eg
at
iv
es
G
ra
m
-p
o
si
ti
ve
s
Y
ea
st
s
Pe
p
ti
d
es
A
m
in
o
ac
id
se
q
u
en
ce
s
C
h
ar
g
e
H
µ
H
D
PC
SD
S
E.
co
li
Y.
ps
eu
do
-t
ub
er
cu
lo
si
s
S.
au
re
us
B.
m
eg
at
er
iu
m
S.
ca
pi
tis
C
.a
lb
ic
an
s
1T
a
FL
PL
IG
RV
LS
G
IL
-N
H
2
+2
0.
22
0.
35
55
50
>
40
20
5
2.
5
5
5
Ta
A
1
A
LP
LI
G
RV
LS
G
IL
-N
H
2
+2
0.
2
0.
33
60
50
>
40
>
40
>
40
20
>
40
>
40
Ta
A
2
FA
PL
IG
RV
LS
G
IL
-N
H
2
+2
0.
2
0.
34
54
49
>
40
40
20
5
20
10
Ta
A
3
FL
A
LI
G
RV
LS
G
IL
-N
H
2
+2
0.
25
0.
33
69
57
>
40
20
2.
5
2.
5
2.
5
1.
25
Ta
A
4
FL
PA
IG
RV
LS
G
IL
-N
H
2
+2
0.
2
0.
36
53
49
>
40
40
40
5
20
10
Ta
A
5
FL
PL
A
G
RV
LS
G
IL
-N
H
2
+2
0.
19
0.
31
50
46
>
40
>
40
40
20
40
20
Ta
A
6
FL
PL
IA
RV
LS
G
IL
-N
H
2
+2
0.
23
0.
35
71
65
>
40
20
2.
5
2.
5
5
2.
5
Ta
A
7
FL
PL
IG
A
V
LS
G
IL
-N
H
2
+1
0.
38
0.
21
63
52
>
40
>
40
>
40
>
40
>
40
>
40
Ta
A
8
FL
PL
IG
RA
LS
G
IL
-N
H
2
+2
0.
2
0.
34
54
51
>
40
40
20
5
20
10
Ta
A
9
FL
PL
IG
RV
A
SG
IL
-N
H
2
+2
0.
2
0.
34
51
46
>
40
>
40
>
40
>
40
>
40
>
40
Ta
A
10
FL
PL
IG
RV
LA
G
IL
-N
H
2
+2
0.
26
0.
32
56
50
>
40
20
2.
5
2.
5
5
2.
5
Ta
A
11
FL
PL
IG
RV
LS
A
IL
-N
H
2
+2
0.
23
0.
35
71
61
>
40
20
2.
5
2.
5
5
2.
5
Ta
A
12
FL
PL
IG
RV
LS
G
A
L-
N
H
2
+2
0.
19
0.
32
55
49
>
40
>
40
40
20
>
40
20
Ta
A
13
FL
PL
IG
RV
LS
G
IA
-N
H
2
+2
0.
2
0.
35
55
50
>
40
>
40
>
40
20
>
40
40
M
ea
n
re
si
d
u
e
h
yd
ro
p
h
o
b
ic
it
y
an
d
h
yd
ro
p
h
o
b
ic
m
o
m
en
tw
er
e
ca
lc
u
la
te
d
u
si
n
g
th
e
Ei
se
n
b
er
g
sc
al
e
o
fh
yd
ro
p
h
o
b
ic
it
y
[3
7]
.
J. Pept. Sci. 2011; 17: 358–365 Copyright c© 2011 European Peptide Society and John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
3
6
2
GRIECO ET AL.
Mean Hydrophobicity H andMean Hydrophobic MomentµH
Eisenberg consensus scale was used to calculate both the mean
hydrophobicity H and the mean hydrophobic moment µH [37].
The mean hydrophobicity is a measure of the amino acid
residue relativeaffinities forhydrophobicphases. Thehydrophobic
moment is a measure of the amphiphilicity or asymmetry of
hydrophobicity of a polypeptide chain’s segment. The helical
wheel presentation of temporin-1Ta is given in Figure 2. We
noted that temporin-1Ta analogs with H ranging from 0.23
to 0.26 (Table 2) and with a mean hydrophobic moment µH
calculated to range between 0.32 and 0.36, had the same or
a two to fourfold lower MIC than that of the natural temporin
(H = 0.22 and µH = 0.35), against all the tested microorganims,
butwithan increasedhemolyticactivity (Tables 2and3).Adifferent
behavior was manifested by the analog lacking the single basic
residue, Ta A7. Indeed, despite its high hydrophobicity (H = 0.38)
and hemolytic activity, ranging from 15 to 52% at a peptide
concentration between 2.5 and 20 µM (Table 3), Ta A7 was the
least active peptide against both bacteria and fungi, together
with Ta A9 (H = 0.2) (Table 2). Otherwise, peptide analogs whose
hydrophobicity was lower than that of temporin-1Ta were almost
devoid of antimicrobial and hemolytic activities, except for Ta A1,
where the loss of the N-terminal Phe increased the lytic effect on
red blood cells (Table 3). Importantly, the hydrophobic moment
was not found to influence the biological activity of the peptide.
Discussion
All living organisms are constantly exposed to multiple harmful
microbes and the capacity to overcome infections is essential for
their survival. Therefore, several host defence mechanisms have
been engendered during evolution, including the generation of
fast acting weapons, such as the CAMPs [39–41]. Among the
several sources for natural CAMPs, amphibian skin is the major
one [42], especially that of frogs of the genus Rana, which has
a worldwide distribution with approximately 250 species [26].
Their synthesis is transcriptionally regulated by the NF-κB/IκBα
machinery [43] and modulated by exposure to microorganisms
[44]. In these animals, CAMPs are stored in granules of holocrine-
type dermal glands and released into the skin secretion, as a
reaction to stress or injury [25]. Remarkably, temporins represent
the largest family and are among the shortest α-helical CAMPs
found in nature to date. In addition, they have unique properties:
(i) they contain only oneor twobasic amino acids; (ii) most of them
are not toxic toward mammalian cells; (iii) they have a fast killing
activity; (iv) some of them synergize in both the antimicrobial and
anti-endotoxin activities; (v) they partially preserve antimicrobial
activity in serum [45]; and (vi) they are endowedwith chemotactic
activity towards human phagocytes [46], which represents an
important link between the innate and adaptive immune system,
recruiting immune cells to the sites of infection. Note that the first
stage of a CAMP in selecting the target microorganism includes
its electrostatic attraction to the cell surface, which contains
anionic molecules such as LPS in Gram-negative bacteria [47], and
teichoic acids in Gram-positive bacteria. Following electrostatic
binding, the CAMP reaches the cell membrane, composed
predominantly of phosphatidylethanolamine and the negatively
charged phosphatidylglycerol, and alters its permeability by
making transmembrane pores or destroying the membrane’s
structure in a detergent-like manner [17]. Importantly, several
studies have pointed out that temporins are membrane-active
CAMPs. However, the range of the crucial peptide parameters
required for their molecular mechanism is still not yet completely
known.
We have presented a structure-activity study of the frog-skin
peptide temporin-1Ta by replacing each individual amino acid
with Ala. This standard Ala-positional scanning has identified
four analogs (Ta A3, Ta A6, Ta A10, and Ta A11) with a higher
hydrophobicity and a higher percentage of α-helix compared to
the natural peptide, in both DPC and SDS. All of them display not
only the same or a better antimicrobial activity than temporin-
1Ta but also a higher lytic effect on human erythrocytes. It
is worthwhile noting that all these substitutions reside at the
hydrophilic face of the peptide (Figure 2). However, substitution
of ArgwithAla (Ta A7), also located at the polar face of the peptide,
suppresses its antimicrobial effect against all microorganisms
(Table 2). This is in agreement with reports of other authors [48]
and is probably due to the loss of the single positively charged
residue (Arg) in the sequence, causing a weaker electrostatic
interaction with the microbial membrane. In comparison, when
amino acid substitutions with the neutral and inert Ala take place
at the hydrophobic side of the molecule (Ta A1, Ta A2, Ta A4, Ta
A5, Ta A8, Ta A9, Ta A12, and Ta A13), (Figure 2) a clear decrease
or almost abolishment of the antimicrobial activity occurs, along
with a significant decrease in the hemolytic activity. Ta A1 is an
exception, because it exhibits two to threefold higher hemolytic
activity compared to the parent peptide (Table 3).
Overall, our data have indicated that hydrophobicity and
cationicity, more than helicity, are the main critical biophysical
properties that determine the antimicrobial potency of temporin-
1Ta, whereas the mean peptide hydrophobicity and helicity
represent the main parameters that govern the peptide’s toxicity
towards eukaryotic cells. In fact, a direct correlation between
the helical content in DPC and the hemolytic activity could be
detected (Tables 2 and 3). The most hemolytic peptides of the
series are those (Ta A1, Ta A3, Ta A6, Ta A7, and Ta A11) adopting
the highest helical content in DPC, while the less hemolytic ones
have the lowest helical percentage (Ta A5 and Ta A9). However,
an exception is given by Ta A12 and Ta A13: indeed, despite their
negligible hemolytic activity, their helical content is similar to that
of 1Ta. Probably, highly hydrophobic residues at the C-terminus,
suchas Ile12 andLeu13, areneededfor thepeptide interactionswith
zwitterionic membranes. Noteworthy, because the cationicity is
a fundamental requisite for the ‘carpet-like’ mechanism of action
of CAMPs and both helicity and hydrophobicity play a crucial
role in the membrane interaction of CAMPs that act via the
‘barrel-stave’ mechanism [17], our findings seem to fit well with
the ‘carpet-like’ and the ‘barrel-stave’ models that explain the
antimicrobial and hemolytic activities of temporins, respectively
[34,49]. Nevertheless, in regard to the latter model, which includes
the formation of a transmembrane pore, it should be recalled that
temporins are not long enough to span a phospholipid bilayer
as α-helices, a property requiring a length of 20 amino acids for
a 30 Å thick phospholipid bilayer [50]. Therefore, these peptides
tend to form holes in a more elaborated way, perhaps due to their
end-to-end dimerization [51].
The finding that enhancement of hydrophobicity increases
the hemolytic and antibacterial activities of temporin-1Ta is con-
sistent with what has already been found in magainin-2 [52];
on the contrary, no correlation between hydrophobicity and
hemolytic/antimicrobial activity could be detected in other mem-
bers of the temporin family, such as temporin-1Tl analogs, the
percentage of helicity being the principal parameter controlling
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Table 3. Hemolytic activity of temporin-1Ta Ala-scan on human erythrocytes, at different peptide concentrations
% Hemolysis
Peptide Peptide
concentration
(µM) 1Ta Ta A1 Ta A2 Ta A3 Ta A4 Ta A5 Ta A6 Ta A7 Ta A8 Ta A9 Ta A10 Ta A11 Ta A12 Ta A13
40 27.5 62.5 15 100 11.5 3.5 97 39 10.5 3.5 70 100 1 3.5
20 12.5 39 5.5 89.5 10 2.5 27.5 52.5 10 4 14 92.5 0.5 3.5
10 9.5 11.5 2.5 23.5 8 1.5 10.5 39 12 1.5 5.5 32.5 0 3
5 3.5 8 1.5 4.5 6.5 0.5 3.5 27.5 8.5 1 5.5 13 0 0
2.5 0.5 5.5 0.5 2 2 0.5 3.5 15 6.5 1 1 5.5 0 0
1.25 0.5 2 0 0 2 0 1 6 1.5 0 0 3.5 0 0
Figure 1. CD spectra of 1Ta analogs in (A) DPC, (B) SDS (1Ta, purple line; Ta A1, black line; Ta A3, red line; Ta A5, green line; Ta A6, blue line; Ta A7, yellow
line). For the sake of clarity, Ta A2, Ta A4, Ta A8, Ta A10, Ta A12, and Ta A13 spectra were not reported since they were almost superposable with those
of 1Ta. Similarly, Ta A9 and Ta A11 spectra were not shown because very similar to those of Ta A5 and Ta A3, respectively. [Q]MR: mean residue molar
ellipticity.
Figure 2. Helical wheel projection of temporin-1Ta. Green squares, yellow
circles, and blue pentagons refer to non polar, polar uncharged, and basic
residues, respectively.
the peptide’s hemolytic effect (Mangoni ML et al., unpublished
results). Obviously, a large number of factors (peptide’s charge dis-
tribution, hydrophobicity, helicity, oligomeric state, amphiphilic-
ity, and composition of the target cell membrane) cooperate in
modulating the ability of a CAMP to disturb the organization of
microbial membranes, and the target cell selectivity and potency
of a CAMP cannot be easily predicted.
In conclusion, we can state that despite other structure–
function relationship studies that have beenperformedwith some
analogs of temporin-1Ta [48,50,53], this work is the first report
demonstrating the contribution of each amino acid residue to the
antimicrobial/hemolytic activity of temporin-1Ta, by the standard
alanine-positional scanning. The correlation found between the
net charge, helicity, hydrophobicity, and hydrophobic moment
due to a single substitution has increased our knowledge on the
physicochemical attributes and structural properties underlying
the biological activity of temporin-1Ta, and should assist in
optimizing the design andmanufacturing of temporin-based lead
structures for the development of new anti-infective agents with
expanding properties.
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The frog skin peptide temporin L (TL, 13-residues long) has a wide and potent spectrum of antimicrobial ac-
tivity, but it is also toxic on mammalian cells at its microbicidal concentrations. Previous studies have indicat-
ed that its analogue [Pro3]TL has a slightly reduced hemolytic activity and a stable helical conformation along
residues 6–13. Here, to expand our knowledge on the relationship between the extent/position of α-helix in
TL and its biological activities, we systematically replaced single amino acids within the α-helical domain of
[Pro3]TL with the corresponding D isomers, known as helix breakers. Structure–activity relationship studies
of these analogues, by means of CD and NMR spectroscopy analyses as well as antimicrobial and hemolytic
assays were performed. Besides increasing our understanding on the structural elements that are responsible
for cell selectivity of TL, this study revealed that a single L to D amino acid substitution can preserve strong
anti-Candida activity of [Pro3]TL, without giving a toxic effect towards human cells.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
Extensive clinical usage of classical antibiotics/antimycotics has led
to the growing emergence of many medically relevant resistant
microbes making the discovery of alternative drugs remarkably critical
[1,2]. Antimicrobial peptides (AMPs) existing in virtually all species of
life have been shown to exert direct killing activity on a large number
of invading microorganisms. They represent the most ancient and
fast-acting elements of the host's innate defence system against micro-
bial pathogens [3,4]. At present, these AMPs are considered as promis-
ing candidates for the generation of a new class of anti-infective
agents [5–8]. They have been thoroughly investigated particularly in
those animals (e.g. insects) lacking an adaptive immune system [9].
However, a large part of the current knowledge on the peptide-
mediated innate immunity comes from studies performed with mam-
malian AMPs and with AMPs from amphibian skin secretions that are
known to be a rich storehouse of various bioactive peptides [10,11]. Al-
though the exact mode of action of AMPs has not been established yet,
all of them interactwithmicrobialmembranes. They accumulatewithin
the membranes and increase their permeability causing the loss of bar-
rier function and death of the microbe [12,13]. Note that recent high
resolution structural studies have provided important mechanistic in-
sights into the conformation of AMPs required for their translocation
across the lipopolysaccharide (LPS or endotoxin) outer membrane of
Gram-negative bacteria [14,15], as well as for their ability to permeate
phospholipid bilayers mimicking various membranes, via the barrel-
stave or carpet-like mechanism (as e.g. in the case of pardaxin [16,17],
LL-37 [18], and MSI-594, a synthetic hybrid of MSI-78 and melittin
[19,20]). Alternatively, peptides can enter the cell and inhibit vital
Biochimica et Biophysica Acta 1828 (2013) 652–660
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processes, e.g. DNAduplication, protein/cellwall synthesis [21–25]. This
multiple targeting and physical disruption of fundamental physiological
cell structures (i.e. the cytoplasmic membrane) makes bacteria and
fungi less likely to become resistant to AMPs, compared to conventional
antimicrobials that usually act via a receptor-mediated mechanism
[26,27].
The skin of several frog species, such as those belonging to the
Rana genus, has proved to be an inexhaustible source of AMPs with
a wide spectrum of activity [28,29]. For example, the amphibian
temporins represent one of the largest families (more than 100 mem-
bers) and are among the smallest-sized AMPs (10–14 amino acids)
found in nature to date. They are mildly cationic peptides, due to
the presence of only 1 or 2 basic residues in their sequence; they
are amidated at the C-terminus and adopt an amphipathic α-helical
preferential conformation in a hydrophobic environment [30]. Gener-
ally speaking, temporins are known to be active particularly against
Gram-positive bacteria, with minimal inhibitory concentrations rang-
ing from 2.5 μM to 20 μM. The only exception is given by the isoform
temporin TL (TL, H-Phe1-Val2-Gln3-Trp4-Phe5-Ser6-Lys7-Phe8-Leu9-
Gly10-Arg11-Ile12-Leu13-NH2), as it is strongly active also against
Gram-negative bacteria and yeast strains [31]. The bacterial killing ki-
netics of temporins overlaps that of membrane perturbation [32]. As
found for other AMPs, some temporins have shown immunomodula-
tory properties (e.g. chemotactic to human phagocytes [33]) and can
neutralize the toxic effect of LPS [34]. In this context, important NMR
studies of different native or de-novo designed host-defence peptides
have recently been carried out to know the specific conformation of
AMPs in their LPS-bound state [14,20,35].
Furthermore, temporins synergize when combined with other
temporin-isoforms (i.e. the couples TA+TL and TB+TL) in both the an-
timicrobial and anti-endotoxin activities [36,37]. Most of them are prac-
tically non-hemolytic, but the highly potent temporin L kills human
erythrocytes at microbicidal concentrations [31] and was revealed to
be toxic in vivo, when tested on Caenorhabditis elegans worms [38].
Therefore, to be developed as a future broad spectrum antibiotic, it is
necessary to increase its therapeutic index which is defined as the
ratio between the concentration of its hemolytic activity and antimicro-
bial activity [39]. Recent studies on the structure/activity relationships of
both native TL and its synthetic analogues have clearly indicated the ex-
istence of a direct correlation between the hemolytic activity of the pep-
tide and its α-helical content [40]. In contrast, no such connection was
found with the antimicrobial activity. Indeed, disrupting the peptide's
α-helix at its N-terminus by replacing Gln3 with a proline ([Pro3]TL)
did not significantly affect the antibacterial activity, while the hemolytic
activity was reduced by more than half, up to 12 μM, a concentration
causing about 90% hemolysis for the native TL [41]. Interestingly, the
effects of proline substitution on the biological activity of other am-
phibian skin AMPs, such as maculatin peptide from the Australian
tree frog species Litoria genimaculata, have been previously evaluat-
ed [42]. Similar to our findings with TL analogues, removal of proline
in maculatin 1.1 increased the peptide's interaction with neutral
phospholipid bilayers, together with enhanced hemolytic activity.
However, in contrast with what has been found with TL analogues,
this was accompanied by a strong reduction in the antibiotic activity
and lytic effect of maculatin on anionic membranes [42,43].
Nevertheless, the disruption of the α-helix of TL at its N and
C-terminal ends, by replacing Gln3 and Gly10 with Pro ([Pro3, Pro10]
TL), induced a drastic decrease in both the hemolytic and anti-
bacterial activities [40]. Previous NMR studies with [Pro3]TL in
sodium dodecylsulphate (SDS) and dodecylphosphocholine (DPC)
micelles, mimicking the anionic and zwitterionic character of bacteri-
al and erythrocyte membrane, respectively [41], revealed a stable he-
lical conformation along residues 6–13 [44]. Here, to get a deeper
insight into the relationship between the extent/position of the
α-helix along the sequence of TL and the biological activity of this
peptide, six derivatives of [Pro3]TL were synthesized and analyzed
by means of antimicrobial and hemolytic assays combined with CD
and NMR spectroscopy. More specifically, such derivatives were
obtained by a systematic replacement of single residues within the
α-helix domain (Lys7 to Leu13) of [Pro3]TL with D enantiomers,
known as helical breakers. The results provide a better understanding
on the structural elements that are responsible for the cell selectivity
of TL. Most importantly, we have identified an analogue endowed
with high anti-Candida activity, a slightly reduced antibacterial
potency than the native TL, but practically devoid of any lytic effect
on mammalian cells. This novel TL derivative represents a fascinating
template for the development of novel temporin-based anti-infective
drugs with increased therapeutic index.
2. Materials and methods
2.1. Materials
Nα-Fmoc-protected amino acids, 2-(1H-benzotriazole-1-yl)-1,
1,3,3-tetramethyluronium hexafluoro-phosphate (HBTU), N-hydroxy-
benzotriazole (HOBt) and Rink amide resin were purchased from
GL Biochem Ltd (Shanghai, China). Peptide synthesis solvents, re-
agents, as well as CH3CN for HPLC were reagent grade and were
acquired from commercial sources and used without further purifi-
cation unless otherwise noted. See Supplementary material for
more details on peptide synthesis and analytical data (Supplemen-
tary Table S1).
The following lipids: 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE); 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol (POPG); cardiolipin (CL); 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) and cholesterol (Cho) were
purchased from Avanti Polar Lipids (Alabaster, AL, USA). SDS-d25
and DPC-d38 were obtained from Cambridge Isotope Laboratories,
Inc. (Andover, MA); calcein, from Sigma (St Louis, MO, USA). All
other chemicals used were of reagent grade.
2.2. Microorganisms
The strains used for the antimicrobial assays were the follow-
ing: the Gram-negative bacteria Acinetobacter baumannii ATCC
19606, Acinetobacter junii RT-4, Escherichia coli ATCC 25922, E.
coli D21, Pseudomonas aeruginosa ATCC 15692, P. aeruginosa
ATCC 27853, Pseudomonas syringae pv tabaci 1918NCPPB, and
Yersinia pseudotuberculosis YPIII; the Gram-positive bacteria Bacillus
megaterium Bm11, Staphylococcus aureus ATCC 25923, S. aureus Cowan
I, Staphylococcus capitis 1, Staphylococcus epidermidis ATCC 12228, and
Streptococcus pyogenes ATCC 21547 and the yeasts Candida albicans
ATCC 10231, C. albicans clinical isolates (strains n. 1, 2, 3 and 4),
Saccharomyces cerevisiae, and Saccharomyces pombe.
2.3. Antimicrobial assay
Susceptibility testing was performed by adapting the microbroth
dilution method outlined by the Clinical and Laboratory Standards
Institute, using sterile 96-well plates (Falcon NJ, USA). The growth
of the bacterial and yeast cells was aseptically measured by absor-
bance at 590 nm with a spectrophotometer (UV-1700 Pharma Spec
Shimadzu, Tokyo, Japan). Afterwards, aliquots (50 μL) of bacteria in
mid-log phase at a concentration of 2×106 colony-forming units
(CFU)/mL in culture medium (Mueller-Hinton, MH) were added to
50 μL of MH broth containing the peptide in serial 2-fold dilutions
ranging from 0.75 to 48 μM. The same procedure was followed with
yeasts inWingemedium [45] (a final cell concentration of approximately
3.5×104 CFU/mL and 3×105 CFU/mL for Candida and Saccharomyces
strains, respectively). Inhibition of microbial growth was determined by
measuring the absorbance at 590 nm, after an incubation of 18 h at
37 °C (30 °C for yeasts), with a microplate reader (Infinite M200; Tecan,
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Salzburg, Austria). Antimicrobial activitieswere expressed as theminimal
inhibitory concentration (MIC), the concentration of peptide at which
100% inhibition of microbial growth is observed after 18 h of incubation.
2.4. Hemolytic assay
The hemolytic activity was measured on human red blood cells as
reported previously [40]. Freshly collected human blood with EDTA
was centrifuged for 10 min at 1000×g and the erythrocytes obtained
were washed three times with 0.9% (w/v) NaCl, centrifuged as above,
and resuspended in 0.9% NaCl to approximately 1.5×108 cells/mL.
Then, 95 μL aliquots of the erythrocyte suspension were incubated
with 5 μL of serial two-fold dilutions of the peptide for 40 min at
37 °C with gentle mixing. The samples were then centrifuged and the
absorbance of the supernatant was measured at 415 nm. Complete
lysis was measured by suspending erythrocytes in distilled water [46].
2.5. Cytotoxic activity
The cytotoxic effect of the peptides was determined by the inhibi-
tion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction to insoluble formazan, by mitochondrial reductases,
on the immortalized human keratinocyte (HaCaT) cells. Cells were
cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma)
supplementedwith 10% heat-inactivated fetal bovine serum, glutamine
(4 mM) and antibiotics (penicillin and streptomycin) and then plated
in triplicate wells at 1×104 cells/well (96-well plates were used).
After 2 h at 37 °C in a 5% CO2 atmosphere, the medium was replaced
with 100 μL fresh DMEM supplemented with the peptide at different
concentrations. The plate was then incubated for 90 min at 37 °C in a
5% CO2 atmosphere. Afterwards, the medium was removed and re-
placed with fresh DMEM containing 0.5 mg/mL MTT. After 4-h incuba-
tion, the formazan crystals were dissolved by adding 100 μL of acidified
isopropanol and viability was determined by absorbance measure-
ments at 595 nm. Cell viability was calculated with respect to control
cells (cells not treated with peptide).
2.6. Calcein-loaded large unilamellar vesicles (LUV) and leakage assay
Lipid films of POPE/POPG (7:3, w/w), POPG/CL (6:4, w/w), and
POPC/Cho (9:1, w/w) were prepared by dissolving dry lipids (2 mg of
each lipid mixture) in chloroform/methanol (2:1, v/v) and evaporating
the solvents under a nitrogen stream. The lipid film was then hydrated
with 10 mM Tris and 150 mMNaCl (pH 7.4) containing 60 mM calcein
solution. The liposome suspension was extruded 10 times through a
polycarbonate filter (pore size, 0.1 μm), and free calcein was removed
by gel filtration, using a Sephadex G-25 column (1.5×10 cm; Pharmacia
Biotech AB Uppsala, Sweden) at room temperature. Calcein in the vesi-
cles is highly concentrated, and the fluorescence is self-quenched.
Calcein release induced by the peptide was monitored at 37 °C by the
fluorescence increase (λexcitation=485 nm; λemission=535 nm).
Complete dye release was obtained using 0.1% Triton X-100, which
causes total destruction of lipid vesicles [47].
2.7. Circular dichroism (CD)
All CD spectra were recorded using a JASCO J710 spectropolarimeter
at 25 °C with a cell of 1 mm path length. The CD spectra were acquired
in the range of 260–190 nm, 1 nm bandwidth, 4 accumulations, and
100 nm/min scanning speed. The CD spectra of TL and TL derivates, at
a concentration of 100 μM, were performed in phosphate buffer
(pH=7.4), SDS (20 mM), DPC (20 mM), or DPC/SDS 18/2 mMmicellar
solutions.
2.8. Nuclear magnetic resonance (NMR) spectroscopy
The samples for NMR spectroscopy were prepared by dissolving the
appropriate amount of [Pro3, DLeu9]TL in 0.55 mL of 1H2O, 0.05 mL of
2H2O to obtain a concentration of 1–2 mM peptide and 200 mM
SDS-d25 or DPC-d38. The NMR experiments were performed at pH 5.0.
NH exchange studies were performed by dissolving peptide in
0.60 mL of 2H2O and 200 mM SDS-d25 or DPC-d38. NMR spectra were
recorded on a Varian Unity INOVA 700 MHz spectrometer equipped
with a z-gradient 5 mm triple-resonance probe head. All the spectra
were recorded at a temperature of 25 °C. The spectra were calibrated
relative to 3-(trimethylsilanyl)propionic acid (0.00 ppm) as internal
standard. One-dimensional (1D) NMR spectra were recorded in the
Fourier mode with quadrature detection. 2D DQF-COSY [48,49],
TOCSY [50], and NOESY[51] spectra were recorded in the phase-
sensitive mode using the method from States [52]. Data block sizes
were 2048 addresses in t2 and 512 equidistant t1 values. A mixing
time of 70 ms was used for the TOCSY experiments. NOESY experi-
ments were run with mixing times in the range of 150–300 ms. The
water signal was suppressed by gradient echo [53]. The 2DNMR spectra
were processed using the NMRPipe package [54]. Before Fourier trans-
formation, the time domain data matrices were multiplied by shifted
sin2 functions in both dimensions, and the free induction decay size
was doubled in F1 and F2 by zero filling. The qualitative and quantita-
tive analyses of DQF-COSY, TOCSY and NOESY spectra were obtained
using the interactive program package XEASY [55]. 3JHN-Hα couplings
were difficult to measure probably because of a combination of small
coupling constants and broad lines. The temperature coefficients of
the amide proton chemical shifts were calculated from 1D 1H NMR
and 2D TOCSY experiments performed at different temperatures in
the range of 298–320 K by means of linear regression.
2.9. Structural determinations
The NOE-based distance restraints were obtained from NOESY
spectra collected with a mixing time of 200 ms. Peak volumes were
translated into upper distance bounds with the CALIBA routine from
the DYANA software package [56]. The requisite pseudoatom correc-
tions were applied for non-stereospecifically assigned protons at
prochiral centers and for the methyl group. After discarding redun-
dant and duplicated constraints, the final list of constraints was
used to generate an ensemble of 200 structures by the standard
DYANA protocol of simulated annealing in torsion angle space. No di-
hedral angle restraints and no hydrogen bond restraints were applied.
An error tolerant target function (tf type 3) was used to account for
the peptide intrinsic flexibility. Then, 20/200 structures were chosen,
whose interproton distances best fitted NOE derived distances, and
refined through successive steps of restrained and unrestrained ener-
gy minimization calculations using the Discover algorithm (Accelrys,
San Diego, CA) and the consistent valence force field [57]. No residue
was found in the disallowed region of the Ramachandran plot. The
final structures were analyzed using the InsightII program (Accelrys,
San Diego, CA). Graphical representations were carried out with the
InsightII program. The root-mean-squared-deviation analysis be-
tween energy-minimized structures was carried out with the pro-
gram MOLMOL [58]. The PROMOTIF program was used to extract
details on the location and types of structural secondary motifs [59].
3. Results
3.1. Biological activity
The antibacterial, anti-yeast and hemolytic activities of the
synthesized [Pro3]TL analogues (Table 1) were compared with those
of TL and [Pro3]TL. The data highlighted the following: (i) Replace-
ment of Lys7 with its DLys enantiomer considerably reduced the
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antimicrobial activity of the peptide on Gram-positive and Gram-
negative bacteria. Indeed, its MIC value was 2 to 8-fold higher than
that of TL and [Pro3]TL (Table 2). More specifically, [Pro3, DLys7]TL al-
most lost activity against the Gram-negative P. aeruginosa and E. coli
strains. Furthermore, a 2-fold higher MIC was found against C. albicans
and S. pombe. However, the lytic effect on human red blood cells was
dramatically reduced compared to [Pro3]TL (8% hemolysis versus 92%
at 24 μM) (Table 3). (ii) Replacing the flanking Phe8 with DPhe ([Pro3,
DPhe8]TL), reduced 2–4 fold the antibacterial/anti-yeast activity, where-
as the hemolytic activity became lower than that observed with [Pro3]
TL but higher compared to [Pro3, DLys7]TL (Table 3). (iii) Interestingly,
when Leu9 was replaced with DLeu ([Pro3, DLeu9]TL), the antibacterial
activity was equal or two-fold lower than that of TL (a 4-fold reduction
against two strains out of 14), with an identical efficacy against Candida
and Saccharomyces strains. Furthermore, the lytic activity on erythro-
cytes was almost completely abolished, causing only 9% hemolysis at a
concentration of 48 μM (Table 3). (iv) Replacing the Arg residue in po-
sition 11 with its D enantiomer also resulted in a lower activity (2 to
4-fold higher MIC for the analogue compared with the wild type TL)
against both Gram-positive and Gram-negative bacteria (8-fold higher
MIC only in the case of S. capitis). However, the anti-yeast activity was
weakly affected (Table 2). The percentage of hemolysis caused by this
peptide was much lower than that of TL (16% lysis at 24 μM and 22%
lysis at 48 μM); nevertheless, it was higher than that shown by the afore-
mentioned [Pro3, DLys7]TL and [Pro3, DLeu9]TL analogues (Table 3). (v)
When the chirality of the penultimate Ile residue changed to the D
configuration, a 4-fold lower activity than TL was displayed against
Gram-positive strains. The activity on Gram-negative bacteria also de-
creased, but to a lesser extent. The toxic effect on human erythrocytes
was comparable to that of [Pro3, DArg11]TL. (vi) Finally, when the last res-
idue Leu13 was replaced by its D enantiomer, the antibacterial/anti-yeast/
hemolytic activitieswere generally found to overlap those of [Pro3, DIle12]
TL.
3.2. Peptides' activity on C. albicans clinical isolates
To further expand our knowledge on the anti-Candida activity of the
best analogue ([Pro3, DLeu9]TL), several clinical isolates of C. albicans
were analyzed for their susceptibility to this analogue and to the native
TL. An antimycotic resistant strain was also included for comparison. As
indicated in Table 4, the same MICs were obtained for the two peptides
on all the microorganisms tested.
3.3. Cytotoxicity towards human keratinocytes
The finding of a TL derivative ([Pro3, DLeu9]TL) with a highly
reduced hemolytic activity and with a similar or identical antimicrobial
potency on bacteria or Candida cells, prompted us to determine its tox-
icity against another important type of eukaryotic cells, i.e. themamma-
lian keratinocytes, which are present in several tissues colonized by
Candida cells such as the skin, the oral mucosa as well as the corneal,
conjunctival and genital epithelia. Remarkably, as reported in Table 5,
viability of human keratinocytes after treatmentwith thenative peptide
ranged from 39% to 23%, at a concentration range from 6 to 48 μM; in
Table 1
Sequences of TL analogues.
Compound Sequencesa
TLb H-Phe1-Val2-Gln3-Trp4-Phe5-Ser6-Lys7-Phe8-Leu9-Gly10-Arg11-Ile12-Leu13-NH2
[Pro3]TLb H-Phe1-Val2-Pro3-Trp4-Phe5-Ser6-Lys7-Phe8-Leu9-Gly10-Arg11-Ile12-Leu13-NH2
[Pro3, DLys7]TL H-Phe1-Val2-Pro3-Trp4-Phe5-Ser6-DLys7-Phe8-Leu9-Gly10-Arg11-Ile12-Leu13-NH2
[Pro3, DPhe8]TL H-Phe1-Val2-Pro3-Trp4-Phe5-Ser6-Lys7-DPhe8-Leu9-Gly10-Arg11-Ile12-Leu13-NH2
[Pro3, DLeu9]TL H-Phe1-Val2-Pro3-Trp4-Phe5-Ser6-Lys7-Phe8-DLeu9-Gly10-Arg11-Ile12-Leu13-NH2
[Pro3, DArg11]TL H-Phe1-Val2-Pro3-Trp4-Phe5-Ser6-Lys7-Phe8-Leu9-Gly10-DArg11-Ile12-Leu13-NH2
[Pro3, DIle12]TL H-Phe1-Val2-Pro3-Trp4-Phe5-Ser6-Lys7-Phe8-Leu9-Gly10-Arg11-DIle12-Leu13-NH2
[Pro3, DLeu13]TL H-Phe1-Val2-Pro3-Trp4-Phe5-Ser6-Lys7-Phe8-Leu9-Gly10-Arg11-Ile12-DLeu13-NH2
a Residue variations compared to TL are highlighted in bold.
b Already described in references [40,41].
Table 2
Antimicrobial activity of the synthesized compounds.
MICa (μM)
Strains TL [Pro3]
TL
[Pro3, DLys7]
TL
[Pro3, DPhe8]
TL
[Pro3, DLeu9]
TL
[Pro3, DArg11]
TL
[Pro3, DIle12]
TL
[Pro3, DLeu13]
TL
Gram-negative bacteria
Acinetobacter baumannii ATCC 19606 6 6 24 12 12 12 24 12
Acinetobacter junii RT-4 3 6 6 12 3 6 3 3
Escherichia coli ATCC 25922 12 24 >48 12 12 24 24 24
Escherichia coli D21 12 12 48 24 12 24 12 12
Pseudomonas syringae pv tabaci 6 6 >48 12 24 12 12 12
Pseudomonas aeruginosa ATCC 15692 24 24 >48 >48 >48 >48 48 48
Pseudomonas aeruginosa ATCC 27853 >48 >48 >48 >48 >48 >48 48 >48
Yersinia pseudotuberculosis YPIII 3 3 12 6 6 12 12 6
Gram-positive bacteria
Bacillus megaterium Bm11 1.5 1.5 3 3 1.5 3 3 3
Staphylococcus aureus ATCC 25923 3 3 24 6 6 12 12 12
Staphylococcus aureus Cowan I 3 1.5 12 6 6 6 12 6
Staphylococcus capitis 1 1.5 1.5 12 6 6 12 12 12
Staphylococcus epidermidis ATCC 12228 3 1.5 6 6 6 6 12 12
Streptococcus pyogenes ATCC 21547 6 6 12 6 6 12 12 12
Yeasts
Candida albicans ATCC 10231 3 3 6 6 3 6 6 6
Saccharomyces pombe 6 3 12 6 6 6 6 6
Saccharomyces cerevisiae 6 6 6 12 6 6 6 6
a The reported MIC values are those obtained from at least three readings out of four independent measurements.
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contrast, only a slightly toxic effect was recorded by [Pro3, DLeu9]TL at
the highest peptide concentration used (48 μM).
3.4. Structural studies
3.4.1. CD analysis
To explore the conformational changes of TL analogues, we
performed CD spectroscopy studies in phosphate buffer (pH 7.4),
DPC, SDS, and DPC/SDS micelle solutions. These micelles were used
as rough mimetics of mammalian, bacterial and yeast membranes,
respectively. CD spectra in phosphate buffer revealed the presence
of disordered conformers for all compounds with a minimum close
to 198 nm (data not shown). In contrast, in DPC (Fig. 1a), SDS
(Fig. 1b), and DPC/SDS (Fig. 1c) micelle solutions, the shape of the
CD spectra displaying two minima around 209 and 222 nm supports
the contribution of an α-helix. CD spectra of [Pro3, DLeu9]TL in the
three environments are shown in Fig. 1d. Helical content was predict-
ed from CD spectra using the SOMCD method [60] (Table 6). Since CD
spectra for short peptides are more affected by the termini than for
long proteins, the error bars for helical content would be of order
10%. The helical content of [Pro3]TL is included for comparison. All
the D analogues showed a reduction in the percentage of helicity com-
pared to [Pro3]TL, in agreement with the design strategy. Further-
more, helical content observed in both SDS and DPC/SDS was about
20% reduced compared to DPC. Indeed, as illustrated in Table 6, helical
content of all peptides ranged from 24% to 10% in DPC, from 18% to 7%
in SDS and from 20% to 8% in DPC/SDS.
3.4.2. NMR analysis
[Pro3, DLeu9]TL was also investigated by NMR spectroscopy. Due
to the very similar behavior of this peptide in the presence of SDS
and DPC/SDS micelles, as manifested by CD analysis (Fig. 1d and
Table 6), NMR spectroscopy was performed only in SDS and DPC mi-
cellar solutions. Complete 1H NMR chemical shift assignments were
effectively achieved for the peptide according to the Wüthrich proce-
dure [61] (Supplementary Tables S2–S3).
3.4.2.1. [Pro3, DLeu9]TL in SDS solution. Diagnostic NMR parameters ob-
served for [Pro3, DLeu9]TL in SDS solution indicated some conformational
propensity toward helical or turn structures. Hα atoms from residue 2 to
residue 13 experienced an upfield shift of the NMR signals compared to
those found for the same amino acids in the random coil state [62,63]
(Supplementary Fig. S1). Only amide protons of residues Phe5, Lys7,
and Ile12 showed exchange rates and temperature coefficients indicating
that they were shielded from the solvent (Supplementary Table S2). The
presence of a number of dαN(i,i+2) NOE contacts indicated the pres-
ence of helical and turn structures along the peptide, in line with CD re-
sults. Structure calculation gave an ensemble of 20 structures satisfying
the NMR-derived constraints (structural statistics are reported in
Table 7). Many structures (17 of 20) of [Pro3, DLeu9]TL showed a
β-turn centered on Pro3 and Trp4 followed by an α-helix along residues
5–8 (Fig. 2a). Also, a β-turn centered on Arg11 and Ile12 could be ob-
served in several structures (15 of 20).
3.4.2.2. [Pro3, DLeu9]TL in DPC solution. [Pro3, DLeu9]TL in DPC solution
exhibited NMR spectral features (Supplementary Fig. S1 and Table
S3) resembling those of the parent [Pro3]TL in the same solution
[44]. Upfield shift of the Hα NMR signals, low values of the exchange
rates and temperature coefficients of the amide protons, and diagnos-
tic NOEs (Supplementary Table S3) indicated that central residues are
in a helical conformation. Structure calculation gave an ensemble of
20 structures satisfying the NMR-derived constraints (violations
smaller than 0.50 Å). As found for [Pro3]TL, a β-turn centered on
Pro3 and Trp4 was detected in the structure of [Pro3, DLeu9]TL in
DPC micelles. It was followed by a 3–10 helix along residues 5–7,
and a bulged helical structure along residues 5–10 (18 of 20 struc-
tures). The bulged helix was stabilized by a H-bond between the NH
group of Gly10 and the C_O group of Phe5 (Fig. 2b). An α-helical con-
formation along residues 10–13 was noted in 5 of 20 structures.
3.5. Permeabilization of large unilamellar vesicles (LUV) by the peptides
To know whether the highly reduced hemolytic activity of [Pro3,
DLeu9]TL was due to its inability to permeate the erythrocyte mem-
brane, we used calcein LUV made of POPC/Cho (9:1,w:w) which
mimic the lipid composition of the outer leaflet of mammalian eryth-
rocyte membrane. In addition, liposomes made of POPE/POPG (7:3,
w:w) were also included to mimic the lipid composition of the
Table 3
Hemolytic activity of TL-analogues on human erythrocytes.
Hemolysis (%)a
[Peptide] (μM) TLb [Pro3]
TLb
[Pro3, DLys7]
TL
[Pro3, DPhe8]
TL
[Pro3, DLeu9]
TL
[Pro3, DArg11]
TL
[Pro3, DIle12]
TL
[Pro3, DLeu13]
TL
48 100 100 18 94 9 22 17 15
24 94 92 8 19 8 16 14 17
12 92 42 5 19 7 8 10 17
6 48 10 7 17 3 6 5 8
3 13 6 4 5 2 4 4 6
1.5 3 4.5 2 4 2 2 2 3
a Values are the mean of three independent experiments with SD not exceeding 1.5%.
b Values already reported in references [31,32].
Table 4
Peptides' activity on clinical isolates of C. albicans.
Microorganisms MICa (μM)
TL [Pro3, DLeu9]TL
Candida albicans strain n. 1 6 6
Candida albicans strain n. 2 3 3
Candida albicans strain n. 3 6 6
Candida albicans strain n. 4b 3 3
a The reported MIC values are those obtained from at least three readings out of four
independent measurements.
b Resistance phenotype: fluconazol, amphotericin B.
Table 5
Peptides' cytotoxicity on HaCat cells.
Peptide concentration (μM) Cell viabilitya
(%)
TL [Pro3, DLeu9]TL
48 23 85
24 26 100
12 29 100
6 39 100
3 77 100
a Cell viability is expressed as percentage with respect to the control (cells not treat-
ed with the peptide). Values are the mean of three independent experiments with SD
not exceeding 2%.
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cytoplasmic membrane of a representative Gram-negative bacterium
(e.g. E. coli). The membrane of a representative Gram-positive bacte-
rium (e.g. S. aureus) was, instead, mimicked by POPG/CL (6:4, w/w)
LUV.
Different concentrations of the peptide were added to the LUV
suspension and membrane permeability was measured by following
fluorescence recovery due to calcein release from the vesicles
(Fig. 3). Interestingly, the effect induced by [Pro3, DLeu9]TL (empty
symbols) on the permeation of both POPE/POPG (blue triangles)
and POPG/CL (red squares) LUV was similar to that of TL (filled sym-
bols) at a peptide/lipid molar ratio of 0.002 and 0.004. Differently, at
the highest peptide/lipid molar ratio used (0.08), the extent of calcein
release caused by TL was about 2-fold higher than that of [Pro3,
DLeu9]TL. The overall low calcein leakage from these lipid vesicles
could be related to a different peptide's conformation/oligomeric
state with respect to that adopted upon contact with bacterial cell
wall components which are absent in model membranes. Further-
more, the preference of both TL and [Pro3, DLeu9]TL for Gram-
positive over Gram-negative model membrane systems correlated
with the higher antimicrobial activity of these peptides towards
Gram-positive bacterial strains compared to Gram-negatives (see
the corresponding MIC values in Table 2).
In contrast, when the zwitterionic POPC/Cho LUV (black circles)
were employed, the effect of [Pro3, DLeu9]TL was drastically less pro-
nounced (3 to 8-fold lower) than that of TL at all concentrations used,
suggesting that the loss in hemolytic activity of [Pro3, DLeu9]TL ismainly
related to its incapability to damage the erythrocyte membrane.
4. Discussion
Therapeutic peptide antibiotics should have advantages over
conventional drugs, due to their diverse potential applications, rang-
ing from antimicrobial to immunomodulatory and/or endotoxin-
neutralizing activities. They can be used either alone or in combination
to synergize one with each other [64]. Although the efficacy of these
AMPs is in general less than certain traditional antibiotics, one of their
attractive properties is the ability to kill sensitive and multi-drug resis-
tant strains at similar concentrations [32]. Moreover, compared to clas-
sical antibiotics, AMPs act extremely rapidly and can attack multiple
bacterial cellular targets [22]. Among AMPs from frog skin, temporins
represent promising potential molecules to be developed for clinics.
Fig. 1. CD spectra of [Pro3]TL and its analogues in a) DPC, b) SDS, c) DPC/SDS. ([Pro3]TL, blue line; [Pro3, DLys7]TL, heavenly line; [Pro3, DPhe8]TL, violet line; [Pro3, DLeu9]TL, black
line; [Pro3, DArg11]TL, green line; [Pro3, DIle12]TL, yellow line; [Pro3, DLeu13]TL, red line). d) CD spectra of [Pro3, DLeu9]TL in DPC (dotted line), SDS (dashed line), and DPC/SDS (solid
line).
Table 6
α-Helix percentage of TL-analogues.
Peptides [Pro3]
TL
[Pro3,
DLys7]
TL
[Pro3,
DPhe8]
TL
[Pro3,
DLeu9]
TL
[Pro3,
DArg11]
TL
[Pro3,
DIle12]
TL
[Pro3,
DLeu13]
TL
DPC 25a 10 24 15 18 20 22
SDS 22a 7 14 10 12 15 18
DPC–SDS 23 8 14 11 12 17 20
a See reference [44].
Table 7
Structural statistics for the final 20 structures of [Pro3, DLeu9]TL in SDS and in DPC
micelles.
Parameter [Pro3, DLeu9]TL
in SDS
[Pro3, DLeu9]TL
in DPC
NOE distance restraints
Total 109 135
Intra 51 55
Short 48 57
Medium 10 23
Backbone RMSD (Å) 0.79 0.48
Overall RMSD (Å) 1.45 0.99
Max restraint violation (Å) 0.68 0.50
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Previously, we studied the effect of the replacement of cationic and hy-
drophobic residues of the native TL on its antimicrobial and hemolytic
activities. Furthermore, the effects of such substitutions on the helicity,
hydrophobicity and hydrophobic moment of the peptide were ana-
lyzed. We demonstrated that the nature of cationic residues can
differently modify the antimicrobial/hemolytic activity of TL, without
changing its helical content. In contrast, a direct correlation was re-
vealed between the percentage of peptide's helicity in zwitterionic mi-
celles and its toxicity on human red blood cells. In addition,we observed
that replacement of Gly10 with a leucine residue almost abrogated the
antimicrobial efficacy of TL causing a dramatic enhancement of hemoly-
sis, probably due to oligomerization of the peptide.
Here, we performed SAR studies using six different analogues of TL,
each containing a single D amino acid starting from position 7 (Table 1).
Biological data have proved that interruption of the helical content of
[Pro3]TL by replacement of D versus L amino acids diminishes the
peptide's antibacterial activity (Table 3). Interestingly, anti-yeast activ-
ity is slightly decreased for all D analogues, but it is preserved for [Pro3,
DLeu9]TL (Table 2). Hemolytic activity drops below8% at 6 μMfor all an-
alogues but [Pro3, DPhe8]TL (Table 3). However, the most promising
outcome is that the anti-Candida activity of [Pro3, DLeu9]TL analogue is
preserved also against an antimycotic resistant strain (Table 4), while
the peptide is practically non-toxic towards human erythrocytes and
keratinocytes (Tables 3 and 5). Considering the conformational behav-
ior, the incorporation of D amino acids reduces the α-helical structure
of [Pro3]TL to different degrees, depending on their position and com-
position of the lipid environment (Table 6). These substitutions can
also differently influence the peptide's biological activity (Table 2). Re-
duction of the helicity is higher when the central Lys7 residue is re-
placed by DLys compared to the effects caused by D substitution at
other positions. In the case of [Pro3, DLeu9]TL, NMR analysis indicated
that the helical structure inDPCmicelles is partially conserved by anun-
usual i to i+5 hydrogen bond between Phe5 and Gly10 residues
(Fig. 2b). The parent peptides TL and [Pro3]TL showed a classical
α-helical structure along these residues [44]. Changing of the backbone
conformation also affects the distribution of the side chains of the pep-
tide. As themain difference, Phe8 and DLeu9 side chains are closer to the
polar side of the helix (defined by the side chains of Lys7 and Arg11) in
[Pro3, DLeu9]TL compared to TL and [Pro3]TL (Supplementary Fig. S2),
thus decreasing the amphipathicity of the first peptide. Note that deter-
gent micelles represent a reliable membrane mimetic model and have
been used extensively for solution NMR spectroscopy of AMPs and
membrane proteins [19]. However, to verify whether the peptide's con-
formation is preserved in more complex lipid environments that better
mimic a biological membrane, solid-state NMR studies in phospholipid
bilayers will be next performed.
In agreement with our previous results [40], the hemolytic activity
of the D amino acid containing analogues correlates well with their in-
creased helical content in DPC (see Tables 3 and 6). Thus, [Pro3, DLys7]
TL and [Pro3, DLeu9]TL are the less toxic peptides; [Pro3, DPhe8]TL,
with the highest percentage of α-helix, the most hemolytic one. Fur-
thermore, in line with our recent findings [40], breaking of the helical
structure at the C-terminal half reduces the antibacterial activity of
[Pro3]TL. In contrast, the anti-yeast efficacy is not directly dependent
on the helicity of the peptide. Indeed, among the six analogues, [Pro3,
DLeu9]TL is endowed with the highest anti-yeast activity, despite hav-
ing a very low content of helix in DPC/SDS micelle solutions (11% vs
23% of [Pro3]TL). Therefore, we can conclude that interruption of
the α-helix of [Pro3]TL at position 9 does not compromise anti-
Candida and anti-Saccharomyces activities of this peptide and practi-
cally abolishes its toxicity towards mammalian cells. This is presum-
ably due to its inability to disrupt the membrane of these cells, as
revealed by the LUV leakage experiments (Fig. 3).
Although usually harbored as a harmless commensal microbe of
healthy humans, C. albicans can cause a variety of superficial and
deep-seated mycoses, particularly in immunocompromised and neu-
tropenic hosts [65]. Such Candida can either circulate in the blood
(e.g. the erythrocytes) or be located at many infection sites (e.g. the
skin, the oral, ocular and genital epithelia). In these cases, candidosis
is becoming a life-threatening disease in patients undergoing aggres-
sive chemotherapy or having T-cell leukemia virus-associated immu-
nodeficiencies. Relatively few antifungal agents are available, particularly
for deep-seated Candida mycoses. Amphotericin B and the azole drugs
such as itraconazole and ketoconazole are currently used. More recently,
fluconazole has been employed, but its use is quite restricted due to the
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Fig. 3. Calcein leakage from POPE/POPG (blue triangles), POPG/CL (red squares) and
POPC/Cho (black circles) LUV after addition of TL (filled symbols) or [Pro3, DLeu9]TL
(empty symbols) at different concentrations. Fluorescence recovery was measured
for 10 min after the peptides were mixed with the vesicles, and its maxima were
reported. Leakage was calculated as indicated in the Materials and methods. Values
are means of three independent measurements with ±SD.
Fig. 2. Superposition of the 10 lowest energy conformers of [Pro3, DLeu9]TL in SDS (a), and DPC (b). Structures were superimposed using the backbone heavy atoms. Heavy atoms
are shown with different colors (carbon, green; nitrogen, blue; oxygen, red). Hydrogen atoms are not shown for clarity. Only side chains of the lowest energy conformer are
displayed for clarity. Backbone atoms of the lowest energy conformer were evidenced as a ribbon.
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limited spectrum of activity and to the emerging appearance of Candida
strains resistant to it. Therefore, the discovery of new compounds to
treat Candida-associated infections, without being toxic to mammalian
cells, is urgently needed.
5. Conclusion
Importantly, the results of the present study have lead to the iden-
tification of a TL analogue ([Pro3, DLeu9]TL) practically devoid of cyto-
lytic effects in vitro and which preserves the effectiveness of the
native peptide against C. albicans. Overall, our studies have shown
that substitution of Gln3 with a proline residue and replacement of
Leu9 with its D enantiomer play a key role in breaking the helicity of
TL as well as in distinguishing between eukaryotic and prokaryotic
membranes. Indeed, while such changes retain the peptide's antimi-
crobial activity, presumably by preserving its ability to lead to micro-
bial membrane injury, they cause a drastic reduction in peptide's
ability to damage mammalian cell membranes, thus abolishing the
toxic effects of the peptide on human cells such as erythrocytes and
keratinocytes. In addition, incorporation of a D amino acid within
the peptide sequence should increase its biostability to proteolytic
enzymes, a fundamental requirement for potential use in clinics.
Overall, these findings should assist in the future development of se-
lective and economically feasible anti-Candida agents, starting from
the short-sized TL template.
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Abstract
The branched M33 antimicrobial peptide was previously shown to be very active against Gram-negative bacterial
pathogens, including multidrug-resistant strains. In an attempt to produce back-up molecules, we synthesized an M33
peptide isomer consisting of D-aminoacids (M33-D). This isomeric version showed 4 to 16-fold higher activity against Gram-
positive pathogens, including Staphylococcus aureus and Staphylococcus epidermidis, than the original peptide, while
retaining strong activity against Gram-negative bacteria. The antimicrobial activity of both peptides was influenced by their
differential sensitivity to bacterial proteases. The better activity shown by M33-D against S. aureus compared to M33-L was
confirmed in biofilm eradication experiments where M33-L showed 12% activity with respect to M33-D, and in vivo models
where Balb-c mice infected with S. aureus showed 100% and 0% survival when treated with M33-D and M33-L, respectively.
M33-D appears to be an interesting candidate for the development of novel broad-spectrum antimicrobials active against
bacterial pathogens of clinical importance.
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Introduction
Antimicrobial resistance (AMR) is not a recent phenomenon,
but it is a critical health issue today. Over several decades, to
varying degrees, bacteria causing common infections have
developed resistance to each new antibiotic, and AMR has
evolved to become a worldwide health threat. With a dearth of
new antibiotics coming to market, the need for action to avert
a developing global crisis in health care is increasingly urgent [1].
Antimicrobial peptides (AMPs) are seen with great interest for
the development of new agents against bacterial infections,
because most of them show strong bactericidal activity against
multidrug-resistant (MDR) bacterial pathogens, and may also
contribute to innate immunity by modulating dendritic cell
differentiation and maturation, angiogenesis and chemokine
production [2]. These features are particularly attractive and
many natural host defense peptides (HDPs) or artificial AMPs are
currently under experimentation for drug development [3].
Unfortunately, certain drawbacks have limited the development
of AMPs as drugs for bacterial infections: i) toxicity to eukaryotic
cells, that may lead to nephrotoxicity, neurotoxicity and
neuromuscular blockade [4,5]; ii) selection of resistant strains
that may be cross-resistant to human-neutrophil-defensin-1, a key
component of the innate immune response to infection [6]; iii)
the fact that natural AMPs are generally very short peptides
easily attacked by circulating proteolytic enzymes, making their
half-life too short to be active against bacteria in vivo. Researchers
and industry have been seeking new AMPs of natural and non-
natural origin, with low toxicity and the longer half-life necessary
for drug development.
A few years ago, we observed that short peptides synthesized in
oligodendrimeric form [7] showed high resistance to proteolytic
degradation, making them suitable for use in vivo [8–10]. The
synthetic peptide M33 was obtained by random selection from
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a home-made phage-display peptide library panned against E. coli
cells and a successive optimization phase for biological activity,
synthesis and purification procedures [11–14]. The M33 sequence
(KKIRVRLSA) is amphipathic and cationic, which is typical for
AMPs, but did not show any sequence homology with known
AMPs of natural or non-natural origin. M33 was synthesized in
tetra-branched form, proving resistant to proteolytic degradation
and very active in vitro against clinical isolates of several Gram-
negative pathogens, including MDR strains of Pseudomonas
aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae and Escherichia
coli, while being less active against the Gram-positive pathogen
Staphylococcus aureus. The peptide also protected mice lethally
infected with multi-resistant clinical isolates of P. aeruginosa and is
currently under preclinical characterization for the development of
a new drug for bloodstream and lower respiratory tract infections.
In previous reports [11–14] the peptide was always synthesized
and used with L aminoacids (M33-L). Recently, we used the same
sequence synthesized in the tetra-branched form using D
aminoacids (M33-D). Here we report that compared to M33-L,
M33-D has stronger activity against S. aureus and coagulase-
negative staphylococci, including methicillin-resistant strains, with
MIC values comparable to those of many antimicrobial agents
used in clinical practice. We also report a study of the mechanism
of action of M33-D compared to M33-L. Since M33-D retains
strong activity against Gram-negative pathogens, it appears to be
an interesting candidate for the development of novel broad-
spectrum AMPs.
Results and Discussion
MIC Determination
MICs of M33-L and M33-D were determined against strains
of different bacterial species, including major Gram-negative
and Gram-positive pathogens (Table 1). Compared to M33-L,
M33-D exhibited the same activity against P. aeruginosa and the
same or a slightly lower (2–4 fold) activity against Enterobacter-
iaceae. On the other hand, M33-D showed higher antimicrobial
activity than M33-L against the Gram-positive bacteria S. aureus
and S. epidermidis, including methicillin-resistant and vancomy-
cin-intermediate strains, with MICs 4 to 16-fold lower than
those of M33-L. As previously observed with M33-L [13], M33-
D exhibited antimicrobial activity (MIC values) against antibi-
otic-susceptible reference bacterial strains and MDR strains of
clinical origin expressing several different mechanisms of
antibiotic resistance.
Binding of M33-L and M33-D to Lipopolysaccharide (LPS)
and Lipoteichoic Acid (LTA)
In a previous report [13] we hypothesized that LPS was the first
bacterial structure to interact with M33-L. In order to evaluate
possible differential binding of M33-L and M33-D to Gram-
negative LPS and to Gram-positive LTA, we therefore analyzed
the interactions of both peptides with LPS and LTA by surface
plasmon resonance. LTA from S. aureus and Streptococcus faecalis,
and LPS from E. coli, P. aeruginosa and K. pneumoniae were injected
at a concentration of 10 mg/ml over immobilized M33-L or M33-
D peptides. No significant difference in binding or kinetic rates
that could explain such dissimilar antimicrobial activity of the two
peptides was observed (Fig. 1).
Interaction of M33 with Liposomes Mimicking Bacterial
Cells
To investigate interaction of peptides M33-D and M33-L
with the bacterial membrane, including possible perturbation,
we used vesicles with two lipid compositions to mimic the
membrane of S. aureus (CL/PG, 4:6 mol/mol) and E. coli (PE/
PG, 7:3 mol/mol) [15]. Both liposome preparations were
treated with increasing peptide concentrations from 0,5 to
15 mM and the membrane permeability was revealed by
measuring the fluorescence increase due to the calcein leakage
from the vesicles. The dose-response curves obtained from CL/
PG or PE/PG liposomes are reported in Fig. 2a. The peptide-
induced effect was dose-dependent in both vesicle lipid
compositions. However, effectiveness on the two lipid composi-
tions was significantly different, since maximum calcein release
from CL/PG liposomes was obtained at peptide concentrations
greater than 10 mM, whereas in PE/PG liposomes total leakage
occurred at peptide concentration of 5 mM. No significant
differences in the effects induced by M33-D and M33-L were
evident, although the D peptide seemed slightly more efficient
towards CL/PG liposomes at doses above 8 mM. Fig. 2b shows
the time-course of probe release when the vesicles were treated
with M33-D or M33-L at 1 or 5 mM final concentrations. In all
cases, the peptide-induced increase in fluorescence showed
a typical biphasic kinetic profile, in which a fast phase due to
the initial membrane-peptide interaction was followed by a slow
steady-state. The greater perturbing effect of both forms of M33
on PE/PG vesicles, compared to vesicles containing cardiolipin,
was evident.
These tests, along with the Biacore analysis described above,
revealed that M33-D and M33-L have substantially similar
behavior in terms of binding to LPS and LTA and of perturbation
of membranes of different phospholipid composition. We deduced
that the mechanism used by M33-L and M33-D for interacting
with bacterial surfaces and disruption of bacterial membranes was
basically the same.
Stability to Bacterial Proteases
Peptide stability to bacterial proteases was analyzed with
purified aureolysin and elastase enzymes derived from S. aureus
and P. aeruginosa, respectively. These proteins play a key role in
bacterial virulence by breaking down natural HDPs produced by
the infected individuals [16–18]. S. aureus aureolysin and
P. aeruginosa elastase are members of the family of M4 metallo-
peptidases (thermolysin family) [19–21] and have similar specific-
ity, hydrolyzing peptide bonds preferentially on the amino-
terminal side of hydrophobic residues. To determine whether
these proteases affect the performance of M33 peptides, M33-L
and M33-D were incubated with aureolysin and elastase, re-
spectively, and after appropriate time intervals the crude solutions
were analyzed by HPLC and mass spectroscopy. Unlike M33
incubated without enzymes (Figs. 3a, 3b, 3c and 3d), M33-L was
degraded within 1h by staphylococcal aureolysin (Fig. 3e), through
hydrolysis at R6-L7 and S8-A9 peptide bonds (Fig. 3f). Converse-
ly, M33-D was completely stable to proteolysis by this metallo-
protease, remaining unaltered after 24 h of incubation (Figs. 3g
and 3h). Incubation of M33-L with P. aeruginosa elastase showed
moderate peptide stability after 5 h (a peak corresponding to
a retention time of 23 min is still present in Fig. 3i), and again the
cleavage sites were R6-L7 and S8-A9 peptide bonds (Fig. 3j). In
contrast, the M33-D peptide resisted degradation by elastase for
24 h (Figs. 3k and 3l). The cleavage sites of both peptides are
illustrated in Fig. 3m and the MS peaks are assigned to the
fragments.
Altogether, these results suggest that the increased stability of
M33-D to staphylococcal aureolysin could be at least partly
responsible for the increased activity exhibited by this isomer
against S. aureus. The same phenomenon could also explain the
Antimicrobial Activity of M33 Peptide D-Isomer
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increased activity of M33-D against S. epidermidis (Table 1), which
produces an ortholog of aureolysin (the metallo-protease SepA,
with 71% aminoacid identity [22–23]).
Assessment of Anti-biofilm Activity
In biofilms, bacteria grow as multicellular aggregates within an
extracellular matrix that protects the cells from host defences.
Biofilms are also more resistant to antimicrobial agents due to the
physiological state of bacterial cells and, in some cases, reduced
antibiotic penetration [24]. Bacterial biofilms form in natural,
medical and industrial settings, and play a major role in several
human infections, including infections of prosthetic devices and
intravascular catheters, bone and joint infections, chronic
rhinosinusitis and otitis media [25,26]. The search for new
antimicrobials that eradicate microbial biofilms has therefore
become extremely pressing.
M33-L and M33-D were tested for their anti-biofilm activity
against the Gram-negative strains E. coli ATCC 25922 and
P. aeruginosa ATCC 27853, as well as the Gram-positive strain
S. aureus ATCC 25923. As reported in Table 2, the minimum
biofilm eradication concentrations (MBECs) of the two peptides
observed with Gram-negatives were on the whole similar. On the
other hand, M33-D exhibited higher anti-biofilm activity against
S. aureus than M33-L (MBEC, 1.5 mM vs. 12 mM), which is
consistent with the difference in MIC of the two isomers for this
strain (Table 1). The minimum bactericidal concentration on
biofilm (MBCb), i.e. the concentration that kills 99.9% of biofilm
cells, was also investigated. The two isomers showed an MBCb of
Table 1. MICs of M33-L and M33-D for different bacteria species and strains.
Species and strains Relevant featuresa M33-L (mM) M33-D (mM)
P.aeruginosa ATCC 27853 Reference strain, wild type 1.5 1.5
P.aeruginosa AV 65 FQr AGr ESCr NEMr (MBL/IMP-13) 3 3
K.pneumoniae ATCC 13833 Reference strain, wild type 1.5 3
K.pneumoniae 7086042 FQr AGr ESCr NEMr (MBL/VIM-1) 3 6
E.coli ATCC 25922 Reference strain, wild type 3 3
E.coli W03BG0025 FQr AGr ESCr (ESBL/CTX-M-15) 0.7 3
S.aureus ATCC 29213 Reference strain, wild type 6 1.5
S.aureus USA 300 MR 6 1.5
S.aureus 3851 MR VANi 12 0.7
S.epidermidis ATCC 14990 Reference strain, wild type 1.5 0.4
S.epidermidis 6154 MR 3 0.7
aM33 antimicrobial activity was evaluated on reference strains and clinical isolates (mostly with an MDR phenotype). Relevant resistance phenotypes and resistance
determinants are indicated. Resistance phenotypes: FQr, resistant to fluoroquinolones; AGr, resistant to aminoglycosides (gentamycin, amikacin, and/or tobramycin);
ESCr, resistant to expanded-spectrum cephalosporins; NEMr, resistant to carbapenems (imipenem and/or meropenem); MRr, methicillin-resistant; VANi, vancomycin-
intermediate. Resistance determinants: ESBL, extended spectrum b-lactamase; MBL, metallo-b-lactamase.
doi:10.1371/journal.pone.0046259.t001
Figure 1. Binding of LTA and LPS on M33-L or M33-D measured by surface plasmon resonance. LPS from P. aeruginosa, K. pneumoniae,
E. coli and LTA from S. faecalis and S. aureus, diluted to 10 mg/ml were injected over M33-L and M33-D immobilized peptides.
doi:10.1371/journal.pone.0046259.g001
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6 mM against the Gram-negatives E. coli and P. aeruginosa (Table 2),
whereas the MBCbs of M33-L and M33-D for the Gram-positive
S. aureus matched the respective MBECs, being 12 and 1.5 mM,
respectively.
In vivo Anti-MRSA Activity of M33-D vs. M33-L
Given the good in vitro activity shown by M33-D against
methicillin-resistant S. aureus (MRSA), we compared the in vivo
activity of this peptide and the original M33-L in an animal model
of infection caused by the highly virulent MRSA strain USA 300,
a lineage that has become a dominant cause of community-
associated MRSA infections in North America [27,28].
The smallest number of bacteria causing 100% lethal infection
(LD100) after intra-peritoneal (i.p.) injection was 16106 in the
presence of 7% mucin. An LD100 killed mice within 20 hours.
Mice were infected with the LD100 of bacteria and treated i.p.
with the peptides 30 minutes later. 100% survival after 7 days was
obtained with mice treated with M33-D, while mice treated with
M33-L showed a mortality overlapping that of controls (Fig. 4),
confirming the potent anti-MRSA activity of M33-D.
Conclusions
The M33 peptide, previously reported as active against a broad
spectrum of Gram-negative bacteria [13], is also strongly active
against staphylococci when synthesized with D-aminoacids. We
hypothesized that the increased stability of M33-D to staphylo-
coccal proteases could at least partly explain this different activity.
It was known that branched peptides, like those used in this study,
are particularly resistant to circulating proteases produced by
higher animals [8–10,29–31]. It was also known that peptides with
D-aminoacids show increased stability to circulating proteases
[32]. Stability of D-peptides to bacterial proteases has also been
reported [33,34]. In our case the concomitant improvement of
stability of M33-D to infected individual proteases and to
infectious agent proteases dramatically increased the overall
performance of the peptide. This is particularly evident in
Figure 2. Release of calcein from bacterial-surface-mimicking liposomes. a, dose-response of M33-induced calcein release. The vesicles
were incubated with different concentration of M33 peptide for 10 min at 20uC (for details see Methods section). CL/PG liposomes (triangles); PE/PG
liposomes (squares); M33-D: full symbols; M33-L: empty symbols. Values are means 6 SE of three independent experiments. b, time course of calcein
release from: CL/PG liposomes (triangles) and from PE/PG liposomes (squares); M33-D: full symbols; M33-L: empty symbols. continuous line 5 mM,
dotted line 1 mM.
doi:10.1371/journal.pone.0046259.g002
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Figure 3. Proteolytic activity of aureolysin and elastase on peptides M33-L and M33-D. a and b, HPLC and MS profiles, respectively, of
M33-L before incubation with enzymes. c and d, HPLC and MS profiles, respectively, of M33-D before incubation with enzymes. In HPLC the retention
time of M33-L and M33-D was 23 minutes. The calculated MW of M33 was 4682. e and f, HPLC and MS, respectively, of M33-L incubated for 1 hour
with aureolysin. f shows the peaks indicating the proteolytic site (RL or SA). g and h, HPLC and MS, respectively, of M33-D incubated for 24 hours with
aureolysin. i and j, HPLC and MS, respectively, of M33-L incubated for 5 hours with elastase. j shows the peaks indicating the proteolytic site (RL or
SA). k and l, HPLC and MS, respectively, of M33-D incubated for 24 hours with elastase.m, proteolytic sites of the two enzymes on the tetrabranched
M33 are indicated by arrows. The table assigns MS peaks to the cleavage fragments.
doi:10.1371/journal.pone.0046259.g003
Table 2. Anti-biofilm activity of M33-L and M33-D towards different bacterial species.
Bacterial species
Minimum biofilm eradication concentration
(MBEC, mM)a
Minimum bactericidal concentration on
biofilm (MBCb, mM)b
M33-L M33-D M33-L M33-D
Gram-negatives
E. coli ATCC 25922 3 3 6 6
P. aeruginosa ATCC 27853 1.5 3 6 6
Gram-positive
S. aureus ATCC 25923 12 1.5 12 1.5
aMBEC is the minimum peptide concentration preventing regrowth of bacteria from the treated biofilm within 4 hours.
bMBCb is the minimum peptide concentration required to reduce the number of viable biofilm cells by $3 log10 (99.9% killing) after 2 h.
doi:10.1371/journal.pone.0046259.t002
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experiments in vivo where M33-D neutralized signs of sepsis due to
S. aureus USA300, while M33-L, stable to mouse [13] but not to
bacterial proteases, was not active at all.
M33-D was highly stable to the proteases aureolysin, from S.
aureus, and elastase, from P. aeruginosa. M33-L was not at all stable
to aureolysin and poorly stable to elastase, as confirmed by its
activity in vivo against P. aeruginosa [13]. For M33-D we propose the
following mechanism of action. M33-D binds LTA and persists on
the bacterial surface for some time by virtue of its resistance to
bacterial proteases, causing membrane perturbation that kills the
bacteria.
Concluding, we identified a new form of the peptide M33,
which is strongly active against S. aureus and retains its
antimicrobial activity irrespective of strain-resistance phenotypes
and mechanisms. MRSA and S. aureus strains with altered
susceptibility to glycopeptides pose a serious clinical threat and
major therapeutic challenge. In this context, development of a new
broad-spectrum therapeutic agent with no cross-resistance to
available drugs would be a major achievement.
Materials and Methods
Peptide Synthesis
Solid-phase synthesis was carried out by standard Fmoc
chemistry on Fmoc4-Lys2-Lys-b-Ala Wang resin with a Syro
multiple peptide synthesizer (MultiSynTech, Witten, Germany).
Side chain protecting groups were 2,2,4,6,7-pentamethyldihydro-
benzofuran-5-sulfonyl for R, t-butoxycarbonyl for K and t-butyl
for S. M33-L was synthesized using Fmoc-L-aminoacids, and
M33-D with Fmoc-D-aminoacids with the exception of the three
lysins of the branched core which were Fmoc-L-Lys(Fmoc)-OH
(M33-D is consequently a diastereomer). The final products were
cleaved from the solid support, deprotected by treatment with
TFA containing triisopropylsilane and water (95/2.5/2.5), and
precipitated with diethyl ether. Crude peptides were purified by
reversed-phase chromatography on a Phenomenex Jupiter C18
column (300 A˚, 10 mm, 250610 mm) in linear gradient form for
30 min, using 0.1% TFA/water as eluent A and methanol as
eluent B. Purified peptides were obtained as trifluoroacetate salts
(TFacetate). The exchange from TFacetate to acetate form was
carried out using a quaternary ammonium resin in acetate form
(AG1-X8, 100–200 mesh, 1.2 meq/ml capacity, Bio-Rad). The
resin-to-peptide ratio was 2000:1, resin and peptide were stirred
for 1 h, the resin was filtered off, washed extensively and the
peptide recovered and freeze-dried. Final peptide purity and
identity were confirmed by reversed phase chromatography on
a Phenomenex Jupiter C18 analytical column (300 A˚, 5 mm,
25064.6 mm) and by mass spectrometry with a Bruker Daltonics
ultraflex MALDI TOF/TOF.
MIC Testing
MICs were determined using a standard microdilution assay as
recommended by the Clinical and Laboratory Standards Institute.
Assays were performed in triplicate using cation-supplemented
Mueller-Hinton (MH) broth (Becton Dickinson, Franklin Lakes,
NJ, USA) and a bacterial inoculum of 5x104 CFU/well, in a final
volume of 100 ml. The tested concentrations ranged from 0.1 mM
to 24 mM for both peptides. Results were recorded after 18–20 h
of incubation at 37uC.
Surface Plasmon Resonance
Biotinylated peptides were immobilized on SA coated flow cells.
M33-L and M33-D peptides, diluted to 10 mg/ml in HBS-EP+
buffer (10 mM Hepes, 150 mM NaCl, 3.4 mM EDTA, 0.05%
polysorbate 20 pH 7.4), were injected for 90 sec at a flow rate of
10 ml/min, obtaining 550 RU and 580 RU for M33-L and M33-
D respectively.
LTA and LPS molecules from different species (LPS from
E. coli, K. pneumonia, P. aeruginosa and LTA from S. aureus and S.
faecalis, were obtained from Sigma-Aldrich: L-3012, L-4268,
L9143, L2515 and L4015, respectively) were diluted in HBS-
EP+ buffer at the concentration of 10 mg/ml and injected for
180 sec with a flow rate of 30 ml/min over immobilized peptides.
An empty flow cell was used as reference. Regeneration was
achieved with a short pulse of SDS 0.05%.
Preparation of Calcein-liposomes and Leakage
Measurement
L-a-phosphatidylethanolamine (PE), L-a-phosphatidyl-DL-glyc-
erol (PG), cardiolipin (CL), calcein, ammonium thiocyanate and
Figure 4. In vivo antibacterial activity of tetrabranched M33-L and M33-D peptides. Balb-c mice (20 g) were injected i.p. with a lethal
amount of S. aureus USA300 cells. Dashed line (Ctr), injection with bacteria and no peptides; dotted line, injection with bacteria and a single injection
of M33-L peptide (25 mg/kg) 30 min later; continuous line, injection with bacteria and a single injection of M33-D peptide (25 mg/kg) 30 min later.
doi:10.1371/journal.pone.0046259.g004
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iron (III) chloride hexahydrate and all other chemical (reagent
grade) were obtained from Sigma.
Calcein-loaded liposomes of two different composition (PE/PG,
7:3 mol/mol and CL/PG, 4:6 mol/mol) were prepared as follows.
The lipids were dissolved in chloroform (1 ml) and sonicated
together with 60 mM calcein solution (1 ml in phosphate buffer,
pH 7.0); the liposomes were obtained by the reverse phase
evaporation method [35]. The calcein excess was removed by gel
filtration (Sephadex G-50) followed by centrifuging at 22000 g for
30 min. For vesicle size homogeneity, the pellet was passed several
times through 200 mm polycarbonate membranes in a Mini-
extruder apparatus (Avanti Polar Lipids Inc., Alabaster AL) [36].
Lipid concentration of vesicles was measured by the method of
Stewart [37] and the final concentration used for all measurements
was 50 mM. Calcein fluorescence in the vesicles is self-quenched
and leakage was measured by relief of quenching; the measure-
ments were carried out at 517 nm, exciting at 490 nm, with
a Perkin-Elmer LS 50B spectrofluorimeter. The maximum value
of leakage was obtained by addition of 10 ml of Triton X-100
(10%, v/v in water) to the liposome suspension, which caused total
disruption of vesicles. Leakage was calculated by the equation:
Leakage (%)~100|(F{F0)=(Ft{F0),
where F and Ft are fluorescence before and after addition of
detergent and F0 the fluorescence of intact vesicles [38].
Protease Sensitivity Assay
Tetrabranched M33-L or M33-D peptides (300 mg) were
incubated at 37uC with Staphylococcus aureus aureolysin (3 mg,
BioCol GmbH) or Pseudomonas aeruginosa elastase (3 mg, Calbio-
chem) in 300 ml 20 mM Tris-HCl, 1 mM CaCl2 pH 7.8. At
indicated time intervals, 50 ml aliquots were removed, diluted with
950 ml of 0.1% trifluoroacetic acid (TFA)/water and analyzed by
HPLC and mass spectrometry. Liquid chromatography was
performed on Phenomenex Jupiter C18 analytical column
(300 A˚, 5 mm, 25064.6 mm) in a 30 min gradient, using TFA
0.1%/water as solvent A and methanol as solvent B. Mass
spectrometry analysis was performed on withdrawn samples and
repeated on HPLC-eluted peaks with a Bruker Daltonic ultraflex
MALDI TOF/TOF mass spectrometer.
Anti-biofilm Activity
Biofilm formation was performed by adapting the procedure
described in [39] using the Calgary Biofilm Device (Innovotech,
Innovotech Inc. Edmonton, Canada). Briefly, 96-well plates
containing the bacterial inoculum were sealed with lids bearing
96 pegs on which the biofilm could build up. The plates were
placed in an orbital incubator at 35uC (for P. aeruginosa and E. coli)
or 37uC (for S. aureus) for 20 h under agitation at 125 rpm. Once
biofilms formed, the lids were removed from the plates and the
pegs were rinsed twice with phosphate buffered saline (PBS) to
remove planktonic cells. The peg-lid was then transferred to a 96-
well challenge microtiter plate, each well containing 200 ml of
a twofold serial dilution of each peptide in LB medium. The
challenge plate was incubated at 37uC for 2 hours. Peptide activity
on pre-formed biofilm was evaluated by two independent
methods: (i) visual observation of bacterial growth and (ii) counting
of living bacterial cells after peptide treatment. In the first case, the
peg-lid was removed from the challenge plate, rinsed with PBS
and used to cover a 96-well recovery microtiter plate, each well
containing 200 ml LB medium. The recovery plate was sealed,
incubated at 37uC for 4 hours and then observed for any visible
growth of bacteria detached from the peptide-treated biofilm.
Growth of bacteria in a particular well indicated regrowth of
planktonic cells from surviving biofilm. Minimum biofilm eradi-
cation concentration (MBEC) was defined as the minimum
peptide concentration preventing regrowth of bacteria from the
treated biofilm within 4 hours.
In the second case, to determine viable cell counts of biofilms
after peptide treatment, pegs from the challenge microtiter plate
were removed and transferred to Eppendorf tubes containing
500 ml PBS. After sonication at room temperature for 15 min to
break up the biofilm and remove bacterial cells from the peg,
aliquots of bacterial suspension were plated on LB-agar plates for
counting. Colony forming units (CFU) were expressed as
percentage with respect to control (peptide-untreated biofilms).
Minimum bactericidal concentration (MBCb) was defined as the
lowest peptide concentration required to reduce the number of
viable biofilm cells by $3 log10 (99.9% killing) [40].
In vivo Experiments
Animal procedures were approved by the Ethical Committee of
the Azienda Ospedaliera Universitaria Senese on November 18,
2010. Balb-c mice (20 g) were infected i.p. with lethal amounts of
bacteria (see results) mixed in 500 ml PBS +7% mucin (mucin from
porcine stomach, type II, Sigma-Aldrich). Bacteria were cultured
overnight, centrifuged, mixed in sterile PBS, and measured by
spectrophotometer. Possible further dilutions in PBS were
sometimes necessary to obtain the right amount of bacteria.
Groups consisted of 5 animals. Moribund animals were killed
humanely to avoid unnecessary distress. Surviving mice were
monitored for 7 days. Thirty minutes after bacterial administra-
tion, peptides were inoculated i.p. with 0.5 ml PBS solution
containing the indicated amount of peptide (see Results). Control
animals received only PBS. P values were calculated using
GraphPad Prism software.
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Abbreviations
CF  Cystic fibrosis
CFU  Colony-forming unit
CV  Crystal violet
EDTA  Ethylenediaminetetraacetic acid
Esc(1-21)  Esculentin(1-21)
LB  Luria-Bertani broth
MBCb  Minimum bactericidal concentration on biofilm 
cells
MBEC  Minimum biofilm eradication concentration
MDR  Multi-drug resistance
MH  Mueller-Hinton
MIC  Minimal inhibitory concentration
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide
ONPG  2-nitrophenyl β-d-galactoside
PBS  Phosphate buffered saline
SDS  Sodium dodecyl sulphate
Introduction
The emergence of microbial strains resistant to conven-
tional antibiotics has become a serious threat for human 
health, particularly in hospitals, where immunocompro-
mised patients can easily be affected by bacterial infections 
mainly those caused by Pseudomonas aeruginosa [1, 2]. 
This bacterium is quite difficult to eradicate because of its 
ability to form sessile communities named biofilms [3–5]. 
Bacterial biofilms are a structured consortium of embed-
ded cells into a self-promoted polymeric matrix consisting 
Abstract Pseudomonas aeruginosa is an opportunistic 
bacterial pathogen that forms sessile communities, named 
biofilms. The non-motile forms are very difficult to eradi-
cate and are often associated with the establishment of per-
sistent infections, especially in patients with cystic fibrosis. 
The resistance of P. aeruginosa to conventional antibiotics 
has become a growing health concern worldwide and has 
prompted the search for new anti-infective agents with new 
modes of action. Naturally occurring antimicrobial peptides 
(AMPs) represent promising future template candidates. 
Here we report on the potent activity and membrane-per-
turbing effects of the amphibian AMP esculentin(1-21), on 
both the free-living and sessile forms of P. aeruginosa, as 
a possible mechanism for biofilm disruption. Furthermore, 
the findings that esculentin(1-21) is able to prolong survival 
of animals in models of sepsis and pulmonary infection 
indicate that this peptide can be a promising template for the 
generation of new antibiotic formulations to advance care of 
infections caused by P. aeruginosa.
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of polysaccharides, proteins, and extracellular DNA. These 
confer protection on the bacterial population from antibiot-
ics, chemicals, as well as opsonization and phagocytosis by 
host immune cells [3, 6–9]. Importantly, biofilm formation 
is often associated with the establishment of persistent infec-
tions, like those found in the lungs of most cystic fibrosis 
(CF) sufferers [10, 11], where the gradual pulmonary dete-
rioration, thick airway mucus and high salt concentration 
hamper clearance of bacteria, leading to lethality. Despite 
the prominent role of biofilms in the infection, limited stud-
ies have been reported on the identification of compounds 
active on both free-living and sessile forms of P. aeruginosa 
[12]. Recently, natural antimicrobial peptides (AMPs) have 
attracted the interest of many researchers as fascinating tem-
plates for the development of alternative therapeutics with a 
new mode of action [13–15]. AMPs are produced by almost 
all unicellular and multicellular organisms and act as the first 
line of defense against noxious microorganisms [16–18]. 
However, there is increasing evidence, mainly in vertebrate 
species, that these peptides display crucial functions also in 
the regulation of the host’s immune system [19–24]. The 
majority of AMPs have a net positive charge at neutral pH 
and a substantial proportion of hydrophobic residues, both 
favoring AMPs’ binding and insertion into the negatively 
charged microbial membranes [21, 25–29]. Among natural 
sources for AMPs, amphibian skin of Rana genus is one of 
the richest storehouses [15, 30], and esculentin-1 represents 
the family of frog skin AMPs with the longest chain (46 
amino acids) [31, 32]. Interestingly, studies with esculen-
tin-1b, originated from the green edible frog Pelophylax 
lessonae/ridibundus (formerly R. esculenta [33]), showed 
that its N-terminal 1-18 region [Esc(1-18)] retained the 
wide spectrum of antimicrobial activity of the full-length 
peptide [34]. Lately, we demonstrated that esculentin(1-21) 
[Esc(1-21)], bearing the first 20 residues of the native escu-
lentin-1a (see Table 1) had a higher activity than Esc(1-18) 
in inhibiting the growth of Gram-negative bacteria, such 
as Escherichia coli and P. aeruginosa [35]. On the basis of 
such findings, we decided to investigate the in vitro and in 
vivo anti-Pseudomonas activity of the N-terminal region of 
esculentin-1 peptides by choosing the Esc(1-21) fragment. 
Specifically, we have analyzed the activity and underlying 
molecular mechanism of Esc(1-21) on both the planktonic 
and biofilm growing cells of P. aeruginosa, together with its 
in vivo efficacy in fighting infections caused by this patho-
gen at different anatomical regions. Importantly, we show 
that this frog skin AMP is a membrane-active peptide highly 
effective on P. aeruginosa strains, including those isolated 
from CF patients. It also has the ability to prolong survival 
of animals in models of peritoneal or pulmonary P. aerugi-
nosa infection, using a systemic or topical peptide adminis-
tration, respectively.
Materials and methods
Materials
Synthetic Esc(1-21) was purchased from Selleck Chemi-
cals (Houston, TX, USA). Briefly, Esc(1-21) was assem-
bled by step-wise solid-phase synthesis using a standard 
F-moc strategy and purified by RP-HPLC on a semiprepara-
tive C18-bonded silica column (Kromasyl, 5 μm, 100 Å, 
25 cm × 4.6 mm) using a gradient of acetonitrile in 0.1 % 
aqueous trifluoroacetic acid (from 25 to 100 % in 30 min) at 
a flow rate of 1.0 ml/min. The product was obtained by lyo-
philization of the appropriate fraction. Analytical RP-HPLC 
indicated a purity >98 %. The molecular mass was verified 
by using MALDI-TOF Voyager DE (Applied Biosystems, 
Carlsbad, CA, USA) as previously described [34]. Sytox 
Green was from Molecular Probes (Invitrogen, Carlsbad, 
CA, USA). Crystal violet (CV), 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 2-nitro-
phenyl β-d-galactoside (ONPG) were all purchased from 
Sigma (St. Louis, MO, USA). All other chemicals were rea-
gent grade.
Microorganisms
The strains of P. aeruginosa used for the antimicrobial 
assays were: the standard non-mucoid ATCC 27853 
[36] and PAO1, the clinical multidrug resistant (MDR) 
Table 1  Amino acid sequences of esculentin peptides
Peptide designation Sequencea
Esculentin-1a(1-21) GIFSKLAGKKIKNLLISGLKG-NH2
Esculentin-1ab GIFSKLAGKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC
a  Amino acid differences are boldfaced. Basic and acidic residues are indicated by red and blue letters, respectively
b  Peptide sequence taken from [31]
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isolates MDR1, MDR2, and MDR3 and the following 
strains from CF patients: the mucoid AA11 and non-
mucoid TR1 isolated at the onset of chronic lung coloni-
zation; both mucoid AA43 and TR67 isolated after years 
of chronic colonization, according to what was reported 
in [37, 38]. These CF strains were chosen from the strains 
collection of the CF clinic Medizinische Hochschule of 
Hannover, Germany [37]. Mode of action studies and 
β-galactosidase activity measurements were carried out 
with P. aeruginosa PAO1 carrying plasmid pPrsaL190 
[39], kindly provided by Prof. Livia Leoni (Roma Tre 
University, Rome, Italy).
Antibacterial activity on free-living bacteria
Susceptibility testing was performed by adapting the micro-
broth dilution method outlined by the Clinical and Labo-
ratory Standards Institute using sterile 96-well plates ("BD 
Falcon", BD Biosciences, Franklin Lakes, NJ, USA). Ali-
quots (50 μl) of bacteria in mid-log phase at a concentra-
tion of 2 × 106 colony-forming units (CFU)/ml in culture 
medium (Müller-Hinton agar) were added to 50 μl of MH 
broth containing the peptide in serial twofold dilutions. The 
ranges of peptide concentrations used were 0.125–32 μM. 
Inhibition of microbial growth was determined by measur-
ing the absorbance at 590 nm, after an incubation of 16–18 h 
at 37 °C with a microplate reader (Infinite M200; Tecan, 
Salzburg, Austria). Antimicrobial activities were expressed 
as the minimal inhibitory concentration (MIC), the concen-
tration of peptide at which 100 % inhibition of microbial 
growth is observed.
Anti-biofilm activity
Biofilm formation was performed by adapting the proce-
dure described in [40, 41] using the Calgary Biofilm Device 
(Innovotech, Innovotech Inc. Edmonton, Canada). Briefly, 
96-well plates (each well containing 150 μl of the bacte-
rial inoculum (1 × 107 cells/ml) in Luria-Bertani (LB) 
medium) were sealed with 96 pegs-lids on which biofilm 
cells can build up. Afterwards, the plates were placed in a 
humidified orbital incubator at 35 °C for 20 h under agita-
tion at 125 rpm. Once the biofilms were allowed to form, 
the pegs were rinsed twice with phosphate buffered saline 
(PBS) to remove planktonic cells. Each peg-lid was then 
transferred to a “challenge 96-well microtiter plate”, each 
well containing 200 μl of a twofold serial dilution of Esc(1-
21) in PBS. The “challenge plate” was incubated at 37 °C 
for 2 h. Peptide activity on preformed biofilm was evalu-
ated by three independent methods: (i) visual observation 
of bacterial growth; (ii) numbering of living bacterial cells 
after peptide treatment, and (iii) evaluation of biomass. In 
the first case, the peg-lid was removed from the “challenge 
plate”, rinsed with PBS, and used to cover a 96-well “recov-
ery microtiter plate”, each well containing 200 μl LB. The 
“recovery plate” was sealed, incubated at 37 °C for 4 h, and 
then observed for detection of any visible growth of bacteria 
detached from the peptide-treated biofilm. Growth of bac-
teria in a particular well indicates re-growth of planktonic 
cells from surviving biofilm. Minimum biofilm eradication 
concentration (MBEC) was defined as the minimum pep-
tide concentration preventing re-growth of bacteria from the 
treated biofilm, within 4 h.
In the second case, to determine viable cell counts 
after peptide treatment, pegs were broken from the lid and 
each peg was transferred into an Eppendorf tube contain-
ing 500 μl of PBS. After sonication to remove bacterial 
cells from the peg, aliquots of bacterial suspension were 
plated on LB-agar plates for counting. Colony-forming 
units (CFU) were expressed as a percentage with respect 
to the control (peptide-untreated biofilms). The minimum 
bactericidal concentration (MBCb) was defined as the low-
est peptide concentration required to reduce the number 
of viable biofilm cells of ≥3 log10 (99.9 % killing) after 
2 h [42]. Viable biofilm cells were also determined by the 
reduction of MTT to its insoluble formazan. Briefly, after 
peptide treatment, the peg lid was washed with PBS and 
used to close another 96-well microtiter plate, each well 
containing 200 μl of 0.5 mg/ml MTT in PBS. The plate 
was incubated at 37 °C for 4 h. Afterwards, 50 μl of 25 % 
sodium dodecyl sulphate (SDS) were added to each well to 
dissolve formazan crystals. Bacterial viability was deter-
mined by absorbance measurements at 595 nm [43] and 
calculated with respect to control cells (bacteria not treated 
with the peptide).
In the third case, to determine the biofilm biomass, pep-
tide-treated pegs were washed in PBS, fixed in 99 % metha-
nol for 15 min at room temperature, and air-dried. Then, 
by using a 96-well microtiter plate, pegs were stained with 
200 μl of a CV solution (0.05 % in water). After 20 min, 
the excess CV was removed by washing the pegs with 
water. Finally, bound CV was released from pegs by adding 
200 μl of 33 % acetic acid. The absorbance was measured 
at 600 nm.
Time-killing curves
About 1 × 105 CFU in 100 μl PBS were incubated at 37 °C 
with Esc(1-21) at 0.5 or 1 μM. Aliquots of 10 μl were 
withdrawn at different intervals, diluted in MH, and spread 
onto LB-agar plates. After overnight incubation at 37 °C, 
the number of CFU was counted. Controls were run with-
out peptide and in the presence of peptide solvent (water). 
Bactericidal activity was defined as the peptide concentra-
tion necessary to cause a reduction in the number of viable 
bacteria of ≥3 log10 CFU/ml.
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Permeation of the cytoplasmic membrane
Sytox Green assay
To assess the ability of Esc(1-21) to alter the bacterial mem-
brane permeability of planktonic cells of Pseudomonas, 
1 × 106 cells in 100 μl of PBS were mixed with 1 μM Sytox 
Green for 5 min in the dark. After adding the peptide, the 
increase in fluorescence, owing to the binding of the dye to 
intracellular DNA, was measured at 37 °C in the microplate 
reader (excitation and emission wavelengths were 485 and 
535 nm, respectively). The peptide concentrations ranged 
from 0.125 to 32 μM. Controls were cells without a peptide, 
whereas the maximal membrane perturbation was obtained 
after treating bacteria with the highest peptide concentra-
tion used (32 μM) followed by the addition of 1 mM ethyl-
enediaminetetraacetic acid (EDTA) + 0. 5 % Triton X-100 
(final concentration) to completely destabilize the lipopoly-
saccharide-outer membrane and solubilize the phospholipid 
bilayer of the cytoplasmic membrane [44]. Note that the 
addition of EDTA + Triton X-100 to the bacteria with the 
highest peptide concentration did not induce any change in 
the fluorescence intensity, thus excluding any possible inter-
ference between the peptide and the detergent used.
In the case of 20 h preformed biofilm, after 2-h peptide 
treatment in the “challenge microtiter plate” [each well 
containing 200 μl of a twofold serial dilution of Esc(1-21) 
in PBS supplemented with 1 μM Sytox Green], pegs were 
broken from the lid and each peg was transferred into an 
Eppendorf tube together with the corresponding 200 μl 
from the “challenge well”. After sonication to detach bacte-
rial cells from the peg, the cell suspension of each sample 
(200 μl volume) was transferred into wells of another micr-
otiter plate for measurement (excitation and emission wave-
lengths were 485 and 535 nm, respectively). Also in this 
case, controls were given by cells without peptide, whereas 
the maximal membrane perturbation was obtained after 
treating biofilm cells with the highest peptide concentration 
(48 μM), followed by the addition of 1 mM EDTA + 0.5 % 
Triton X-100 to dissolve the extracellular matrix [45] and 
make the bacterial membranes fully permeable [44].
β-galactosidase assay
The ability of Esc(1-21) to cause more pronounced dam-
age to the cytoplasmic membrane of Pseudomonas was 
determined by measuring the extracellular release of 
β-galactosidase, using ONPG as a substrate [46]. For the 
planktonic form, P. aeruginosa PAO1 was grown at 37 °C 
in LB to an OD590 nm of approximately 0.8, washed twice, 
centrifuged for 10 min (1.4 × g) and resuspended in PBS 
at the same OD. About 1 × 106 cells (in 100 μl PBS) were 
incubated with different concentrations of Esc(1-21) for 
30 min at 37 °C. Controls were bacteria without peptide, 
whereas the maximal membrane perturbation was obtained 
as described for the Sytox Green assay on planktonic cells. 
At the end of the incubation time, 2-μl aliquots were with-
drawn, diluted 1:100 in LB, and spread on LB plates for 
counting. Afterwards, 450 μl of PBS was added to the 
remaining bacterial suspension, which was passed through 
a 0.2-μm filter. The hydrolysis of 2 mM ONPG, added to 
the culture filtrate, was recorded at 420 nm using a spectro-
photometer (UV-1700 Pharma Spec Shimadzu).
In the case of preformed biofilm, pegs were broken from 
the lid of the “challenge plate”, transferred into Eppendorf 
tubes together with the corresponding 200 μl from the wells 
of the “challenge plate”, and then sonicated. Then, 2-μl ali-
quots of the cell suspension were withdrawn and diluted as 
described above, for counting. One ml of PBS was added to 
the sonicated cell suspension, which was filtered; hydrolysis 
of 2 mM ONPG was followed as described above. Controls 
and maximal membrane perturbation were obtained as for 
the Sytox Green assay on biofilm cells.
Scanning electron microscopy
Approximately 1 × 106 bacterial cells in PBS were treated 
with the peptide at different concentrations for 30 min at 
37 °C and then fixed with 2.5 % glutaraldehyde in 0.2 M 
cacodylate buffer (pH 7.2). The samples were deposited on 
glass coverslips of 12-mm diameter. Afterwards, they were 
washed three times in cacodylate buffer, post-fixed with 
1 % (w/v) osmium tetroxide for 1 h, and dehydrated using 
a graded ethanol series (70; 85; 95 %). After the passage in 
100 % ethanol, the samples were air-dried (overnight) and 
gold coated by sputtering (SCD 040 Balzers device, Bal-
Tec). The samples were examined with a scanning electron 
microscope (FEI Quanta Inspect FEG, USA)
To visualize biofilm-colonized pegs, after 20 h of biofilm 
formation by P. aeruginosa ATCC 27853 or P. aeruginosa 
PAO1 on Calgary microtiter plates, pegs were broken from 
the lid, washed with PBS, and fixed with 2.5 % glutaralde-
hyde in 0.2 M cacodylate buffer. Pegs were placed in this 
solution at 4 °C for 16 h. Following this fixing step, the pegs 
were washed in 0.2 M cacodylate buffer for approximately 
10 min. Then, they were post-fixed, dehydrated, and gold 
coated as described above. The pegs were examined under 
the same scanning electron microscope and those portions 
containing bacterial cells were photographed.
Hemolytic and cytotoxic activity
The hemolytic activity of Esc(1-21) was determined using 
fresh human erythrocytes. The blood was centrifuged and 
the erythrocytes were washed three times with 0.9 % NaCl. 
Peptide solutions were incubated with the erythrocyte 
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suspension (1 × 107 cells/ml) at 37 °C for a short (1 h) and 
a long (24 h) time. Then, the extent of hemolysis was meas-
ured on the supernatant, from the optical density at 540 nm 
of the supernatant. Hypotonically lysed erythrocytes were 
used as a standard for 100 % hemolysis.
The cytotoxic effect of Esc(1-21) was determined by 
the inhibition of MTT reduction to insoluble formazan, by 
mitochondrial reductases. We used the murine Raw 264.7 
macrophage cell line and the human lung adenocarcinoma 
epithelial cell line A549 from the American Type Culture 
Collection (ATCC, Manassas, VA). Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma) sup-
plemented with 10 % heat inactivated fetal bovine serum, 
glutamine (4 mM), and antibiotics (penicillin and strepto-
mycin). Afterwards, cells were plated in triplicate wells of 
a microtiter plate at 1 × 105 cells/well in DMEM supple-
mented with 2 % serum without antibiotics. After overnight 
incubation at 37 °C in a 5 % CO2 atmosphere, the medium 
was replaced with 100 μl fresh DMEM supplemented with 
Esc(1-21) at different concentrations. The plate was incu-
bated for a short (1 h) and a long (24 h) time at 37 °C in a 
5 % CO2 atmosphere. Afterwards, the medium was removed 
and replaced with Hank’s medium (136 mM NaCl; 4.2 mM 
Na2HPO4; 4.4 mM KH2PO4; 5.4 mM KCl; 4.1 mM 
NaHCO3, pH 7.2, supplemented with 20 mM d-glucose) 
containing 0.5 mg/ml MTT. After 4 h incubation, the 
formazan crystals were dissolved by adding 100 μl of acidi-
fied isopropanol and viability was determined by absorb-
ance measurements at 570 nm. Cell viability was calculated 
with respect to control cells (cells not treated with peptide).
In vivo experiments
Animal procedures were approved by the Ethics Commit-
tee of the Azienda Ospedaliera Universitaria Senese on 
November 18, 2010. For both mice models of sepsis and 
lung infections, Balb-c mice (20 g) were rendered neutro-
penic by cyclophosphamide (Sigma-Aldrich C7397) given 
intraperitoneally (i.p.) 150 mg/kg (300 μl of a solution 10 
mg/ml) 4 days and 1 day before the infection.
Regarding the sepsis model [47], animals were infected 
i.p. with a lethal amount of P. aeruginosa PAO1 (1.5 × 103 
CFU/mouse) mixed in 500 μl PBS. Groups consisted of five 
animals. Moribund animals were killed humanely to avoid 
unnecessary distress. After 24 and 72 h from the bacterial 
administration, the peptide was inoculated intravenously 
(i.v.) with 0.2 ml PBS solution containing 5 mg/kg of Esc(1-
21). Control animals received only PBS. Surviving mice 
were monitored for 12 days.
In the pneumonia model, the infection was initiated 
through intra-tracheal (i.t.) instillation of P. aeruginosa 
PAO1 (1–3 × 103 CFU/mouse). Animals were first anesthe-
tized with Avertin (Sigma-Aldrich 2,2,2-Tribromoethanol 
T48402) (600 μl i.p. of a solution 10 mg/ml) and, after 
10 min from anesthesia, bacteria were administered i.t. 
through a small incision at the trachea level where a 22-G 
catheter connected to a syringe was inserted (volume injected 
60 μl). Approximately 2–3 min later, using the same cath-
eter inserted in the trachea, 60 μl of PBS solution contain-
ing the peptide (5 or 2.5 or 1.25 mg/kg) were injected in the 
lungs with a different syringe. Afterwards, the wound was 
closed by a small clip. Animals were generally awake after 
30 min. Groups consisted of 16 animals. Moribund animals 
were killed humanely as above. All p values were calculated 
using GraphPad Prism 5.0 software.
Results
Antimicrobial activity on planktonic and  
biofilm cells of P. aeruginosa
The antimicrobial activity of Esc(1-21) was tested by the 
microdilution broth assay on reference strains (ATCC 27853 
and PAO1) and MDR-clinical isolates of P. aeruginosa (i.e., 
MDR1, MDR2, and MDR3) whose resistance phenotype is 
illustrated in Table 2. In addition, P. aeruginosa strains from 
CF patients were included for comparison. Esc(1-21) was 
equally active on both reference and MDR-strains, with a 
MIC value of 4 μM except for MDR2 (8 μM) (Table 3). 
Furthermore, it displayed the same efficacy also against CF 
strains either with a mucoid or non-mucoid phenotype. To 
verify whether the anti-Pseudomonas activity of Esc(1-21) 
was preserved against the sessile form of this microorgan-
ism, the peptide’s activity on 20-h pre-formed biofilm of 
P. aeruginosa ATCC 27853 (a well-known biofilm-form-
ing strain) was studied by three independent methods, as 
described in the Experimental procedure section, using 
microtiter plates endowed with a 96-peg lid: (i) visual 
observation of bacterial growth; (ii) evaluation of living 
bacterial cells after peptide treatment, and (iii) estimation 
Table 2  Resistance phenotype of MDR-clinical isolates of P. aerugi-
nosa
MDR strain Resistance phenotype
1 AMP–CAZ–CIP–CTX–CXM–FEP–GEN–MEM–PIP–
SXT–TOB
2 AMP–CFZ–CIP–CTX–CXM–GEN–LVX–IPM–MEM–
SXT–TET
3 AMP–CFZ–CTX–CIP–GEN–IPM–LVX–SXT–TET–
TOB
AMP ampicillin; CAZ ceftazidime; CFZ cefazolin; CIP ciprofloxacin; 
CTX cefotaxime; CXM cefuroxime; FEP cefepime; GEN gentamicin; 
IPM imipenem; LVX levofloxacin; MEM meropenem; PIP pipera-
cillin; SXT trimethoprim/sulfamethoxazole; TET tetracyclin; TOB 
tobramicin
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of the peptide’s effect on the bacterial biomass. As shown in 
Table 3, the minimum peptide concentration able to inhibit 
re-growth of bacteria from peptide-treated biofilm (MBEC) 
was found to be equal to 6 μM. Most importantly, the same 
peptide caused a 3-log10 reduction in the number of viable 
biofilm Pseudomonas cells (i.e., MBCb in Table 3) at a con-
centration twofold higher the MBEC. Note that the percent-
age of living cells in biofilm-colonized pegs upon treatment 
with different concentrations of Esc(1-21) was determined 
either by colony counts or by MTT reduction (Table 4). 
Using the latter procedure, a slightly lower percentage of 
viable bacteria was recorded, whereas, by CV staining, from 
15 to 32 % biofilm biomass was detected at those concentra-
tions giving rise to almost total microbial death (from 48 to 
12 μM, respectively) (Table 4).
Mode-of-action studies on planktonic cells
Killing kinetics
Esculentin(1-21) was first analyzed for its killing kinetic 
on reference (Fig. 1a) and some representative CF strains 
of Pseudomonas (Fig. 1b) in physiologic solution. Interest-
ingly, in all cases, bactericidal effects (99.9 % killing) were 
apparent with 1 μM peptide within 15 min, which excludes 
inhibition of intracellular processes (e.g., DNA, protein or 
cell wall synthesis) as the major mechanism(s) for the bac-
tericidal activity of Esc(1-21) against Pseudomonas.
Membrane perturbation
The ability of Esc(1-21) to injure the cytoplasmic mem-
brane of planktonic cells of P. aeruginosa PAO1 was evalu-
ated within the first 50 min after addition of the peptide at 
concentrations ranging from 0.125 to 32 μM, by means of 
the Sytox Green assay (Fig. 2). Sytox Green (MW 900 Da) 
is an impermeant probe, which is excluded from intact cells, 
but not from those having lesions whose size is enough to 
allow its entrance. As found for the killing kinetic assay 
(Fig. 1), the bacterial membrane perturbation occurred 
Table 3  Anti-Pseudomonas activity of Esc(1-21)a
MIC (µM)b
Pseudomonas aeruginosa strains
Reference strains MDR clinical isolatesd CF clinical isolates
Early Late
Peptide ATCC 27853c PAO1c MDR1 MDR2 MDR3 AA11e TR1c AA43e TR67e
Esc(1-21) 4 4 4 8 4 4 4 4 4
Anti-biofilm activity on P. aeruginosa ATCC 27853
Minimum biofilm eradication concentration (MBEC, µM)f Minimum bactericidal concentration (MBCb, µM)g
6 12
a
  Values are those obtained from at least three readings out of four independent measurements
b  The minimum growth inhibitory concentration (MIC) is reported against the planktonic form of P. aeruginosa strains
c  Non-mucoid strains
d  The mucoid phenotype was not investigated
e  Mucoid phenotype
f  MBEC is defined as the minimum peptide concentration preventing re-growth of bacteria from the treated biofilm, within 4 h
g  MBCb is defined as the minimum peptide concentration required to reduce the number of viable biofilm cells of ≥ 3 log10 (99.9 % killing) after 
2 h
Table 4  Anti-biofilm activity of Esc(1-21) at different concentra-
tionsa
Peptide  
concentration  
(μM)
Viable biofilm cells (%)b Biofilm  
biomass 
(%)cColony counts MTT reduction
48 0 0 15
24 0.08 0 17
12 0.1 0 32
6 32 28 53
3 50 47 65
1.5 75 71 100
0.75 100 100 100
a
  The activity was evaluated as enumeration of viable cells and bio-
film biomass. The results are the mean of three independent experi-
ments with SD not exceeding 0.6 %
b  The percentage of viable cells was determined either by colony 
counts of pegs after sonication or by MTT reduction to its insolu-
ble formazan with respect to control samples (bacterial biofilm not 
treated with the peptide)
c  The percentage of biofilm biomass was determined by CV staining. 
See "Materials and methods" for further experimental details
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within the first 15 min from peptide addition and in a dose-
dependent manner (Fig. 2). Similar results were obtained 
with P. aeruginosa ATCC 27853 (data not shown). Note 
that an optimal detection of membrane perturbation by the 
Sytox Green assay required a higher number of bacterial 
cells (1 × 107 CFU/ml) compared to the regular amount 
(1 × 106 CFU/ml) used for MIC (Table 3) and killing kinet-
ics assays (Fig. 1). However, the relationship between the 
peptide’s effect on the viability of PAO1 cells and the per-
turbation of their membrane under the same conditions (e.g. 
number of cells and incubation time) is reported in Fig. 3a, 
where the results of bactericidal and membrane perturbation 
assays performed with 1 × 107 CFU/ml after 30 min of pep-
tide treatment are compared. This higher number of bacte-
rial cells explains the differences in viable counts previously 
shown in Fig. 1 at 0.5 and 1 μM peptide concentrations. 
The maximal membrane perturbation was reached at 8 μM; 
however, a membrane disturbing activity was observed 
already at peptide concentrations of 0.25–0.5 μM, which 
did not significantly affect the survival of bacteria (Fig. 3a). 
To further expand our knowledge on the extent of peptide-
induced membrane disruption, the leakage of large cytosolic 
Fig. 1  Killing kinetic of Esc(1-21) on P. aeruginosa strains. Bacteria 
(1 × 106 CFU/ml) were incubated with 0.5 μM (triangle) or 1 μM 
(square) of Esc(1-21) in PBS at 37 °C. The number of surviving cells 
at different incubation time is indicated as CFU/ml. The control (cir-
cle) is given by bacteria without peptide. Data points represent the 
mean of triplicate samples ± SD from a single experiment, repre-
sentative of three independent experiments. The dotted lines indicate 
99.9 % bacterial killing
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components, such as the enzyme β-galactosidase, from 
peptide-treated cells was investigated. As reported in the 
"Materials and methods" section, the P. aeruginosa PAO1 
recombinant strain, used in our experiments, constitutively 
expresses the β-galactosidase. As shown in Fig. 3a, Esc(1-
21) provoked from ~50–60 % enzyme release at those con-
centrations (from 8 to 32 μM) causing the complete micro-
bial death and making the membrane fully permeable to 
Sytox Green. Hereafter, to shed light onto the direct effect 
of the peptide on the morphology of bacterial cells, we used 
scanning electron microscopy. Untreated bacteria appeared 
as rods with a bright surface (Fig. 4). In contrast, Esc(1-21) 
elicited a remarkable modification of the cell shape with the 
formation of blebs (pustules) and cell debris arising from 
the bacteria (Fig. 4).
Mode-of-action studies on bacterial biofilm
The ability of Esc(1-21) to harm the membrane of Pseu-
domonas PAO1 cells in their sessile form was also studied 
by measuring both the intracellular influx of Sytox Green 
and the extracellular release of β-galactosidase, 2 h after 
peptide treatment at different concentrations (Fig. 3b). Sur-
prisingly, similar results to those achieved with the motile 
form of this microorganism were found, although a weaker 
Fig. 2  Kinetics of cytoplasmic membrane permeabilization of the 
planktonic form of P. aeruginosa PAO1. Cells (1 × 107 CFU/ml) 
were incubated with 1 μM Sytox Green in PBS. Once basal fluo-
rescence reached a constant value, the peptide was added (arrow, 
t = 0) and changes in fluorescence (λexc = 485 nm, λems = 535 nm) 
were monitored for 50 min and plotted as the percentage of mem-
brane perturbation relative to that obtained after treating bacteria 
with the highest peptide concentration (32 μM) and the addition of 
1 mM EDTA + 0.5 % Triton-X100. Data points represent the aver-
age values of three independent experiments, with SD not exceeding 
2.5 %. Peptide concentrations used were the following: 0.125 μM 
(hyphen); 0.25 μM (diamond); 0.5 μM (square); 1 μM (filled circle); 
2 μM (triangle); 4 μM (cross); 8 μM (filled triangle); 16 μM (filled 
square); 32 μM (filled diamond). Control (circle) is given by bacteria 
without peptide
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Fig. 3  Effect of Esc(1-21) on the viability and membrane pertur-
bation of the planktonic (a) and biofilm (b) forms of P. aeruginosa 
PAO1. Planktonic cells (1 × 107 CFU/ml in PBS) were incubated 
with the peptide at different concentrations for 30 min at 37 °C. The 
number of CFU is given as percentage with respect to the control 
(bacteria not treated with the peptide). Membrane perturbation was 
evaluated by the Sytox Green and β-galactosidase assay. In the first 
case, bacteria (1 × 107 CFU/ml) were incubated with 1 μM Sytox 
Green in PBS. Once basal fluorescence reached a constant value, 
the peptide was added and changes in fluorescence (λexc = 485 nm, 
λems = 535 nm) were monitored. The fluorescent signal obtained 
after 30 min was plotted as the percentage of membrane perturbation 
as described in the legend to Fig. 2. All readings were normalized 
by subtracting fluorescence values of control (bacteria without pep-
tide). In the second case, β-galactosidase activity was measured in the 
culture filtrate following the hydrolysis of 2 mM ONPG at 420 nm. 
Enzymatic activity detected in the control (bacteria without peptide) 
was subtracted from all values, which are expressed as percentage 
with respect to that found after treating bacteria with the highest 
peptide concentration and 1 mM EDTA + 0.5 % Triton X-100 (see 
"Materials and methods" section for more details). Bacterial biofilms 
grown on pegs were treated with the peptide diluted in PBS at differ-
ent concentrations for 2 h at 37 °C. The percentage of surviving bio-
film cells and membrane perturbation (measured by both the Sytox 
Green and β-galactosidase assays) were expressed as described for 
the planktonic cells. All data points represent the means of three inde-
pendent measurements ± SD
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damage to the membrane was recorded, as demonstrated 
by the minor leakage of β-galactosidase at those peptide 
concentrations causing ~100 % microbial killing. Overall, 
these findings are indicative of membrane perturbation as 
a plausible mechanism subtending the anti-biofilm activ-
ity of Esc(1-21) towards Pseudomonas. As evidenced from 
electron microscopy analysis (Fig. 5), cells embedded in an 
unordered extracellular matrix were observed after 20 h of 
biofilm formation (Fig. 5a). Remarkably, clear protrusions 
from the surface of bacteria were detected at a peptide con-
centration bringing about 95 % killing of biofilm (24 μM) 
with an evident disintegration of the extracellular matrix, 
becoming less packed and thinner (Fig. 5c). In contrast, 
no appreciable morphological changes were discerned at a 
sublethal peptide dosage (e.g., 0.75 μM, Fig. 5b). Note that 
P. aeruginosa PAO1 formed a more consistent biofilm with 
respect to P. aeruginosa ATCC 27853 (1 × 107 CFU/peg 
after 20-h biofilm growth versus 1 × 106 of P. aeruginosa 
ATCC 27853 in agreement with the supplementary Table 
of ref [42]), thus explaining the lower anti-biofilm potency 
of Esc(1-21) towards the former strain (see cell viability in 
Fig. 3b; Table 4).
Besides, when the peptide’s effect on the morphology 
of P. aeruginosa ATCC 27853 biofilm cells was visualized, 
we found that Esc(1-21) led to a dose-dependent shrinking 
shape of bacterial cells, even if trapped into the extracellu-
lar polymeric substances (Fig. 5e–f). Such an outcome was 
noticed at a peptide concentration causing approximately 
50 % biofilm eradication (3 μM, Fig. 5e), and it became 
more pronounced at 24 μM Esc(1-21), when almost all bio-
film cells were killed (Table 4; Fig. 5f).
In vitro cytotoxic activity
The potential toxic effect of the peptide toward mammalian 
cells was investigated on human erythrocytes, lung epithe-
lial cells, and murine macrophages, at a short (1-h) and long 
(24 h) incubation time, at its MIC (4 μM). Esc(1-21) was 
devoid of lethal effect on these cell types even after 24 h 
of treatment. Interestingly, no appreciable cytotoxic activity 
was detected when macrophages and lung epithelial cells 
were incubated for 24 h with a peptide concentration up to 
eightfold the MIC (data not shown).
In vivo anti-Pseudomonas activity
The promising results of the in vitro experiments prompted 
us to seek insight into the in vivo activity of Esc(1-21) 
against two different types of P. aeruginosa infection by 
employing mice models of sepsis or lung infection. In the 
sepsis model, the peptide was injected i.v. (5 mg/kg) at 24 
and 72 h post-infection and the animals were monitored for 
their survival. As illustrated in Fig. 6a, the peptide was able 
to protect 40 % of animals from death after 12 days from the 
start of the infection, whereas the control mice (infected but 
not treated with the peptide) died within the first 72 h. In the 
lung infection model, the peptide was i.t. administered in a 
single dose at the concentrations of 5, 2.5, or 1.25 mg/kg. 
Esc(1-21) allowed 50 and 33 % survival at 5 and 2.5 mg/kg, 
respectively, after 40 h from the infection, and 31 and 13 % 
survival at 5 and 2.5 mg/kg, respectively, at 50 h post- 
infection (Fig. 6b). However, after 60 h, only the dosage of 
5 mg/kg gave an appreciable animal survival (25 %). Con-
trol animals died within the first 40 h. The good percent-
age of animal survival after many hours from the infection, 
along with the dose-dependent response, confirmed the in 
vivo efficacy of Esc(1-21), also when applied into the lungs.
Discussion
Pseudomonas aeruginosa infections and their persistence to 
aggressive antibiotic therapy has been the subject of many 
investigations during the past decades [48–50]. P. aerugi-
nosa is an opportunistic Gram-negative bacterium infecting 
burns, wounds, colonizing medical devices (e.g., catheters 
Fig. 4  Scanning electron 
microscopy of Pseudomonas 
PAO1 cells in their planktonic 
form after 30 min peptide treat-
ment at 8 μM (causing ~100 % 
killing, as shown in Fig. 3). 
Controls are cells not treated 
with the peptide. See Results 
section for other experimental 
details and descriptions of the 
images. Inset is a magnification 
of a portion indicated by the 
white dotted frame
control treated
P. aeruginosa PAO1
1 µm
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and implants) and different types of human tissues, such as 
the pulmonary epithelium, especially in patients with CF, 
the most common eventually fatal recessive genetic disease 
in Caucasian populations [51, 52]. Colonization of lungs by 
Pseudomonas usually starts with the tissue adhesion of non-
mucoid strains followed by secretion of anionic polysaccha-
rides, mainly alginate, to create a protective layer around the 
cells [53, 54]. Subsequently, motility is repressed and bac-
teria frequently evolve a mucoid phenotype forming thicker 
biofilms, which are more resistant to antibiotic therapy [55]. 
Importantly, to date, only a few studies on the activity of 
naturally occurring AMPs on preformed P. aeruginosa bio-
film have been reported [2, 56]. However, they do not deal 
with the mechanism(s) underlying the killing of biofilm 
cells. In addition, some peptides have recently been found 
to inhibit biofilm formation, but without being active on the 
planktonic form of this microorganism [57].
Overall, our study provides information regarding five 
important properties that make frog skin AMPs promising 
candidates for anti-Pseudomonas therapeutics.
Activity on free-living P. aeruginosa strains
Esculentin(1-21) displays the same efficacy against refer-
ence and CF clinical isolates of P. aeruginosa with a rapid 
bactericidal activity (15 min), regardless of their resistance 
or mucoid phenotype, as revealed by the similar MIC val-
ues (Table 2) and killing kinetics (Fig. 1). This is in con-
trast with currently available drugs for the treatment of lung 
infection by this bacterium, such as the aminoglycoside 
tobramycin, whose effectiveness is highly reduced towards 
P. aeruginosa mucoid strains [58].
Activity on P. aeruginosa biofilm and  
the corresponding assays
Esculentin(1-21) is able to inhibit re-growth of cells from 
Pseudomonas-treated biofilm and to eliminate biofilm cells 
within 2 h (Table 3). Note that the MBCb, 12 μM, is three-
fold higher than the MIC, whereas some medically used 
antibiotics such as aminoglycosides, fluoroquinolones, and 
Fig. 5  Scanning electron 
microscopy of biofilm cells 
of Pseudomonas after 2-h 
incubation at 37 °C at different 
concentrations of Esc(1-21): 
0.75 μM (b); 3 μM (e) and 
24 μM (c, f). Controls (a, d) 
are given by biofilm cells not 
treated with the peptide. Left 
panels P. aeruginosa PAO1; 
right panels P. aeruginosa 
ATCC 27853. See Results 
section for other experimental 
details and description of the 
images. Insets are magnifica-
tions of a portion indicated by 
the white dotted frame
P. aeruginosa PAO1 P. aeruginosa ATCC 27853 
a
b
c
d
e
f
0.5µm
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tetracycline require a concentration that is 100-fold higher 
the MIC, in order to kill sessile bacteria [3, 59]. Moreover, 
it has been demonstrated that some conventional drugs can 
even act as intercellular signaling molecules stimulating 
bacterial biofilm formation at sub-inhibitory concentrations 
[60, 61].
Regarding biofilm quantitation methods, it is worthwhile 
noting that although CV staining has been used for several 
years as a common and cheap assay to explore the antibio-
film activity of antimicrobial compounds [62, 63], it cannot 
provide any information on the efficacy of such compounds 
in killing biofilm cells: this is due to the ability of CV to 
bind both living and dead bacteria, as well as the extracel-
lular polymeric substances of biofilm communities. Indeed, 
in our hands, from 15 to 32 % biomass was obtained after 
treating Pseudomonas biofilm with peptide concentrations 
inducing almost its complete killing, suggesting that such 
a percentage was only related to the presence of lifeless 
biological material. The reduction of MTT to its insoluble 
formazan may also give inaccurate results on the quantity 
of viable biofilm cells. As reported in Table 4, a slightly 
lower amount of viable cells was found by this method with 
respect to the results of colony counts. This may be due 
to an impaired enzymatic activity in peptide-treated cells, 
despite being still alive. In addition, the minimal number 
of bacterial cells necessary to get detectable signals in this 
assay (i.e., absorbance measurement of reduced MTT) is 
much higher (approximately 3 × 105 cells) compared to that 
needed for CFU counting on plates that we believe to be a 
more accurate and appropriate viability method [64].
The peptide is active at high salt concentration  
and is devoid of cytotoxic effects
Esculentin(1-21) is endowed with antimicrobial activ-
ity at high salt concentration against both reference and 
CF strains. This is a considerable advantage taking into 
account that elevated salt concentrations in airways mucus 
of CF patients [51, 52] hinder endogenous bactericidal pep-
tides, i.e., LL-37 and hBD-2 found in mammalian mucosal 
surfaces, including airways epithelia [65]. Furthermore, 
according to our previous studies [35], Esc(1-21) was 
found to be devoid of toxic effect on mammalian cells (e.g., 
erythrocytes, macrophages, and lung epithelial cells), when 
tested at its microbicidal concentrations at short (1 h) and 
long (24 h) incubation time.
The peptide acts via membrane permeation
Esculentin(1-21) perturbs the membrane of planktonic and 
sessile Pseudomonas cells in a dose-dependent fashion. 
In both cases, this effect is manifested also at concentra-
tions below those decreasing bacterial survival. The degree 
of membrane injury enhances in parallel with the peptide 
dosage, presumably enlarging the size of membrane break-
ages that lead to an increasing loss of bulky intracellular 
compounds, such as the β-galactosidase (Stokes radius 69 Å 
[66]). As highlighted by SEM images, the peptide elicits 
similar changes on the morphology of Pseudomonas PAO1 
cells either in their motile or non-motile forms. However, a 
different outcome could be appreciated between biofilms of 
the two strains: the appearance of surface corrugation with 
distinct blisters in case of PAO1, and a collapse of the cel-
lular structure with a ghost-like appearance for P. aerugi-
nosa ATCC 27853. Importantly, such alterations represent 
Fig. 6  In vivo antibacterial activity of Esc(1-21). a Neutropenic 
Balb-c mice were injected i.p. with a lethal amount of P. aeruginosa 
PAO1 cells. The percentage of animal survival is indicated at 2, 3, 
and 12 days post-infection for both controls (Ctr, white bars) and ani-
mals treated with Esc(1-21) at 5 mg/kg after 24 and 72 h from the 
infection (black bars). b Neutropenic Balb-c mice were injected i.t. 
with a lethal amount of P. aeruginosa PAO1 cells. The percentage of 
animal survival after treatment with Esc(1-21) (a single dose at 5, 2.5, 
and 1.25 mg/kg) is indicated at 40, 50, and 60 h post-infection. Ani-
mals not treated with the peptide (0 % survival at 40 h) are not indi-
cated. The experiments derived by repeated tests in animals where 
different preparations of bacteria were used. p < 0.05
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an obvious sign of serious deformation of the bacterial wall, 
according to the peptide-induced membrane perturbation, as 
proved by the results of the Sytox Green and β-galactosidase 
assays (Figs. 2, 3). On the basis of our data, we may specu-
late that Esc(1-21) has the same mode of action on the static 
and dynamic forms of Pseudomonas, with a different upshot 
on the target cell’s shape, depending on the peptide concen-
tration or bacterial strain used.
In vivo activity
Esculentin(1-21) has the capability to significantly prolong 
survival of mice with P. aeruginosa sepsis or lung infection. 
We chose these types of mouse models to mimic some of 
the most common human infections by this pathogen, such 
as those provoked by abdominal trauma (e.g., organ perfo-
ration) or highly diffused in CF patients. The percentage of 
animal survival obtained upon i.v. or i.t. administration of 
Esc(1-21), although not very high, is very promising, con-
sidering that Esc(1-21) is a short-sized linear peptide deriv-
ing from the N-terminal region of a native AMP to which 
only the addition of a glycinamide at the C-terminus was 
introduced. Note that the amidation of the C-terminal resi-
due represents a common post-translational enzymatic mod-
ification for the majority of linear AMPs from amphibian 
skin [67, 68]. Overall, we think that the protective effects 
of Esc(1-21) in these animal models is mainly due to a 
direct antibacterial activity of the peptide rather than to the 
immune system of the mouse. This is because the animals 
are made neutropenic before infection, producing an impair-
ment of native and adaptive immune response. However, we 
cannot exclude the possibility that an immunomodulatory 
activity of Esc(1-21) is involved in promoting the animal’s 
survival, by enhancing the elimination of bacteria from the 
body.
Conclusions
To our knowledge, this study represents the first demonstra-
tion of the potent and rapid activity of an amphibian AMP 
on both planktonic and biofilm cells of Pseudomonas along 
with the underlying molecular mechanism. In addition, to 
the best of our knowledge, this is the first report showing 
the effect(s) of AMPs on the membrane permeability of ses-
sile bacterial communities, as a plausible mechanism for 
biofilm eradication. This should reduce the development of 
biofilm resistance. Furthermore, considering: (i) the ability 
of Esc(1-21) to preserve activity at high salt concentrations 
and against mucoid strains of Pseudomonas; and (ii) the 
results of its in vivo efficacy in mouse models, this peptide 
may serve as a promising template for the generation of new 
drugs to be applied either systemically or topically (e.g., in 
a nebulized form by inhalation) for the treatment of P. aer-
uginosa infection, mainly in CF sufferers.
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Abstract
Previous investigations indicate that a-melanocyte-stimulating hormone (a-MSH) and certain synthetic analogues of it exert
antimicrobial effects against bacteria and yeasts. However, these molecules have weak activity in standard microbiology
conditions and this hampers a realistic clinical use. The aim in the present study was to identify novel peptides with broad-
spectrum antimicrobial activity in growth medium. To this purpose, the Gly10 residue in the [DNal(29)-7, Phe-12]-MSH(6–13)
sequence was replaced with conventional and unconventional amino acids with different degrees of conformational
rigidity. Two derivatives in which Gly10 was replaced by the residues Aic and Cha, respectively, had substantial activity
against Candida strains, including C. albicans, C. glabrata, and C. krusei and against gram-positive and gram-negative
bacteria. Conformational analysis indicated that the helical structure along residues 8–13 is a key factor in antimicrobial
activity. Synthetic analogues of a-MSH can be valuable agents to treat infections in humans. The structural preferences
associated with antimicrobial activity identified in this research can help further development of synthetic melanocortins
with enhanced biological activity.
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Introduction
a-Melanocyte stimulating hormone (a-MSH), a pro-opiomela-
nocortin (POMC) derivative, is an ancient tridecapeptide that
exerts pleiotropic influences on the host physiology [1]. A major
contribution of a-MSH to tissue protection resides in its capacity
to prevent cell injury induced by harmful stimuli including
endotoxin, reperfusion injury, blood loss, and oxidative stress
[1,2]. Of interest, a-MSH involvement in host defense includes
antimicrobial activity [3,4]. Indeed, the peptide and its C-terminal
sequence Lys-Pro-Val were found to inhibit growth of both the
yeast Candida albicans and the gram-positive bacterium Staphylococ-
cus aureus [4]; further, the N-terminal sequence His-Phe-Arg-Trp
showed antimicrobial activity against Cryptococcus neoformans [5].
Although the natural a-MSH peptide has a very short half-life
that makes it unsuitable for clinical use, synthetic analogues of it
could form the basis for novel antimicrobial agents. However, key
issues need to be solved before a therapeutic use is realistic. A
crucial question concerns potency of the antimicrobial activity.
Indeed, a-MSH and the synthetic derivatives described to date
were found to exert their activity against infectious agents that
were suspended in physiologic solution or in water but not in
culture media that allow microorganisms to grow [4,6,7,8,9,10].
Therefore, although data indicate a potential for melanocortin
derivatives to combat infections, none of the known molecules is
active against microorganisms in growth medium. Because this is a
major obstacle to a realistic clinical use, the aim in this research
was to design novel melanocortin analogues that could overwhelm
this weakness. The lead sequence selected was [DNal(29)-7, Phe-
12]–MSH(6–13) (DNal), a promising antimicrobial compound that
contains the invariant ‘core’ sequence His-Phe-Arg-Trp (6–9)
common to all melanocortins [7]. Indeed, although DNal did not
kill Candida in growth medium, it did kill 100% organisms
incubated in distilled water [7]. Conformational analysis of DNal
indicated the presence of two b-turns along residues 7–10 and 10–
13 (type I, and distorted type III, respectively) [11]; these two
turns, which likely form the pharmacophoric moieties, are linked
by a highly flexible glycine residue that can orient them differently
[11]. Therefore, in the present research we produced novel
antimicrobial peptides based on replacement of Gly10 in the DNal
sequence with natural and unnatural amino acids with different
degrees of conformational rigidity (Table 1). Activity against
various pathogenic agents including gram-positive and gram-
negative bacteria and yeasts was assessed using standard culture
tests. We report results of a conformational study on the most
effective peptides.
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Materials
N9-fluorenylmethoxycarbonyl (Fmoc)-protected natural amino
acids were purchased from GLS Biochem (Shangai-China),
NFmoc-protected special amino acids from NeoMPS (Stasbourg-
France) and Chem-Impex International, Inc. (Wood Dale-Illinois),
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluoro-
phosphate (HBTU) and N-hydroxybenzotriazole (HOBt) from Iris
Biotech GmbH (Marktredwitz-Germany) and Rink amide resin
from Advanced Chemtech (Lousville-KY). For the N–Fmoc-
protected amino acids, the following side chain protecting groups
were used: Arg(Nc-2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-
sulfonyl (Pbf)), His(Nim- triphenylmethyl(trityl) (Trt)), Trp(Nin- tert-
butyloxycarbonyl (Boc)), Lys(Boc). Peptide synthesis solvents,
reagents, as well as CH3CN for HPLC were reagent grade and
were acquired from commercial sources and used without further
purification unless otherwise noted. ESI-MS analyses were
performed by API 2000. The purity of the finished peptides was
checked by analytical reversed-phase high performance liquid
chromatography (RP-HPLC) using a Shimadzu mod. CL-
10ADVP system with a built-in diode array detector. In all cases,
the purity of the finished peptides was greater than 95% as
determined by these methods.
General Method for Peptide Synthesis and Purification
All peptides were synthesized using the solid-phase method of
peptide synthesis and purified by RP-HPLC. Each peptide was
synthesized on 0.250 g of Rink amide resin (substitution
0.75 mmol/g) by manual method using N-Fmoc chemistry and
an orthogonal side chain protection strategy. The resin was first
swollen in dichloromethane (DCM)/(N,N-dimethylformamide)
DMF (1:1) for 2 h and the following amino acids were then
added to the growing peptide chain by stepwise addition of N-
Fmoc-Val-OH, N-Fmoc-Phe-OH, N-Fmoc-Lys(Boc)-OH, N-
Fmoc-(L)-AA-OH (AA: Gly-Gly dipeptide, b-alanine, b-cyclohex-
ylalanine, 1-amino-cyclopentane carboxylic acid, 1-amino-cyclo-
propane carboxylic acid, a-t-butylglycine, 2-aminoindane-2-car-
boxylic acid, 1-amino-cyclobutane carboxylic acid, (1R,2R)-2-
aminocyclopentane-1-carboxylic acid, diethylglycine, 1-amino-
cyclohexanecarboxylic acid, phenylalanine; Figure S1), N-Fmoc-
Trp(Boc)-OH, N-Fmoc-Arg(Nc-Pbf)-OH, N-Fmoc-(D)-2-Nal-OH,
and N-Fmoc-His(Nim-Trt)-OH, using standard solid phase meth-
ods. Each coupling reaction was achieved using a 3-fold excess of
each amino acid, HBTU, and HOBt in presence of a 6-fold excess
of (N,N-diisopropylethylamine) DIPEA for 1 h. Deprotection of
the N-Fmoc group was carried out by treating the protected
peptide resin with 25% piperidine solution in DMF (164 mL,
20 min). After each coupling and deprotection, the peptide resin
was washed with DMF (364 mL), DCM (3650 mL) and again
with DMF. The peptide sequences were thereafter assembled by
alternate cycles of coupling and deprotection. After coupling of the
N-terminal amino acid, the N-terminal Fmoc group was deblocked
as described above and the peptide-resin was thoroughly washed
with DCM (4625 mL) and dried under argon to yield dried
peptide-resin.
The peptide-resin was then cleaved by treatment with 5 mL of a
solution of triethylsilane (Et3SiH) (5%), water (5%), in trifluor-
oacetic (TFA) with shaking at room temperature for 3 h. The resin
was then removed from the solution by filtration and the crude
peptide was recovered by precipitation with cold anhydrous ethyl
ether. Centrifugation at 1500 g for 3 min followed by decantation
of the supernatant ether and air-drying of the residue yielded the
crude peptide as a white to pale beige-colored amorphous solid.
Final peptide purification was achieved using a preparative RP-
HPLC Phenomenex Jupiter Proteo, 10 m 90 A˚. The peptide
samples were injected onto the column at a concentration of
20 mg/mL in 20% aqueous CH3CN and were eluted with a
CH3CN gradient (10 to 90%) over 40 min at a flow rate of
15.0 mL/min, with a constant concentration of TFA (0.1% v/v).
The separations were monitored at 230 and 254 nm and
integrated with a Shimadzu diode array detector mod. SPD-
M10AVP dual wavelength absorbance detector model UV-D.
Fractions corresponding to the major peak were collected, pooled,
and lyophilized to yield the final peptides as pure (.95%) white
solids. The final yields of the peptides ranged between 42 and
57%. The analytical data and the amino acid analysis for each
compound are reported in Tables S1, S2 and Figure S2.
Candida spp
Two Candida albicans isolates were purchased from the ATCC
(No. 24433 and 76615). The other yeast isolates were obtained
from the collection of Fondazione Ca’ Granda- Ospedale
Maggiore Policlinico, Milano. The collection included C. albicans
(7 isolates), C. glabrata (3 isolates), and C. krusei (3 isolates).
Bacteria
The strains used for the antimicrobial assays were the Gram-
negative bacteria Acinetobacter baumani ATCC 19606, Escherichia coli
D21, Pseudomonas aeruginosa ATCC 27853, and Pseudomonas syringae
pv tabaci 1918NCPPB and the Gram-positive bacteria Bacillus
megaterium Bm11, Staphylococcus aureus ATCC 25923, and Staphylo-
coccus epidermidis ATCC 12228.
Anti-Candida assay
Antifungal susceptibility testing was performed using the broth
microdilution method according to the NCCLS M27-A guidelines
(National Committee for Clinical Laboratory Standards. 1997,
Reference method for broth dilution antifungal susceptibility
testing of yeasts and approved standard NCCLS document M27-
A. National Committee for Clinical Laboratory Standards,
Wayne, Pa.). The organisms were removed from frozen glycerol
stock (10% sterile glycerol suspensions stored at 270uC),
Table 1. Lead sequence DNal and Gly10 substituted
peptides.
Peptide Sequence
DNal H-His-D(29)Nal-Arg-Trp-Gly-Lys-Phe-Val-NH2
1 H-His-D(29)Nal-Arg-Trp-Aib-Lys-Phe-Val-NH2
2 H-His-D(29)Nal-Arg-Trp-Deg-Lys-Phe-Val-NH2
3 H-His-D(29)Nal-Arg-Trp-tBuGly-Lys-Phe-Val-NH2
4 H-His-D(29)Nal-Arg-Trp-Ac3c-Lys-Phe-Val-NH2
5 H-His-D(29)Nal-Arg-Trp-Ac4c -Lys-Phe-Val-NH2
6 H-His-D(29)Nal-Arg-Trp-Ac5c-Lys-Phe-Val-NH2
7 H-His-D(29)Nal-Arg-Trp-Ac6c -Lys-Phe-Val-NH2
8 H-His-D(29)Nal-Arg-Trp-Aic-Lys-Phe-Val-NH2
9 H-His-D(29)Nal-Arg-Trp-Phe-Lys-Phe-Val-NH2
10 H-His-D(29)Nal-Arg-Trp-Cha-Lys-Phe-Val-NH2
11 H-His-D(29)Nal-Arg-Trp-bAla-Lys-Phe-Val-NH2
12 H-His-D(29)Nal-Arg-Trp-Acpc-Lys-Phe-Val-NH2
13 H-His-D(29)Nal-Arg-Trp-Gly-Gly-Lys-Phe-Val-NH2
doi:10.1371/journal.pone.0061614.t001
a-MSH Analogues with Antimicrobial Activity
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e61614
subcultured onto Sabouraud’s dextrose plates, and incubated at
35uC. After 48 h of incubation, the plates were inspected for purity.
A colony was taken from the agar plate and transferred into 5 mL
Sabouraud-dextrose broth and incubated for 48 h at 35uC. Cells
were centrifuged at 1,0006g for 10 min and the pellet was washed
twice with distilled water. Cells were counted and suspended in
RPMI 1640 medium buffered to pH 7.0 with 0.165 mol l21
morpholinepropanesulphonic acid (MOPS) buffer (Sigma) to obtain
the two times test inoculum (16103 to 56103 CFU/mL). Each well
of 96 U-shaped well-plates received 100 ml of each antifungal
peptide in concentrations from 1024 to 7.8610 27 M.
The plates were incubated at 35 C and were observed for
growth at 48 h. The MIC90, i.e. the minimum inhibitory
concentrations endpoint were determined as 90% reduction in
turbidity measured using a spectrophotometer (Titertek multiscan
at 690 nm wave length).
Antibacterial assay
Susceptibility testing was performed by adapting the microbroth
dilution method outlined by the Clinical and Laboratory
Standards Institute, using sterile 96-well plates (Falcon NJ,
USA). The bacterial growth was aseptically measured by
absorbance at 590 nm with a spectrophotometer (UV-1700
Pharma Spec Shimadzu, Tokyo, Japan). Afterwards, aliquots
(50 ml) of bacteria in mid-log phase at a concentration of 26106
colony-forming units (CFU)/mL in culture medium (Mueller-
Hinton, MH) were added to 50 ml of MH broth containing the
peptide in serial 2-fold dilutions ranging from 1.56 to 100 mM.
Inhibition of microbial growth was determined by measuring the
absorbance at 590 nm, after an incubation of 18 h at 37uC with a
microplate reader (Infinite M200; Tecan, Salzburg, Austria).
Antibacterial activity was expressed as the minimal inhibitory
concentration (MIC), the concentration of peptide at which 100%
inhibition of microbial growth is observed after 18 h of incubation.
Hemolytic assay
The hemolytic activity was measured on human red blood cells
as reported previously [12]. Briefly, aliquots of a human
erythrocyte suspension in 0.9% (w/v) NaCl were incubated with
serial two-fold dilutions of peptide (dissolved in 20% ethanol prior
to use) for 40 min at 37uC with gentle mixing. The samples were
then centrifuged for 5 min at 900 g and the absorbance of the
supernatant was measured at 415 nm. Complete lysis was
measured by suspending erythrocytes in distilled water [13].
Cytotoxic activity
Effects on viability was tested in the immortalised keratinocyte
cell line HaCaT using the [3(4,5-dimethylthiazol-2yl)2,5-diphe-
nyltetrazolium bromide] (MTT) colorimetric method in which the
intensity of the dye is proportional to the number of viable cells.
MTT is a tetrazolium salt which is reduced to a colored formazan
product by mitochondrial reductases present only in metabolically
active cells. Cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma) supplemented with 10% heat inactivat-
ed fetal bovine serum, glutamine (4 mM) and gentamicin.
Afterwards, cells were plated in triplicate wells of a microtiter
plate, at 46104 cells/well in DMEM supplemented with 2%
serum without antibiotic. After overnight incubation at 37uC in a
5% CO2 atmosphere, the medium was replaced with 100 l fresh
DMEM supplemented with the peptides at different concentra-
tions. The plate was incubated for 24 h at 37uC in a 5% CO2
atmosphere. Then, DMEM was removed and replaced with
Hank’s medium (136 mM NaCl; 4.2 mM Na2HPO4; 4.4 mM
KH2PO4; 5.4 mM KCl; 4.1 mM NaHCO3, pH 7.2, supplement-
ed with 20 mM D-glucose) containing 0.5 mg/ml MTT. After 4 h
incubation, the formazan crystals were dissolved by adding 100 l
of acidified isopropanol and absorption of each well was measured
using a microplate reader (Infinite M200; Tecan, Salzburg,
Austria) at 570 nm. Cell viability was e expressed as percentage
of viability in control cells (cells not treated with peptide).
Nuclear Magnetic Resonance (NMR) spectroscopy
The samples for NMR spectroscopy were prepared by
dissolving the appropriate amount of peptide in 0.55 mL of
1H2O, 0.05 mL of
2H2O and 160/40 mM dodecylphosphocho-
line (DPC) -d38/sodium dodecylsulphate (SDS)-d25 micelles
solution to obtain a concentration of 1–2 mM peptide. The
NMR experiments were performed at pH 5.0. NH exchange
studies were made by dissolving peptide in 0.60 mL of 2H2O and
200 mM 160/40 mM DPC-d38/SDS-d25. NMR spectra were
recorded on a Varian Unity INOVA 700 MHz spectrometer
equipped with a z-gradient 5 mm triple-resonance probe head. All
the spectra were recorded at a temperature of 25uC. The spectra
were calibrated relative to 3-(trimethylsilanyl)propionic acid
(0.00 ppm) as internal standard. One-dimensional (1D) NMR
spectra were recorded in the Fourier mode with quadrature
detection. 2D double quantum filtered correlated spectroscopy
(DQF-COSY) [14], total correlation spectroscopy (TOCSY) [15],
and nuclear Overhauser enhancement spectroscopy (NOESY)
[16] spectra were recorded in the phase-sensitive mode using the
method from States [17]. Data block sizes were 2048 addresses in
t2 and 512 equidistant t1 values. A mixing time of 70 ms was used
for the TOCSY experiments. NOESY experiments were run with
mixing times in the range of 150–300 ms. The water signal was
suppressed by gradient echo [18]. The 2D NMR spectra were
processed using the NMRPipe package [19]. Before Fourier
transformation, the time domain data matrices were multiplied by
shifted sin2 functions in both dimensions, and the free induction
decay size was doubled in F1 and F2 by zero filling. The
qualitative and quantitative analysis of DQF-COSY, TOCSY and
NOESY spectra were obtained using the interactive program
package XEASY [20]. JHN-Ha couplings were difficult to measure
probably because of a combination of small coupling constants
and broad lines. The temperature coefficients of the amide proton
chemical shifts were calculated from 1D 1H NMR and 2D
TOCSY experiments performed at different temperatures in the
range 298–320 K by means of linear regression.
Structural determinations
The NOE-based distance restraints were obtained from
NOESY spectra collected with a mixing time of 200 ms. Peak
volumes were translated into upper distance bounds with the
CALIBA routine from the DYANA software package [21]. The
requisite pseudoatom corrections were applied for non-stereospe-
cifically assigned protons at prochiral centers and for the methyl
group. After discarding redundant and duplicated constraints, the
final list of constraints was used to generate an ensemble of 200
structures by the standard DYANA protocol of simulated
annealing in torsion angle space. No dihedral angle restraints
and no hydrogen bond restraints were applied. An error tolerant
target function (tf type 3) was used to account for the peptide
intrinsic flexibility. Then, 20/200 structures were chosen, whose
interproton distances best fitted NOE derived distances, and
refined through successive steps of restrained and unrestrained
energy minimization calculations using the Discover algorithm
(Accelrys, San Diego, CA) and the consistent valence force field
[22]. No residue was found in the disallowed region of the
Ramachandran plot. The final structures were analyzed using the
a-MSH Analogues with Antimicrobial Activity
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InsightII program (Accelrys, San Diego, CA). Graphical repre-
sentations were carried out with the InsightII program. The root-
mean-squared-deviation analysis between energy-minimized struc-
tures was carried out with the program Molmol [23].
Results and Discussion
In preliminary tests, the antimicrobial activity of the lead
compound DNal was tested using the present standard culture
conditions. As expected, the peptide did not have substantial
antimicrobial activity in broth culture medium (Tables 2 and 3).
However, despite these negative results, DNal was a valuable basis
for development of novel analogues.
The Gly10 residue was replaced with several conventional and
unconventional amino acids characterized by different degrees of
conformational rigidity (Table 1 and Figure S1). Such changes
were expected to significantly influence the folding preference of
the peptide and, consequently, the antimicrobial activity. The
Gly10-substituted peptides were tested against several pathogenic
strains of C. albicans, C. glabrata, and C. krusei (Table 2) and against a
panel of gram-positive and gram-negative bacteria (Table 3).
The peptides 1 and 2 are Ca,a-disubstituted. Ca-alkylation,
and in particular Ca-methylation, by means, for example, of 2-
aminoisobutyric acid (Aib), has been widely used to explore the
conformational requirements for bioactivity [24]. A further
rationale for introduction of Ca,a- disubstituted glycine residues
was that the isovaline (a-methyl-a-ethylglycine) residue is present
in antifungal peptides such as alamethicin, zervamicin, and
antiamboebin [25]. Among Ca,a-disubstituted glycine, Aib-LXxx
segments are the preferred option to populate local type-I/III
conformations [24]. In addition, the conformational behavior of
the cycloaliphatic sub-family of the Ca.a-symmetrically disubsti-
tuted Gly residues, generally denoted as Acnc, is closely correlated
to that of Aib [26]. Conversely, diethylglycine (Deg) containing
peptides have a greater tendency to form extended backbone
conformations in strongly interacting solvents such as water [26].
Similarly, the tert-butyl glycine (tButGly) also called tert-leucine
residue, inserted in peptide 3, prefers extended (b sheet-like) or
semiextended [(Pro)n-like] conformations [27]. Peptides 1 and 2
containing an Aib and a Deg residue in position 10, respectively,
did not show antimicrobial activity. The L-a-t-butylglycine
(tButGly) substituted peptide 3 was likewise inactive.
Subsequently, we designed derivatives containing the cyclic
achiral dialkylglycine residues 1-amino-cyclopropane carboxylic
acid (Ac3c), 1-amino-cyclobutane carboxylic acid (Ac4c), 1-amino-
Table 2. Anti-Candida activity of DNal and Gly10 substituted peptides expressed as MIC 90 (mM) at 48 h.
Peptide
Candida strain DNal 1 2 3 4 5 6 7 8 9 10 11 12 13
C.albicans
ATCC 76615 .100 .100 .100 .100 .100 .100 .100 51 25 .100 52 .100 .100 .100
ATCC 24433 .100 .100 .100 .100 .100 .100 51 51 25 .100 26 .100 .100 .100
995439 .100 .100 .100 .100 .100 99 51 51 25 .100 26 .100 .100 .100
995147 .100 .100 .100 .100 .100 .100 .100 51 25 .100 26 .100 .100 .100
000954 .100 .100 .100 .100 .100 .100 .100 51 25 .100 52 .100 .100 .100
991185 .100 .100 .100 .100 .100 99 51 51 25 51 52 .100 .100 .100
994199 .100 .100 .100 .100 .100 99 51 51 25 51 26 .100 .100 .100
983201- R1 .100 .100 .100 .100 .100 .100 .100 51 50 .100 52 .100 .100 .100
011587 .100 97 .100 .100 .100 99 .100 51 50 .100 26 .100 .100 .100
C.glabrata
18012 .100 .100 .100 .100 .100 .100 .100 .100 100 .100 .100 .100 .100 .100
995667 .100 .100 .100 .100 .100 .100 .100 .100 100 .100 .100 .100 .100 .100
995651 .100 .100 .100 .100 .100 .100 .100 .100 100 .100 .100 .100 .100 .100
C.krusei
995668 .100 97 .100 .100 .100 99 .100 .100 50 .100 52 .100 .100 .100
991388 .100 97 .100 .100 .100 99 .100 .100 50 .100 26 .100 .100 .100
004490 .100 97 .100 .100 .100 99 .100 51 25 .100 26 .100 .100 .100
Each MIC value is the average of at least three independent experiments.
doi:10.1371/journal.pone.0061614.t002
Table 3. Antibacterial activity of selected peptides expressed
as MIC 100 (mM) at 18 h.
Peptide
Bacterial strain DNal 3 4 8 9 10
Gram-negative bacteria
Acinetobacter b. ATCC 19606 .100 100 50 12.5 25 12.5
Escherichia coli D21 .100 50 100 12.5 50 6.25
Pseudomonas a. ATCC 27853 100 50 50 50 25 25
Pseudomonas syringae pv tobaci .100 .100 .100 25 100 25
Gram-positive bacteria
Bacillus megaterium Bm 11 6 6.25 6.25 1.56 3.125 3.125
Staphylococcus a. ATCC 25923 .100 .100 100 12.5 50 12.5
Staphylococcus e. ATCC 12228 50 50 25 6.25 12.5 6.25
Each MIC value is the average of at least three independent experiments.
doi:10.1371/journal.pone.0061614.t003
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cyclopentane carboxylic acid (Ac5c), and 1-amino-cyclohexane
carboxylic acid (Ac6c) (Figure S1) in the same position 10.
Compound 4, in which Gly10 was replaced by Ac3c containing a
cyclopropane moiety, was inactive. Conversely, the peptides 5, 6,
and 7, in which the size of cycloalkyl moiety of the residues Ac4c,
Ac5c, and Ac6c progressively increases, showed a parallel increase
in their antimicrobial activity. Indeed, whereas compound 5
showed only weak activity, compounds 6 and 7, containing the
Ac5c and Ac6c residues, respectively, possessed substantial
activity.
Based on these results, we designed the compound 8 containing
the 2-aminoindane-2-carboxylic acid (Aic) residue that, from a
structural point of view, can be considered an aromatic analogue
of the Ac5c. Considering the conformational preferences, Aic
torsional angles are limited to values around Q=250u, y=250u,
and Q=+50u, y= +50u [28]. Compound 8 showed a quite good
anti-Candida activity. In addition to the anti-Candida activity,
compound 8 effectively inhibited the bacterial strains examined.
Therefore, this compound represents a promising agent, marked
by both antifungal and antibacterial activity. Because compound 8
can also be considered as a phenylalanine with a constrained side
chain, we synthesized an analogue bearing a Phe residue in
position 10. However, the resulting compound, peptide 9, had
decreased activity in all biological assays. Therefore, it appears
that the conformational constraints imposed by the Aic residue are
essential for activity.
Activity was preserved when a L-cyclohexylalanine (Cha)
residue was inserted in position 10 (peptide 10). Cha can be
considered an aliphatic analogue of phenylalanine with high
tendency to helical formation [29]. This compound exerted both
anti-Candida and antibacterial activity with a potency similar to
that of peptide 8.
A comprehensive toxicological investigation was not an aim in
this paper. Indeed, the objective was definition of structure/
activity relationship that could help design of melanocortin-based
novel antimicrobials. However, as a preliminary assessment of
potential toxicity, peptides DNal, 3, 4, 8, 9, and 10 were tested for
their hemolytic activity (Table 4). No significant hemolysis was
noted for the peptides DNal, 3, 8, and 10 up to a concentration of
12.5 mM. A weak activity (,10% hemolysis) was associated with
the parent peptide DNal up to 100 mM whereascompounds 3, 8,
and 10 caused moderate lysis of human red blood cells (from 10%
to 24–34%) at concentrations from 25 to 100 mM, with a slightly
greater effect for compound 10. Peptides 4 and 9 exerted the
greatest hemolytic effect, causing from ,20% to 30 or 49% cell
lysis at concentrations ranging from 25 mM to 100 mM. The
potential cytotoxic activity of these compounds was also investi-
gated in nucleated mammalian cells, such as human keratinocytes.
As reported in Figure 1, peptide 10 was completely devoid of toxic
activity up to a concentration of 12.5 mM, but it exerted toxic
effects at 50–100 mM concentrations. Conversely, a moderate
toxic effect (less than 20% mortality), was found for the other
compounds up to 25 M. At the highest peptide concentration used
(100 mM) peptides 3, 4 and 9 produced less than 30% cell death,
whereas a more pronounced toxicity was found for the peptides
DNal and 8, that caused approximately 50–100% killing.
In further investigations on structure-activity relationships,
Gly10 was replaced with -amino acids. The a-amino acids exist
as part of certain natural occurring peptides isolated from
prokaryotes and marine organisms. Because of their extra
methylene group, b-amino acids are not recognized by mammal
proteases and are intrinsically resistant to enzymatic degradation
[30]. Further, they show precise conformational preferences. In
particular, the conformationally flexible noncoding b-alanine (b-
Ala) residue shows two energetically preferred conformations: a
folded conformation (m,665610u) and an extended conforma-
tion (m,6165610u) that are easily accommodated in both acyclic
and cyclic peptides where they determine the overall molecular
structures [31]. The cyclic (1R,2R)-2-aminocyclopentane carbox-
Table 4. Hemolytic activitya (%) of selected peptides.
Peptide
conc. (mM) 1.5 3 6.25 12.5 25 50 100
DNal 060.2 060.9 160.6 160.5 261.06 561.5 762.1
3 561.9 5.663 661.6 760.4 1563.1 1661 2360.1
4 060 260.5 460.4 1061 2062.1 2260.5 3060.2
8 0.561 261.7 261.1 361.7 961.9 1361.8 2460.4
9 460.1 660.4 961.9 1461.4 2460.1 3361.3 4964.1
10 160.7 261.3 560.1 560.4 1061.5 1060.2 3461
Values are the mean of three independent experiments 6 SD.
doi:10.1371/journal.pone.0061614.t004
Figure 1. Effects of the synthetic melanocortins on viability of HaCat cells. Cells were plated in wells of a microtiter plate, at 46104 cells/
well in DMEM supplemented with 2% serum without antibiotic. After overnight incubation at 37uC in a 5% CO2 atmosphere, the medium was
replaced with 100 ml fresh DMEM supplemented with the peptides at different concentrations. After 24 h of peptide treatment, cell viability was
determined by the inhibition of MTT reduction to insoluble formazan (see Materials and Methods for additional information). Cell viability is
expressed as percentage of viability in control cells (cells not treated with the peptide).
doi:10.1371/journal.pone.0061614.g001
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ylic acid (Acpc) is a more constrained -amino acid that determines
a so called ‘‘12-helix’’ (a 12-membered ring hydrogen bonds) when
inserted into a peptide sequence [32]. Compounds 11 and 12,
containing b-Ala and Acpc in position 10, respectively, were
synthesized and examined; both showed no anti-Candida activity.
Finally, we synthesized an analogue of DNal in which an
additional Gly residue was inserted between the Trp9 and the
Lys11 residues (peptide 13). The aim was to evaluate the effect of
increased peptide flexibility on antimicrobial activity; compound
13 showed no activity.
Subsequently, we performed a conformational study using
solution NMR on compounds 8 and 10; the parent peptide DNal
was investigated for comparison. NMR spectroscopy studies were
performed in DPC/SDS 8:2 micelles solution. These micelles were
used as rough mimetics of yeast membranes [33]. Complete 1H
NMR chemical shift assignments were effectively achieved for the
peptides according to the Wu¨thrich procedure [34]. (Tables S3,
S4, S5). For both compounds 8 and 10, upfield shift of the Ha
NMR signals, low values of the temperature coefficients of the
amide protons, and diagnostic NOEs (Tables S6 and S7) indicated
that residues 8–13 are in a helical conformation. Few medium
range NOEs between the hydrophobic side chains of residues 7
and 10 were observed in the NOESY spectrum of 10 but not in
that of 8 (Tables S6 and S7), suggesting higher conformational
stability for the former peptide. Conversely, NMR parameters,
including for example lower number of medium range diagnostic
NOEs (Table S8), indicate that DNal has greater conformational
flexibility relative to peptides 8 and 10.
NMR-derived constraints for peptides 8, 10, and DNal were
used as input data for a simulated annealing structure calculation
according to the standard protocol of DYANA program [21].
Figures 2a and 2b show the superposition of the best 10 NMR
structures of the peptides 8 and 10, respectively, overlapped at the
level of backbone atoms. The bundle reveals a high structural
similarity (backbone RMSD#0.40 A˚ for peptide 8, and #0.20 A˚
for peptide 10), suggesting that NMR structures are defined with
high precision.
Analysis of these NMR structures using Molmol [23] identified
the prevalence of regular a-helices in the Arg8-Val13 segment of
both peptides. Interestingly, the helical structure showed amphi-
pathic distribution of the side chains, with Arg8 and Lys11 side
chains on one side of the helix and DNal(29)7, Aic10 (Cha10),
Phe12 and Val13 on the other side (Figure 2a, b).
The DNal structure was much more flexible (backbone
RMSD = 0.84 A˚) and only turn motifs could be detected along
its structure. In particular, two b-turns along residues 7–10 and
10–13 (Figure 2c) are consistent with our earlier results [11]. The
DNal structure is better described as a nascent helix i.e. a helix in
equilibrium with disordered structures [35].
Conformational differences could account for the enhanced
antimicrobial activity observed in peptides 8 and 10 relative to the
parent sequence DNal. The amphipathic helical structure along
residues 8–13 is likely responsible for the superior antimicrobial
activity of the substituted peptides whereas the partial lack of
helicity in DNal probably contributes to its reduced activity.
Indeed, the residues Deg [26], tButGly [27], Ac3c [36], b-Ala
[31], and Acpc [32], which do not stabilize regular right handed
helices, did not promote activity in the corresponding pepti-
des.Therefore, consistent with previous observations, the amphi-
pathic helical content proved to be a key factor in the activity of
antimicrobial peptides [37,38].
Conclusions
The present research discovered novel synthetic melanocortins
that exert broad-spectrum antimicrobial activity. The main
advance of these molecules, relative to the known a-MSH-related
compounds, consists of their capacity of killing growing organisms
in standard culture conditions. Indeed, previous investigations on
antimicrobial melanocortins were not performed in culture media
that allow microorganisms to grow. Although, those studies were
very helpful to promote discovery of synthetic antimicrobial
melanocortins, standard microbiology testing is required for a
realistic use in clinical settings. This prerequisite was clearly met by
the peptides 8 and 10, in which Gly10 of DNal was replaced by the
residues Aic and Cha, respectively. Although these peptides also
reduced viability of human cells, these detrimental influences
occurred at greater concentrations relative to effective antibacte-
rial concentrations. Overall, the structural preferences associated
with antimicrobial activity identified in this research can help
further development of synthetic melanocortins with enhanced
therapeutic index.
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Candida; (2) to promote survival of Candida-infected liv-
ing organisms and (3) to inhibit transition of these fungal 
cells from the roundish yeast shape to the more dangerous 
hyphal form at sub-inhibitory concentrations.
Keywords antimicrobial peptide · anti-Candida 
activity · Membrane permeabilization · Caenorhabditis 
elegans · Simple infection model
Abbreviations
aMP  antimicrobial peptide
CFU  Colony-forming units
esc(1–18)  esculentin-1b(1–18)
hP  hyphal growth-promoting medium
Mh  Mueller-hinton
MFC  Minimal fungicidal concentration
MIC  Minimal inhibitory concentration
Mtt  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide
NaPB  Sodium phosphate buffer, ph 7.4
NGM  Nematode growth medium
rho-esc(1–18)  Rhodamine-labelled esc(1–18)
Introduction
Candida species are normally harmless commensals of the 
gastrointestinal and urinary tracts of human beings. how-
ever, under some circumstances, e.g., when the immune 
system is weakened or competing bacterial flora is elimi-
nated following a broad-spectrum antibiotic treatment, Can-
dida cells can invade host tissues and cause life-threatening 
infections. Invasive candidiasis is particularly common in 
intensive care units where mortality rates reach 45–49 % [1–
4]. In North america, it is the fourth most common cause of 
Abstract Candida albicans represents one of the most 
prevalent species causing life-threatening fungal infec-
tions. Current treatments to defeat Candida albicans have 
become quite difficult, due to their toxic side effects and 
the emergence of resistant strains. antimicrobial peptides 
(aMPs) are fascinating molecules with a potential role 
as novel anti-infective agents. however, only a few stud-
ies have been performed on their efficacy towards the most 
virulent hyphal phenotype of this pathogen. the purpose 
of this work is to evaluate the anti-Candida activity of the 
N-terminal 1–18 fragment of the frog skin aMP esculen-
tin-1b, esc(1–18), under both in vitro and in vivo condi-
tions using Caenorhabditis elegans as a simple host model 
for microbial infections. Our results demonstrate that 
esc(1–18) caused a rapid reduction in the number of viable 
yeast cells and killing of the hyphal population. esc(1–18) 
revealed a membrane perturbing effect which is likely the 
basis of its mode of action. to the best of our knowledge, 
this is the first report showing the ability of a frog skin 
aMP-derived peptide (1) to kill both growing stages of 
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hospital-acquired infections [5–7], with Candida albicans 
being the most prevalent species either in mucosal or sys-
temic diseases [8, 9]. a striking feature of C. albicans biol-
ogy is its ability to grow in different morphological forms 
that range from unicellular budding yeast, more suited for 
dissemination in the bloodstream [10–12], to the filamen-
tous form (pseudo and true-hyphae) responsible for promot-
ing tissue penetration and colonization [13–15]. the hyphal 
stage has often been considered essential for adhesion to 
mucosal surfaces and initiation of clinical infectious dis-
eases [14, 16, 17]. treatment of these infections with con-
ventional antifungals, e.g., fluconazole and amphotericin B 
[18–21], is frequently ineffective. In addition, amphotericin 
B is toxic to the kidneys and hematopoietic and nervous sys-
tems [22, 23]. therefore, the search for new anti-Candida 
compounds is critical [24], and naturally occurring antimi-
crobial peptides (aMPs) represent attractive candidates for 
the generation of new anti-mycotics. aMPs are produced 
by almost all unicellular and multicellular organisms and 
act as the first line of defense against noxious microorgan-
isms [25–31]. the majority of these peptides are positively 
charged at neutral ph and with an amphiphatic character in 
a membrane-mimicking environment. these characteris-
tics enhance selective binding and insertion of aMPs into 
microbial membranes, which are much richer in anionic 
phospholipids than mammalian cells [32, 33].
In view of the potential role of Candida dimorphism, the 
evaluation and understanding of the activity of new anti-
fungal agents on the two morphological phenotypes of this 
pathogen can help in the development of better anti-Can-
dida agents. to this aim, we performed an in-depth study on 
the activity and related molecular mechanism of the 1–18 
fragment of the frog skin aMP esculentin-1b [esc(1–18): 
GIFSKLaGKKLKNLLISG-Nh2] [34], on the two forms of 
growth of C. albicans. Previous studies reported on the anti-
Candida activity of the full 46-residue peptide esculentin-1 
when tested in solid medium against the yeast form, and 
showed that it was only slightly higher than that of esc(1–
18) [35, 36]. Note that the 19–46 C-terminal tail of escu-
lentin-1 has five basic residues that are neutralized by the 
four negatively charged amino acids located in this region. 
according to what was stated by avrahami and Shai [37], 
this could assist in peptide assembly and partitioning into 
the fungal membrane. By contrast, no acidic residues are 
present in esc(1–18), and its four positively charged amino 
acids are spread along the entire peptide sequence, presum-
ably hampering the formation of peptide oligomers and 
their partition from the cell wall into the membrane. how-
ever, it is worth noting that the difference in the anti-Can-
dida activity between esc(1–18) and the full-length parental 
esculentin-1 is not very large [34, 35]. Furthermore, recent 
studies revealed a microbial membrane-perturbing activity 
of esc(1–18) as one of the major mechanisms underlying 
its killing activity [38]. this should limit the induction of 
resistance to it, thus making the shorter-sized esc(1–18) a 
more attractive candidate for further antifungal studies.
Importantly, experiments described in this work were 
carried out under both in vitro and in vivo conditions, using 
a simple model system, the nematode Caenorhabditis ele-
gans. historically, C. elegans has been of great value in 
many fields of biological research [39]. It is a differentiated 
multicellular organism with a nervous system, reproduc-
tive organs and digestive apparatus. Furthermore, it has a 
simple structure, a short life-cycle (< 3 days) and can be 
infected by different human pathogens (including Candida 
species) that can replace the regular Escherichia coli food 
source. Indeed, they can pass through the mouth, ultimately 
reaching the nematode’s gut [40]. Once the microbes start 
to proliferate, an infection process is initiated, which leads 
to the animal’s death. We have recently demonstrated that 
esc(1–18) peptide is highly effective in promoting survival 
of C. elegans worms following infection by a multi-drug 
resistant strain of Pseudomonas aeruginosa [39]. Impor-
tantly, this peptide shows no toxicity towards mammalian 
cells, such as erythrocytes, lymphocytes [34, 38], mac-
rophages and keratinocytes at microbicidal concentrations 
(Mangoni et al. unpublished data).
Results of the present study suggest that esc(1–18) is an 
attractive membrane-perturbing anti-Candida aMP with 
the ability to block hyphal development, also in vivo.
Materials and methods
Materials
Synthetic all-l and all-d esc(1–18) as well as the rhoda-
mine-labelled form of the all-l peptide [rho-esc(1–18)] 
were purchased from Selleck Chemicals (houston, tX, 
USa). the purity of the peptides, their sequences and 
concentrations were determined as previously described 
[34]. Sytox Green was from molecular probes (Invitro-
gen, Carlsbad, Ca, U.S.a.); 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (Mtt), and poly-l-lysine 
(150,000–300,000 mol wt) were purchased from Sigma (St. 
Louis, MO, USa). all other chemicals were reagent-grade.
Microorganisms and nematode strains
the following C. albicans strains were used: the reference 
atCC 10231, atCC 90028 and the clinical isolates C. albi-
cans n. 1s and C. albicans n.1r. the wild-type C. elegans 
strain N2 was used in all experiments and propagated on 
nematode grow medium (NGM) plates containing E. coli 
OP50 as a food source [41]. C. albicans atCC 10231 was 
used for all the experiments with C. elegans.
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anti-yeast activity
Susceptibility testing was performed by the microbroth 
dilution method, according to the procedures outlined by 
the National Committee for Clinical Laboratory Standards 
(2001) using sterile 96-well plates according to [42]. Mini-
mal inhibitory concentration (MIC) was determined as the 
lowest peptide concentration at which 100 % inhibition of 
growth was observed after 18 h at 37 °C.
Peptide’s effect on the viability of yeast cells and hyphae
the peptide’s effect on the viability of both yeast and 
hyphal forms of C. albicans atCC 10231 was determined 
by the Mtt colorimetric method. In the first case, 100 μl of 
yeast cells suspension in 10 mM sodium phosphate buffer 
(NaPB), ph 7.4 (about 1 × 107 CFU/ml) were incubated 
at 37 °C with esc(1–18) at different concentrations for 10, 
20, 30 and 60 min. after incubation time with the peptide, 
samples were centrifuged and resuspended in 100 μl RPMI 
1640 medium (Sigma) supplemented with 0.5 mg/ml Mtt. 
after 2 h incubation at 37 °C, Mtt formazan crystals were 
solubilized by adding 100 μl of 10 % sodium dodecyl sul-
phate. the absorbance at 590 nm of triplicate samples was 
measured spectrophotometrically with a microplate reader 
(Infinite M200; tecan, Salzburg, austria). Cell viability 
was expressed as percentage of survival with respect to the 
control (yeast cells not treated with the peptide) at the cor-
responding time intervals.
In the second case, RPMI supplemented with 2 mM 
l-glutamine and 0.165 M morpholinepropanesulfonic 
acid (ph 7.0) was used as the hyphal growth-promoting 
(hP) medium [43, 44]. about 3 × 104 or 1 × 10 4 yeast-
form cells in hP medium were transferred into wells of a 
96-well flat-bottom poly-l-lysine-coated microplate and 
incubated for 3 h or a longer time (12 and 18 h) respectively, 
at 37 °C, as indicated in the Results section. the medium 
was then discarded and the adhesive Candida hyphae were 
treated with different concentrations of esc(1–18) dissolved 
in NaPB, at 37 °C for different times. the peptide was 
then removed, 100 μl of Mtt solution (0.5 mg/ml in hP 
medium) were added to each well and the plate was incu-
bated at 37 °C for 4 h. afterwards, formazan crystals were 
solubilized and their absorbance was measured as described 
above. the minimal fungicidal concentrations (MFC50 and 
MFC90) were defined as the minimal peptide concentrations 
causing a reduction in hyphae viability by 50 and 90 %, 
respectively, within 60 min, compared with the control.
Inhibition of hyphal development
Briefly, 100 μl of yeast suspension (1 × 106 CFU/ml) in 
Winge broth [45] were transferred into poly-l-lysine-coated 
wells of a 96-well plate and incubated at 37 °C for 3 h in 
the presence of different concentrations of esc(1–18). 
the inhibition of hyphal development was visualized 
microscopically under an inverted microscope (Olympus 
CKX41) at ×40 magnification and photographed with a 
Color View II digital camera.
Membrane permeabilization
the ability of esc(1–18) to alter the membrane permeabil-
ity of fungal cells was assessed by the Sytox Green assay in 
microtiter plates, according to [46]. Briefly, 1 × 106 yeast 
cells or 3 h-grown hyphae obtained as described above 
were incubated in 95 μl of NaPB supplemented with 1 μM 
Sytox Green. after 20 min in the dark, 5 μl of peptide were 
added. the increase in fluorescence, owing to the binding 
of the dye to intracellular DNa, was measured at differ-
ent times at 37 °C in the microplate reader (excitation and 
emission wavelengths were 485 and 535 nm, respectively).
Staining protocols: fluorescent probes for assessment 
of peptide’s distribution and fungal membrane integrity
to visualize, in a single preparation, the distribution of 
esc(1–18) and to detect, at the same time, the membrane 
permeabilization induced by the peptide on yeast or hyphal 
forms of Candida, we used rho-esc(1–18) and the two fol-
lowing fluorochromes: (1) the double-stranded DNa-bind-
ing dye DaPI, to stain the nuclei of all cells, and (2) the 
green fluorescent probe Sytox Green, to stain membrane 
perturbation. after exposure of yeast cells (1 × 107 CFU/
ml in NaPB) to 16 μM rho-esc(1–18) (100 μl as a final 
volume) for 30 min at 37 °C, the microbial suspension was 
centrifuged, washed with NaPB and incubated with 100 μl 
of 1 μM Sytox Green (in NaPB) for 15 min at room tem-
perature. the sample was washed again and treated with 
100 μl of DaPI solution (10 μg/ml in NaPB) for 15 min 
at room temperature [47]. afterwards, yeast cells were 
resuspended in a drop of NaPB, poured onto a glass slide 
and examined by phase-contrast and fluorescence micros-
copy. Both phase-contrast and fluorescence images were 
recorded using the Olympus optical microscope equipped 
with an oil-immersion objective (×100).
In the case of hyphae, 96-well glass bottom microplates 
(MGB096-1-2-LG-L, Matrical Bioscience Spokane Wa, 
USa) were used and coated with poly-l-lysine. about 
3 × 104 yeast cells in hP medium were added to each sin-
gle well and the plate was incubated at 37 °C for 3 h to 
permit hyphal development. afterwards, treatment with 
rho-esc(1–18) and staining with Sytox Green and DaPI 
solutions were performed as described above. Finally, 50 μl 
of NaPB were added to each well prior microscope observa-
tion. In all cases, controls were run in the absence of peptide.
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C. elegans infection
Freshly grown Candida cells were inoculated into 2 ml 
of yeast extract-peptone-dextrose (YPD) broth and grown 
overnight with agitation at 28 °C. Fungal lawns used for 
C. elegans infection assays were prepared by spreading 
100 μl of the overnight culture (diluted 1:100 in distilled 
water) on brain heart infusion (BhI) agar plates. the plates 
were then incubated for approximately 20 h at 28 °C before 
being seeded with adult hermaphrodite nematodes from a 
synchronized culture grown at 16 °C [41]. about 100–200 
worms were washed with M9 buffer [41] and placed in the 
middle of C. albicans lawns. the infection was performed 
at 25 °C for 20 min.
Worm survival assay
the infected worms were washed with M9 buffer to 
remove C. albicans cells from their surface. twenty worms 
were then transferred into plates (3-cm diameter) contain-
ing 2 ml of liquid medium (79 % M9, 20 % BhI, 10 μg/
ml cholesterol and 90 μg/ml kanamycin) according to [48]. 
the peptide was either added to the plates, or omitted as 
indicated. the plates were incubated at 25 °C and exam-
ined for worm survival after 24 h. Worms were considered 
to be dead if they did not respond to being touched by a 
platinum wire pick. Living nematodes maintain a sinusoi-
dal shape, whereas dead nematodes appear as straight, rigid 
rods as the corpses become filled with fungal cells [49].
Peptide’s effect on the number of yeast cells and their 
switch to the hyphal form, within the nematode intestine
twenty infected nematodes in triplicate were treated (or not 
treated in case of controls) with the peptide at 25 °C for 24 h. 
afterwards, for each replicate, worms were broken with 
50 μl of M9 buffer-1 % tritonX-100. appropriate dilutions of 
whole-worm lysates were plated on YPD agar plates for col-
ony counts. In parallel, to evaluate the effect of esc(1–18) on 
the morphology of fungal cells, peptide-treated and untreated 
infected worms were mounted onto pads of 3 % agarose in 
M9 buffer supplemented with 20 mM sodium azide to para-
lyze them. animals were then observed under a Zeiss aXIO-
VeRt25 microscope and photographed with a Zeiss axi-
oCam camera using axiovision 4.6 (Zeiss) software.
In another set of experiments, infected nematodes were 
treated with 25 μM rho-esc(1–18) for 3 h and observed by 
fluorescence microscopy as reported above.
Statistical analysis
Data are presented as mean ± SD, and the Student’s test 
(GraphPad Prism 4.0 software) was used to determine the 
statistical significance between experimental groups. the 
difference was considered significant if the p value was < 
0.05.
Results
In vitro studies
MIC determination
the activity of esc(1–18) in inhibiting the growth of 
C. albicans yeast cells was evaluated using a standard 
inoculum of 3.5 × 104 CFU/ml. Note that the MIC was 
4 μM against all the strains tested with the exception of 
C. albicans n.1r (table 1), and that the same MIC value 
was obtained when samples were incubated at 28 °C 
instead of 37 °C (data not shown). the conventional anti-
fungal amphotericin B was also included for comparison 
(table 1). In our experiments C. albicans atCC 10231 
was selected as a representative strain to perform further 
additional studies, since it is a well-characterized stand-
ard strain with the ability to grow under both yeast and 
hyphal forms under the experimental conditions [50]. as 
most of the experiments described below required a higher 
number of yeast cells, i.e., 1 × 106 and 1 × 107 CFU/ml, 
such cell densities were also used as an inoculum to deter-
mine the MICs against the atCC 10231 strain. they were 
found to be directly related to cell number: 16 and 64 μM, 
respectively.
Time kill on both yeast and hyphal forms
In order to confirm a fungicidal activity of esc(1–18), a 
killing kinetics study with different peptide concentrations 
was first carried out on the yeast cells. a dose-dependent 
candidacidal activity was observed, with approximately 
80 % reduction in cell survival within the first 20 min at 
16 μM (Fig. 1a).
as found for the yeast cells, esc(1–18) provoked about 
80 % killing of 3 h-grown hyphae at 16 μM after 20 min 
Table 1  antimicrobial activity of esc(1–18) and amphotericin B on 
different C. albicans strains
a
 the reported MIC values are those obtained from at least three 
readings out of four independent measurements
MICa (μM)
Compound C. albicans 
atCC 10231
C. albicans 
atCC 90028
C. albicans 
n.1s
C. albicans 
n.1r
esc(1–18) 4 4 4 2
amphotericin B 0.5 0.5 2 2
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from peptide addition (Fig. 1b), whereas approximately 
90 % killing of hyphal population was recorded after a 
longer incubation time (60 min) at the same concentra-
tion of 16 μM (MFC90). Importantly, when hyphae were 
grown for 12 or 18 h instead of 3 h, a well-organized cel-
lular community, named biofilm, was formed (Fig. 2 upper 
panels). Indeed, an inner layer containing microcolonies 
of yeast cells and an outer layer rich in pseudohyphae and 
hyphae were observed, according to the typical phenotype 
of Candida biofilm [51, 52]. Remarkably, the peptide’s effi-
cacy was found to be only fourfold or eightfold lower, as 
indicated by the corresponding MFC50 and MFC90 on 12 
or 18 h-grown biofilm, respectively, after 60 min of pep-
tide treatment (table 2). Phase-contrast images of Candida 
biofilm treated or not treated with the peptide at its MFC90, 
after Mtt colorimetric assay, are reported in Fig. 2 (lower 
panels).
Effect on membrane perturbation
the ability of esc(1–18) to alter the membrane perme-
ability of Candida cells was monitored by the intracellu-
lar influx of Sytox Green upon addition of the peptide to 
the cells. esc(1–18) caused dose-dependent membrane 
damage, as supported by increased fluorescence signal at 
increasing peptide concentrations (Fig. 3a), with kinetics 
overlapping that of yeasts killing (Fig. 1a). Note that only 
a modest increase in fluorescence intensity was generated 
within the first 20 min after the addition of amphotericin B, 
even when used at a concentration up to 64-fold the MIC 
(data not shown). however, it gradually increased with 
time, reaching its maximum value, which was found to be 
identical to that obtained with 16 μM esc(1–18), within 
3 h. this finding is in agreement with the slower fungicidal 
activity (higher than 2–3 h, depending on the strain [53]) 
of this membrane-perturbing antifungal drug [54, 55] with 
respect to that of esc(1–18). In line with what was obtained 
for the unicellular budding cells, esc(1–18) disturbed the 
structural organization of the membrane of the filamen-
tous form of Candida in a concentration-dependent man-
ner (Fig. 3b) that directly correlates with its killing activity 
(Fig. 1b).
Furthermore, to find out whether the peptide-induced 
membrane-perturbation was mediated by interaction with 
chiral components of the lipid membrane and/or recog-
nition of specific targets, we also investigated the influx 
of Sytox Green into yeast and hyphal cells, upon their 
treatment with the all-d enantiomer of esc(1–18), which 
was found to display the same MIC (4 μM) of the all-l 
isoform.
Fig. 1  Killing kinetic of 
esc(1–18) on C. albicans atCC 
10231 yeast (panel a) and 
hyphal (panel b) cells in NaPB. 
either yeast cells or 3 h-grown 
hyphae, were incubated at 37 °C 
with different peptide concen-
trations: 0.25 μM (unfilled 
diamond); 0.5 μM (unfilled 
circle); 1 μM (filled circle); 
2 μM (unfilled square); 4 μM 
(unfilled triangle); 8 μM (filled 
triangle); 16 μM (filled square); 
32 μM (filled diamond). Data 
points represent the mean of 
triplicate samples ± SD from 
a single experiment, repre-
sentative of three independent 
experiments. the killing activity 
was determined with respect to 
the control at each time interval. 
Right insets show phase-con-
trast images of yeast and hyphal 
forms of Candida used for the 
experiments. Scale bars are 
10 μm long
a
b
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Interestingly, the all-D peptide showed similar ability to 
kill yeast and hyphal forms and to permeabilize their cell 
membrane as the L form (data not shown).
Fluorescence studies
to visualize the distribution of esc(1–18) and its induced 
alteration of the cell membrane integrity, either yeast or 
hyphal forms were treated with 16 μM of rho-esc(1–18), 
followed by DaPI and Sytox Green staining. We noted that 
rhodamine did not affect the anti-Candida activity of esc(1–
18), since the MIC value of rho-esc(1–18) was equal to that 
of the unlabelled peptide (data not shown). as reported in 
Fig. 4, rho-esc(1–18) appeared to be distributed evenly over 
the yeast cells and hyphae, and the membrane perturba-
tion (as detected by the green fluorescence of Sytox Green) 
occurred in a similar manner along the entire cell structure.
Inhibition of hyphae formation
It is largely known that the ability of a drug to prevent the 
morphological change of fungal cells from their budding 
12 h growth 18 h growth
12 h growth
Fig. 2  Phase-contrast images of Candida biofilm obtained after 12 
and 18 h growth of yeast cells at 37 °C (upper panels). the peptide’s 
effect on the viability of 12 h-grown biofilm is shown after the Mtt 
colorimetric assay (lower panels). the black color in the peptide-
untreated (control) sample indicates viable cells, whereas the trans-
parency in the peptide-treated sample indicates the presence of dead 
yeast and hyphal cells. Scale bar is 20 μm long
Table 2  Fungicidal activity of esc(1–18) on the biofilm form of 
C. albicans atCC 10231
a
 the reported MFC values are those obtained from at least three 
readings out of four independent measurements. MFC50 and MFC90 
are defined as the minimal peptide concentrations causing 50 and 
90 % fungal killing, respectively, within 60 min. Note that MFC50 
and MFC90 on 3 h-grown hyphae are equal to 4 and 16 μM, respec-
tively (see Fig. 1b)
Minimal fungicidal concentration (MFC, μM)a on C. albicans hyphae
12 h growth 18 h growth
MFC50 16 32
MFC90 64 > 64
a
b
Fig. 3  Peptide-induced membrane permeabilization of yeast cells 
(panel a) and 3 h-grown hyphae (panel b). Samples were incubated 
with 1 μM Sytox Green in NaPB. Once basal fluorescence reached a 
constant value, the peptide was added (arrow, t = 0) and changes in 
fluorescence were monitored. Peptide concentrations used are the fol-
lowing: 0.25 μM (unfilled diamond); 0.5 μM (unfilled circle); 1 μM 
(filled circle); 2 μM (unfilled square); 4 μM (unfilled triangle); 8 μM 
(filled triangle); 16 μM (filled square); 32 μM (filled diamond). Con-
trol (asterisk) is given by bacteria without peptide. Data points repre-
sent the mean of triplicate samples from a single experiment, repre-
sentative of three independent experiments
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shape into the filamentous form would be extremely advan-
tageous. We therefore studied the capability of esc(1–18) 
to block hyphal formation and found out that this effect 
was more pronounced when 1 × 106 CFU/ml were used. 
Indeed, a clear inhibition of germ tubes was detected after 
a 3 h treatment of yeast cells with sub-inhibitory concen-
trations of esc(1–18) (Fig. 5). More precisely, the minimal 
peptide concentration causing such inhibition was found 
to be 4 μM, corresponding to 1/4 the MIC (16 μM with 
1 × 106 CFU/ml). Importantly, this effect was maintained 
up to 24 h, despite the achieved high cell density, due to 
cell proliferation (data not shown).
In vivo studies
When infected wild-type nematodes were transferred to liq-
uid medium (see experimental section), yeast cells under-
went hyphal development, likely induced by environmental 
factors of the animal’s intestine. this usually results in a 
very aggressive infection leading to worm lethality in about 
40 h. Indeed, hyphae penetrate and destroy the cuticle to 
finally pierce through the body. In our case, esc(1–18) 
was added to the worms, at 50 μM, after 20 min of their 
exposure to Candida. Interestingly, the peptide increased 
C. elegans survival by more than 50 % within 24 h 
(Fig. 6a), causing approximately 40 % reduction in the 
number of CFU within the nematode’s intestine (Fig. 6b). 
In addition, in line with our in vitro results, esc(1–18) dra-
matically hampered hyphae formation within the worm’s 
gut in 3 h (Fig. 7). In order to accurately assess the in vivo 
distribution of the peptide, the rho-esc(1–18) analog was 
used. as illustrated in Fig. 8, the peptide was homogene-
ously confined to the worm’s intestinal lumen and uni-
formly associated with the cell perimeter of Candida cells.
Discussion
C. albicans is a versatile microorganism that can become 
an important pathogen in superficial (e.g., oral and vagini-
tis) and systemic fungal infections [56]. Currently available 
antifungals are limited in both number and level of effec-
tiveness, mainly due to their undesirable side effects and 
to the emergence of resistant strains [2, 57, 58]. For these 
reasons, novel anti-infective agents are of great interest to 
the medical community [59]. In this context, we have stud-
ied the anti-Candida properties of esc(1–18) along with the 
underlying molecular mechanism.
Fig. 4  Detection of peptide 
distribution and membrane 
perturbation in both yeast cells 
(upper panels) and hyphae 
(lower panels). Samples were 
treated with 16 μM of rho-
esc(1–18) and then stained 
with DaPI and Sytox Green. 
afterwards, they were examined 
by light (a) and fluorescence 
microscopy (b–d). Blue (b); red 
(c) and green (d) fluorescence 
indicate the distribution of 
DaPI, the labelled-esc(1–18) 
and Sytox-Green, respectively. 
Scale bars are 5 μm long and 
apply to all images
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although a considerable amount of effort has been 
devoted to the study of the effect(s) of native and de novo 
designed aMPs on C. albicans (e.g. the human cathelici-
dins [60], piscidin [61], lactoferrin, istatins [62], lipopep-
tides [63], Leu/Lys-rich peptides [64], plant defensins [65, 
66] temporins [42], pleurocidin [67] and synthetic dodeca-
peptides [68]), very little is known regarding their efficacy 
against the hyphal and biofilm forms of this microorgan-
ism [69], as well as the subtending mechanism of action. 
Remarkably, Candida biofilms are highly resistant to the 
action of conventional antifungal agents and very diffi-
cult to eradicate either from biological surfaces or implant 
devices [70]. here, we have shown that esc(1–18) displays 
a fast fungicidal activity (within 20 min), causing approxi-
mately 80 % reduction in the number of viable yeast/
hyphal cells at 16 μM. Furthermore, a quite good fungi-
cidal activity is exerted by the peptide on an intermedi-
ate developmental phase of C. albicans biofilm, produced 
after 12 and 18 h of cell growth. In addition, according to 
the results of the Sytox Green assay (Fig. 3), this peptide 
has a membrane-perturbing activity against both stages of 
Candida, despite their different membrane lipid composi-
tion [71, 72]. Overall, we can conclude that a direct peptide 
interaction with membrane lipids followed by membrane 
permeabilization is likely the primary cause of antifun-
gal activity of esc(1–18) and one that is probable to limit 
the emergence of fungal resistance. this conclusion is 
supported by the following findings: (1) a fast membrane 
perturbation process that is concomitant with the killing 
activity on the two morphological phenotypes; (2) a direct 
correlation between the extent of membrane damage and 
the percentage of microbial death; (3) the ability to cause 
release of fluorescent dyes entrapped in artificial phospho-
lipid vesicles [38], which does not occur for those anti-
fungal aMPs, e.g., plant defensins, provoking membrane 
perturbation in Candida as a final result of a mechanism 
of specific peptide-induced intracellular signaling pathways 
(e.g., involving the generation of reactive oxygen species, 
ROS) [65, 66, 73]; and (4) a non-significant production of 
ROS from esc(1–18)-treated yeast and hyphal forms (data 
not shown), in contrast with plant defensins and what has 
recently been found  for de novo designed low molecular 
weight cationic peptides [68]. Importantly, we can also 
exclude that the membrane perturbation is the consequence 
of a binding-site mediated insertion of esc(1–18) into 
the fungal membrane, as in the case of the plant defensin 
RsaFP2 [74]. Indeed, such a stereospecific mechanism 
would likely not allow the all-l and all-d enantiomers of 
esc(1–18) to achieve the same results, in terms of MIC, 
fungicidal activity and membrane perturbation.
as evidenced by fluorescence microscopy (Fig. 4), the 
membrane alteration appears to be distributed over the 
cell structure, ruling out a local peptide-induced mem-
brane disruption. Moreover, the even distribution of the 
µ µ
µ µ µ
Fig. 5  effect of esc(1–18) on the development of the hyphal form of C. albicans after 3 h from peptide addition at different sub-MIC concentra-
tions to yeast cells. Scale bar is 20 μm long and applies to all images
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rho-esc(1–18) along the hyphae excludes intracellular 
organelles (i.e., the nucleus and mitochondria) as its poten-
tial targets. Such an outcome is in contrast with what is 
manifested by other membrane-active aMPs, e.g., the frag-
ment LL13–37 of the human cathelicidin LL-37, which was 
found to affect the membrane permeability of only some 
of the hyphae [75]. Interestingly, when tested on infected 
C. elegans, the frog skin esc(1–18) is able to prolong worm 
survival by twofold within 24 h and to hinder hyphal devel-
opment from the yeast form. Presumably, these findings 
are due to a direct effect of esc(1–18) on Candida cells, 
reducing their number (Fig. 6b) and avoiding their shift to 
the more virulent and toxic phenotype (Fig. 7). this is con-
sistent with the results obtained with the labelled peptide, 
showing: (1) the presence of esc(1–18) exclusively along 
the worm’s gut, without diffusing to other tissues; and (2) 
its adhesion around the fungal cells, which mainly appear 
in their yeast budding form (Figs. 7b and 8). however, fur-
ther experiments are required to better elucidate the in vivo 
mode(s) of action of esc(1–18). In fact, we cannot leave 
out the possibility that additional processes, mediated by 
an enhanced host’s immune reaction, can contribute to 
increase survival of Candida-infected worms after peptide 
treatment. Crucial pathways controlling immune responses 
have been highly conserved throughout evolution, from 
nematodes to mammals [76], and the genome of C. elegans 
has been fully sequenced and annotated. even if this mini-
host model cannot substitute for mammalian models, it 
offers a number of advantages over vertebrates, including 
the study of strain collections without the ethical consid-
erations associated with studies in mammals [40]. Note that 
Candida infection in C. elegans occurs through the gastro-
intestinal tract upon cell ingestion by the nematode [77], 
Fig. 6  effect of esc(1–18) on both the survival (panel a) and the 
number of live Candida cells within the gut (panel b) of infected 
nematodes after 24 h of peptide treatment [INF + esc(1–18)] in com-
parison with untreated infected nematodes (INF). Control uninfected 
worms treated with the peptide [UI + esc(1–18)] exhibited 100 % 
viability. Values represent the means of at least three independent 
experiments; the error bars indicate SD. *Indicates p < 0.05 compared 
to values from INF
Fig. 7  Morphology of Candida cells within the gut of a representa-
tive infected animal, after 3 h of peptide treatment (t). a representa-
tive infected nematode not treated with the peptide (Ut) is included 
for comparison. Arrows and corresponding insets at higher magni-
fication indicate germ tube formation or yeast budding cells in the 
untreated or peptide-treated sample, respectively. Scale bar is 8 μm 
long
V. Luca et al.
1 3
which is an accurate representation of what physiologically 
takes place in susceptible human hosts, where fungal cells 
in the intestinal mucosa can disseminate to other organs 
[78]. Conversely, in other simple invertebrate animal mod-
els, such as Drosophila, infection by Candida requires the 
injection of the yeast into the thorax. another important 
benefit in using C. elegans is linked to the transparency 
of its body. Indeed, this makes it possible for research-
ers to directly examine and visualize in real time, under 
a dissecting microscope, yeast cell distribution within the 
host together with their change into hyphae, at all stages 
of infection. Overall, C. elegans can certainly provide an 
advanced step for a rapid and cost-effective high-through-
put screening of in vivo anti-infective agents [79], as well 
as for identifying their location and their effect(s) on the 
outcome of the infection (e.g., amount of microbial cells 
and their form of growth). to the best of our knowledge, 
this report is the first to demonstrate: (1) the fungicidal 
activity and plausible mode of action of a frog skin aMP 
on the two cell shapes of C. albicans; (2) its ability to 
prolong survival of Candida-infected living multicellular 
organisms; and (3) its capability to inhibit transition from 
the roundish yeast cell to the more dangerous hyphal form 
at sub-MIC dosages, which is a very important finding for a 
rational design of new antifungal agents with more favora-
ble properties. It is worthwhile underlining that transition 
of yeast cells to their filamentous form is a pivotal biologi-
cal process required for biofilm formation in C. albicans. 
Finally, this paper highlights C. elegans as a convenient 
infection model to select anti-Candida compounds to be 
further investigated in more complex animal models for a 
future application in the treatment of candidiasis.
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